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Nitrogen-containing heterocycles are present in a variety of chemical compounds, ranging 
from pharmaceutical and agrochemical agents to diverse organic dyes.1 Therefore, numerous 
efforts have been made to develop efficient and convenient methods for the formation of 
substituted heteroarenes.2 
The traditional transition metal-catalyzed cross-coupling of organometallics 2 (M = MgX, 
ZnX, BR2, SnR3, SiR3, etc.) and organic (pseudo)halogenides 3 has emerged as a powerful 















Scheme 1: Traditional cross-coupling versus C–H arylation. 
In spite of these advances, drawbacks of transition metal-catalyzed cross-coupling reactions 
continue to be remarkable. Substrates need to be prefunctionalized to the organometallics 2 
through time-consuming and economically inefficient multi-step transformations, and 
stoichiometric amounts of metal salts as by-products are formed during these reactions. To 
avoid these disadvantages and to streamline organic syntheses, catalytic C–H 
1 (a) M. U. Schmidt, R. E. Dinnebier, H. Kalkhof, J. Phys. Chem. B 2007, 111, 9722–9732; (b) P. 
Goupy, A.-B. Bautista-Ortin, H. Fulcrand, O. Dangles, J. Agric. Food Chem. 2009, 57, 
5762–5770; (c) G. Bringmann, T. Gulder, T. A. M. Gulder, M. Breuning, Chem. Rev. 2011, 111, 
563–639; (d) R. Dua, S. Shrivastava, S. K. Sonwane, S. K. Srivastava, Advan. Biol. Res. 2011, 5, 
120–144. 
2 (a) J. Hassan, M. Sévignon, C. Gozzi, E. Schulz, M. Lemaire, Chem. Rev. 2002, 102, 
1359–1469; (b) L. Djakovitch, N. Batail, M. Genelot, Molecules 2011, 16, 5241–5267; (c) I. 
Hachiya, I. Mizota, M. Shimizu, Heterocycles 2012, 85, 1017–1043; (d) A. Majumder, R. Gupta, 
A. Jain, Green Chem. Lett. Rev. 2013, 6, 151–182; (e) X.-F. Wu, H. Neumann, M. Beller, Chem. 
Rev. 2013, 113, 1–35; (f) A. Dhakshinamoorthy, H. Garcia, Chem. Soc. Rev. 2014, 43, 
5750–5765. 
3 (a) Metal-Catalyzed Cross-Coupling Reactions; F. Diederich, P. J. Stang, Eds.; Wiley-VCH: 
New York, 1998; (b) Transition Metals for Organic Synthesis; M. Beller, C. Bolm, Eds.; 
Wiley-VCH: Weinheim, 2004. 
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functionalization has been developed as an excellent alternative, which has been intensively 
investigated during last ten years.4 
An obvious challenge for these C–H functionalizations is the activation of inert C–H bonds. 
To overcome this challenge, a deep insight into the mechanism of the elementary C–H bond 


























































Scheme 2: Possible mechanisms for insertion of a transition metal into a C–H bond. 
Typically, four possible modes of action could be envisioned (Scheme 2).5 The first pathway 
(a) is the electrophilic substitution often occurring with electron-deficient late transition 
metals, such as Pd2+, Pt2+ or Pt4+. For the electron-rich, low-valent complex of the late 
transition metal (Fe, Pd, Ru, Ir), the oxidative addition (b) of a C–H bond is largely preferred. 
Because the early transition metal with d0-configuration cannot undergo the oxidative 
addition, σ-bond metathesis (c) becomes predominant here. The transition metal mediated 
C–H bond insertion can also proceed via 1,2-addition (d) to an unsaturated [TM]=X bond. 
4 For selected representative reviews on C–H activation, see: (a) L. Ackermann, A. Althammer, R. 
Born, Synlett 2007, 2833–2836; (b) I. V. Seregin, V. Gevorgyan, Chem. Soc. Rev. 2007, 36, 
1173–1193; (c) J. C. Lewis, R. G. Bergman, J. A. Ellman, Acc. Chem. Res. 2008, 41, 
1013–1025; (d) L. Ackermann, R. Vicente, A. R. Kapdi, Angew. Chem. Int. Ed. 2009, 48, 
9792–9826; (e) K. M. Engle, T.-S. Mei, M. Wasa, J.-Q. Yu, Acc. Chem. Res. 2012, 45, 788–802; 
(f) R. Rossi, F. Bellina, M. Lessi, C. Manzini, Adv. Synth. Catal. 2014, 356, 17–117; (g) R. 
Rossi, F. Bellina, M. Lessi, C. Manzini, L. A. Perego, Synthesis 2014, 46, 2833–2883; (h) S. A. 
Girard, T. Knauber, C.-J. Li, Angew. Chem. Int. Ed. 2014, 53, 74–100. 
5 (a) D. Alberico, M. E. Scott, M. Lautens, Chem. Rev. 2007, 107, 174–238; (b) D. Balcells, E. 
Clot, O. Eisenstein, Chem. Rev. 2010, 110, 749–823. 
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In addition to these reaction pathways, more recent mechanistic studies demonstrate the 
existence of a continuum of electrophilic, ambiphilic and nucleophilic interactions at the C–H 
bond metalation step.6 Furthermore, it is often found that a base is not a simple bystander 
regenerating the active catalyst, but that it is directly involved in the transition state of the 
C–H bond metalation.7, 8 These strongly indicate a novel mechanism, namely the base- 
assisted C–H bond metalation.6 A bidentate base, such as a carboxylate8 or a phosphinous 
acid,9 binds to a transition metal and interacts with a C–H bond, resulting in a six-membered 
transition state (Figure 1). This intramolecular metalation pathway is coined as concerted 
metalation-deprotonation (CMD)10 or ambiphilic metal ligand activation (AMLA).6b,11 An 








Figure 1: Base-assisted C–H bond metalation. 
Another challenge for the direct C–H bond functionalization is the presence of numerous 
similarly reactive C–H bonds in the substrate. In order to regioselectively functionalize a 
specific C–H bond, a commonly exploited strategy is the installation of a removable directing 
group (Scheme 3).13 By elaborately designing the directing group, ortho-14 und remote-C–H 
6 (a) D. H. Ess, W. A. Goddard III, R. A. Periana, Organometallics 2010, 29, 6459–6472; (b) L. 
Ackermann, Chem. Rev. 2011, 111, 1315–1345. 
7 (a) J. C. Gaunt, B. L. Shaw, J. Organomet. Chem. 1975, 102, 511–516; (b) V. I. Sokolov, L. L. 
Troitskaya, O. A. Reutov, J. Organomet. Chem. 1979, 182, 537–546; (c) D. L. Davies, O. 
Al-Duaij, J. Fawcett, M. Giardiello, S. T. Hilton, D. R. Russell, Dalton Trans. 2003, 
4132–4138. 
8 L. Ackermann, Acc. Chem. Res. 2014, 47, 281–295. 
9 L. Ackermann, Synthesis 2006, 1557–1571. 
10 D. Lapointe, K. Fagnou, Chem. Lett. 2010, 39, 1118–1126. 
11 Y. Boutadla, D. L. Davies, S. A. Macgregor, A. I. Poblador-Bahamonde, Dalton Trans. 2009, 
5820–5831. 
12  (a) J. Oxgaard, W. J. Trenn III, R. J. Nielsen, R. A. Periana, W. A. Goddard III, 
Organometallics 2007, 26, 1565–1567; (b) D. Conner, K. N. Jayaprakash, T. R. Cundari, T. B. 
Gunnoe, Organometallics 2004, 23, 2724–2733; (c) J. R. Webb, T. BolaÇo, T. B. Gunnoe, 
ChemSusChem 2011, 4, 37–49. 
13 For reviews on removable directing groups, see: (a) C. Wang, Y. Huang, Synlett 2013, 24, 
145–149; (b) F. Zhang, D. R. Spring, Chem. Soc. Rev. 2014, 43, 6894–6905. 
14 (a) Modern Arylation Methods; L. Ackermann, Ed.; Wiley-VCH: Weinheim, 2009; (b) D. 
Takeda, M. Yamashita, K. Hirano, T. Satoh, M. Miura, Chem. Lett. 2011, 40, 1015–1017; (c) T. 
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Scheme 3: Site-selective intermolecular C–H metalations through the use of directing groups 
(DG). 
Furthermore, a variety of reactions exploiting appropriate ligands,16 electron-rich substrates,17 
or the kinetic C–H bond acidity18 among others have been developed to enhance the 
site-selectivity. 
1.1 Transition Metal-Catalyzed C–H Alkynylations of Azoles 
Since Sonogashira discovered the pioneering cross-coupling reaction between terminal 
acetylene and vinyl-, or arylhalogenide in the presence of (PhP3)2PdCl2 and the cocatalyst 
CuI,19 the obstacle to the mild and convenient synthesis of unsymmetrical acetylenes was 
remarkably overcome. Besides Sonogashira-type reactions, the site-selective direct C–H 
alkynylation of azoles as a viable alternative could be realized by exploiting significantly 
different kinetic C–H bond acidities between the ubiquitous C–H bonds present in the azoles 
compounds, as indicated by their pKa values (Figure 2).20 
Okazawa, T. Satoh, M. Miura, M. Nomura, J. Am. Chem. Soc. 2002, 124, 5286–5287. 
15 (a) D. Leow, G. Li, T. Mei, J.-Q. Yu, Nature, 2012, 486, 518–522; (b) N. Hofmann, L. 
Ackermann, J. Am. Chem. Soc. 2013, 135, 5877–5884; (b) G. Yang, P. Lindovska, D. Zhu, J. 
Kim, P. Wang, R.-Y. Tang, M. Movassaghi, J.-Q. Yu, J. Am. Chem. Soc. 2014, 136, 
10807–10813. 
16 (a) B. Glover, K. A. Harvey, B. Liu, M. J. Sharp, M. Tymoschenko, Org. Lett. 2003, 5, 
301–304; (b) T. W. Lyons, K. L. Hull, M. S. Sanford, J. Am. Chem. Soc. 2011, 133, 4455–4464. 
17 (a) S. Pivsa-Art, T. Satoh, Y. Kawamura, M. Miura, M. Nomura, Bull. Chem. Soc. Jpn. 1998, 
71, 467–473; (b) S. Yanagisawa, T. Sudo, R. Noyori, K. Itami, J. Am. Chem. Soc. 2006, 128, 
11748–11749. 
18 (a) L.-C. Campeau, S. Rousseaux, K. Fagnou, J. Am. Chem. Soc. 2005, 127, 18020–18021; (b) 
D. Garcia-Cuadrado, A. A. C. Braga, F. Maseras, A. M. Echavarren, J. Am. Chem. Soc. 2006, 
128, 1066–1607; (c) L. Ackermann, S. Fenner, Chem. Commun.2011, 47, 430–432. 
19 (a) K. Sonogashira, Y. Tohda, N. Hagihara, Tetrahedron Lett. 1975, 16, 4467–4470; (b) R. 
Chinchilla, C. Nájera, Chem. Rev. 2007, 107, 874–922. 
20 K. Shen, Y. Fu, J.-N. Li, L. Liu, Q.-X. Guo, Tetrahedron 2007, 63, 1568–1576. 
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Figure 2: Calculated pKa values of azoles. 
Compared to significant advances in transition metal-catalyzed C–H arylations and 
alkenylations of azoles, C–H alkynylations of heteroarenes received relatively low attention 
until Gevorgyan reported a palladium-catalyzed direct alkynylation of N-fused heteroarene 5 
with haloacetylene 6 (Scheme 4).21a 
+







Scheme 4: Palladium-catalyzed direct alkynylations of N-fused heterocycles 5. 
Later, Piguel's work demonstrated that copper complexes were also capable of efficiently 
catalyzing direct C2-alkynylations of oxazoles 8 in the presence of DPEPhos as the ligand 




CuBr·SMe2 (15 mol %)
DPEPhos (15 mol %)
LiOtBu




8 6 9  
Scheme 5: Cu-catalyzed direct alkynylations of oxazoles 100. 
Despite the great tolerance of haloacetylenes 6 in the direct alkynylations, these electrophiles 
are instable. The moisture-stable gem-dihaloalkenes seem to be a viable candidate for 
replacing haloacetylenes.23 As reported by Piguel (Scheme 6),24 gem-dibromoalkene 10 could 
oxidatively add to the heteroarylcopper species 12 generated from 8 and 11 as well as LiOtBu, 
and then reductively couple with the heteroaryl group to form alkenyloxazole 14, which was 
further converted to alkynylated product 9 by elimination of a molecular HBr (Scheme 6, path 
A). Alternatively, gem-dibromoalkene 10 could first be transformed to bromoacetylene 6, and 
21 (a) I. V. Seregin, V. Ryabova, V. Gevorgyan, J. Am. Chem. Soc. 2007, 129, 7742–7743. For the 
further development of this approach, see: (b) S. H. Kim, S. Chang, Org. Lett. 2010, 12, 
1868–1871. 
22 F. Besselièvre, S. Piguel, Angew. Chem. Int. Ed. 2009, 48, 9553–9556. 
23 G. Chelucci, Chem. Rev. 2012, 112, 1344–1462. 
24 B. P. Berciano, S. Lebrequier, F. Besselièvre, S. Piguel, Org. Lett. 2010, 12, 4038–4041. 
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the subsequent oxidative addition and the reductive elimination would lead to desired product 
9 via the intermediate 15 (path B). Given that no alkenyloxazole 14 was observed, Piguel 
tended to regard the path B as more likely. Notably, LiOtBu as a strong base was necessary 
















CuBr.SMe2 (5 mol %)
DPEPhos (10 mol %)
LiOtBu
1,4-dioxane, 120 °C, 2 h
N
X Ar




























LiOtBu tBuOH + LiBr












Scheme 6: Copper-catalyzed direct alkynylations of oxazoles 8 with gem-dibromoalkenes 10. 
In addition to Sonogashira-type or to direct alkynylations, the approach via dehydrogenative 
oxidative alkynylation provides a straightforward access to diverse alkynylated heterocycles 
as well. In 2010, Miura reported on the CuCl2-mediated direct alkynylation of oxazoles 8 
with terminal alkynes 16 and oxygen as the terminal oxidant (Scheme 7).25 Despite the 
stoichiometric exploitation of the transition metal in this work, it has laid the foundation for 
further more convenient catalytic protocols utilizing nickel, 26  palladium 27  and gold 28  
25 M. Kitahara, K. Hirano, H. Tsurugi, T. Satoh, M. Miura, Chem. Eur. J. 2010, 16, 1772–1775. 
26 N. Matsuyama, M. Kitahara, K. Hirano, T. Satoh, M. Miura, Org. Lett. 2010, 12, 2358–2361. 
27 (a) S. H. Kim, J. Yoon, S. Chang, Org. Lett. 2011, 13, 1474–1477; (b) F. Shibahara, Y. Dohke, 
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8 16 9  
Scheme 7: Oxidative alkynylation of oxazoles 8. 
1.2 Transition Metal-Catalyzed C–H Arylations of Indoles 
Indole is one of the most frequently appearing nitrogen heterocycles in nature. Because of its 
immense structural variety, indole is of especial importance in the field of pharmaceutics and 
functional materials.29 Besides well-known traditional methods, such as Fischer30 or Larock31 
indole syntheses as well as cyclizations,32,33 the C–H arylation has emerged as a highly 
powerful tool for the synthesis of arylated indoles.34 
1.2.1 Palladium-Catalyzed C–H Arylations of Indoles 
Due to the electron density distribution, the C(2)–H and the C(3)–H bond of electron-rich 
indoles are more susceptible to the direct palladium-catalyzed arylation as compared the 
aromatic C–H bonds in these molecules. 
During the pioneering investigation of palladium-catalyzed direct C–H bond 
functionalizations of indoles 17 with chloropyrazines 18, Ohta observed that a protecting 
T. Murai, J. Org. Chem. 2012, 77, 5381–5388. 
28 T. de Haro, C. Nevado, J. Am. Chem. Soc. 2010, 132, 1512–1513. 
29 (a) A. P. Kozikowski, D. Ma, J. Brewer, S. Sun, E. Costa, E. Romeo, A. Guidotti, J. Med. 
Chem. 1993, 36, 2908–2920; (b) S. Cacchi, G. Fabrizi, Chem. Rev. 2005, 105, 2873–2910; (c) N. 
K. Kaushik, N. Kaushik, P. Attri, N. Kumar, C. H. Kim, A. K. Verma, E. H. Choi, Molecules 
2013, 18, 6620–6662. 
30 B. Robinson, The Fischer Indole Synthesis, Wiley & Sons: Chichester, 1982. 
31 (a) R. C. Larock, E. K. Yum, J. Am. Chem. Soc. 1991, 113, 6689–6690; (b) G. Zeni, R. C. 
Larock, Chem. Rev. 2006, 106, 4644–4680. 
32 (a) K. Iritani, S. Matsubara, K. Utimoto, Tetrahedron Lett. 1988, 29, 1799–1802. Reviews: (b) 
R. Vicente, Org. Biomol. Chem. 2011, 9, 6469–6480; (c) L. Djakovitch, N. Batail, M. Genelot, 
Molecules 2011, 16, 5241–5267; (d) L. Ackermann, Synlett 2007, 507–526. 
33 (a) L. Ackermann, Org. Lett. 2005, 7, 439–442; (b) L. T. Kaspar, L. Ackermann, Tetrahedron, 
2005, 61, 11311–11316; (c) L. Ackermann, S. Barfüßer, H. K. Potukuchi, Adv. Synth. Catal. 
2009, 351, 1064–1072; (d) L. Ackermann, R. Sandmann, M. V. Kondrashov, Synlett 2009, 
1219–1222; (e) L. Ackermann, R. Sandmann, M. Schinkel, M. V. Kondrashov, Tetrahedron 
2009, 65, 8930–8939; (f) L. Ackermann, A. V. Lygin, Org. Lett. 2012, 14, 764–767; (g) W. 
Song, L. Ackermann, Chem. Commun. 2013, 49, 6638–6640. 
34 (a) L. Joucla, L. Djakovitch, Adv. Synth. Catal. 2009, 351, 673–714; (b) G. Broggini, E. M. 
Beccalli, A. Fasana, S. Gazzola, Beilstein J. Org. Chem. 2012, 8, 1730–1746. 
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group on the indole nitrogen can significantly affect the C3/C2-site-selectivity (Scheme 8). 
While the reaction of free (NH)-indole 17a exclusively proceeded affording the 
C2-functionalized product 19a (Scheme 8a),35 a tosyl group as an electron-withdrawing 
substituent on the indole nitrogen switched the selectivity towards the formation of the 






AcOK (1.2 equiv) 

















AcOK (1.2 equiv) 











Scheme 8: Palladium-catalyzed arylation of indoles 5 with chloropyrazines 6. 
After two decades, Sames applied similar reaction conditions for the arylation of indoles 17 
with iodoarenes 3 and obtained C2-arylated heterocycles 20 in moderate to good yields 
(Scheme 9).37 Notably, Sames also mentioned that the C3-regioisomer became the major 
product, when a sterically demanding iodoarene 3, such as 1-iodo-2-[(4-methoxybenzyl)- 





CsOAc (2 equiv) 
DMA, 125 °C, 24–48 h
R1 R1Ar–I
R2 R2
R2 = Me, SEM, H17 203  
Scheme 9: C2-Arylations of indoles. 
In 2008, Larrosa disclosed a convenient, mild and high yielding method for the 
palladium-catalyzed phosphine-free direct arylation of N-methylindole 17c (Scheme 10).38 
35 Y. Akita, A. Inoue, K. Yamamoto, A. Ohta, T. Kurihara, M. Shimizu, Heterocycles 1985, 23, 
2327–2333. 
36 Y. Akita, Y. Itagaki, S. Takizawa, A. Ohta, Chem. Pharm. Bull. 1989, 37, 1477–1480. 
37 (a) B. S. Lane, D. Sames, Org. Lett. 2004, 6, 2897–2900; (b) B. B. Touré, B. S. Lane, D. Sames, 
Org. Lett. 2006, 8, 1979–1982; (c) X. Wang, D. V. Gribkov, D. Sames, J. Org. Chem. 2007, 72, 
1476–1479. 
38 N. Lebrasseur, I. Larrosa, J. Am. Chem. Soc. 2008, 130, 2926–2927. 
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Ag2O as the base reacted with arylpalladium complex to provide a more electrophilic 
palladium species, likely via precipitation of silver iodide. Thus, the resulting highly reactive 
palladium species reinforced the subsequent coordination of indole and the reductive 
elimination. Moreover, it was observed that the pKa of the stoichiometrically added 
carboxylic acid correlated closely with the catalytic reactivity, with o-nitrobenzoic acid (21) 
providing optimal results. 
N N
Ph+
Pd(OAc)2 (5 mol %)
Ag2O (0.75 equiv)
additive (1.5 equiv) 
DMF, 25 °C, 8 h
Me Me
Ph–I
17c 20cb3b  





o-O2NC6H4CO2H (21) >99 
Scheme 10: Palladium-catalyzed phosphine-free direct arylations of indoles 17c. 
As mentioned above, palladium-catalyzed C–H bond functionalizations were generally 
observed with C2-regioselectivity. In order to shift the regioselectivity to C3, a withdrawing 
protecting group on indolic nitrogen or sterically bulky arylating reagent is usually 
required.34a Besides this, a suitable ligand coordination in the palladium catalyst could also 
lead to the same result (Scheme 11). For instance, Zhang used the air-stable palladium/ 
phosphinous acid complex 22 as the catalyst for the reaction of indole 17a with arylbromides 
3, which afforded 3-arylindoles 24 in moderate to good yields (Scheme 11a).39 Moreover, 
Ackermann designed a palladium complex generated in situ from an air-stable 
heteroatom-substituted secondary phosphine oxide 23 (HASPO), and this resulted in a high 
C3-regioselectivity likewise (Scheme 11b).40 
39 Z. Zhang, Z. Hu, Z. Yu, P. Lei, H. Chi, Y. Wang, R. He, Tetrahedron Lett. 2007, 48, 
2415–2419. 
40 L. Ackermann, S. Barfüßer, Synlett 2009, 808–812. 
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22 (5 mol %)
K2CO3 (3.0 equiv)












Pd(OAc)2 (5 mol %)
23 (10 mol %)
K2CO3 (3.0 equiv)



















Scheme 11: Palladium-catalyzed direct C3-arylations of indoles 17a. 
Following Itahara’s pioneering study,41 Fagnou performed investigations on the oxidative 
direct arylations of indoles 17 with an excess of arene (Scheme 12).42 2-Arylindole 20d was 
produced by employing Pd(TFA)2, AgOAc and PivOH (Scheme 12a). When the Pd(TFA)2 
loading was increased from 5 to 300 mol % in the absence of AgOAc, only 3-phenylindole 
24d was obtained (Scheme 12b). Moreover, the replacement of AgOAc by Cu(OAc)2 also 
gave rise to the C3-arylated regioisomer 24e with a ratio of 8.9:1 (Scheme 12c). These results 
indicated that the C3/C2-regioselectivity was presumably related to the concentration of 
higher-order palladium clusters. While a catalytic quantity of the monomeric palladium 
species formed by carboxylate-induced cleavage of palladium clusters led to a selective 
functionalization of the C(2)–H bond, superstoichiometric quantities of Pd(TFA)2 as well as 
the mixed palladium–copper intermediate clusters,43 formed by the addition of Cu(OAc)2, 
maintained a high concentration of palladium clusters and facilitated a site-selective 
C3-arylation. 
41 T. Itahara, J. Chem. Soc., Chem. Commun. 1981, 254–255. 
42 D. R. Stuart, E. Villemure, K. Fagnou, J. Am. Chem. Soc. 2007, 129, 12072–12073. 
43 (a) R. W. Brandon, D. V. Claridge, J. Chem. Soc., Chem. Commun. 1968, 677–678; (b) O. D. 
Sloan, P. Thornton, Inorg. Chim. Acta 1986, 120, 173–175. 
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Scheme 12: Palladium-catalyzed oxidative direct arylations of indoles 17. 
As to the mechanism for palladium-catalyzed C2-arylations of indoles 17 with aryliodides 3, 
Sames suggested a palladium(0)/palladium(II) catalytic cycle involving an initial electrophilic 
substitution of Ar-PdII-X species 25 at the C3 position and a subsequent 1,2-migration to C2 
(Scheme 13), which was strongly supported by mechanistic studies including kinetic isotope 










































Scheme 13: Possible reaction mechanism for the palladium-catalyzed C–H arylation of indole 
17. 
44 B. S. Lane, M. A. Brown, D. Sames, J. Am. Chem. Soc. 2005, 127, 8050–8057. 
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Meanwhile, Sames pointed out that the C3/C2-regioselectivity was strongly related to the 
reaction rates of the electrophilic substitution and the 1,2-migration, both of which were 
kinetically relevant and remarkably influenced by the size of the arylating reagents and 
metal-ligand complexes. If the reaction rate of the 1,2-migration was lower than those for the 
abstraction of the proton at the C3 position, the probability to obtain 3-arylindoles 24 
increased. 
1.2.2 Arylations of (Hetero)Arenes with Diaryliodonium Salts 
1.2.2.1 Structure of Diaryliodonium Salts 
Since Hartmann and Meyer first synthesized diaryliodonium salts 26 in 1894,45 the air- and 
moisture-stable hypervalent iodine(III) compounds have received high attention due to their 
highly electrophilic nature and excellent leaving group ability of the aryliodonium moiety. 
They have been widely utilized in direct electrophilic arylations of various nucleophiles and 
in transition metal-catalyzed cross-coupling reactions.46,47 
In general, hypervalent iodine(III) compounds ArIL1L2 exhibit pseudotrigonal bipyramidal 
structures and are roughly T-shaped at the iodine center, as shown in Figure 3. An aryl group 
and two electron lone pairs are equatorial in the λ3-iodane, and two ligands L trans to each 
other are apical. In 1951, on the basis of molecular orbital theory, Pimentel48 and Rundle49 
explained the structure and the electrophilic nature of λ3-iodanes by utilizing the concept of a 
three-center-four-electron (3c-4e) bond for the L1–I–L2 moiety. The filled 5p orbital of the 
iodine atom interacts with the half-filled orbitals of the two ligands L to form three molecular 
orbitals: bonding, nonbonding and antibonding. The electron pair in the nonbonding 
45 C. Hartmann, V. Meyer, Chem. Ber. 1894, 27, 426–432. 
46  (a) Hypervalent Iodine Chemistry: Preparation, Structure and Synthetic Applications of 
Polyvalent Iodine Compounds; V. V. Zhdankin, Ed.; John Wiley & Sons: Chichester West 
Sussex, 2014; (b) Iodine Chemistry and Applications; T. Kaiho, Ed.; John Wiley & Sons: 
Hoboken, 2015. 
47 For selected reviews on hypervalent iodine(III) chemistry: (a) P. J. Stang, V. V. Zhdankin, 
Chem. Rev. 1996, 96, 1123–1178; (b) A. Varvoglis, Tetrahedron 1997, 53, 1179–1255; (c) V. V. 
Zhdankin, P. J. Stang, Chem. Rev. 2002, 102, 2523–2584; (d) V. V. Zhdankin, P. J. Stang, 
Chem. Rev. 2008, 108, 5299–5358; (e) E. A. Merritt, B. Olofsson, Angew. Chem. Int. Ed. 2009, 
48, 9052–9070. 
48 G. C. Pimentel, J. Chem. Phys. 1951, 19, 446–448. 
49 R. J. Hach, R. E. Rundle, J. Am. Chem. Soc. 1951, 73, 4321–4324. 
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molecular orbital is delocalized to the two ligands, so that this L1–I–L2 hypervalent bond is 
highly polarized and makes iodine atom partially electropositive. Hence, more electronegative 
ligands such as hydroxide, carboxylate, are more likely to occupy the apical positions. 
Depending on the different electronegativity of the ligands, the polarization of the hypervalent 











Figure 3: Molecular orbital description of the (3c-4e) bond in ArIL2. 
In 1977, Alcock and Countryman published a detailed X-ray crystal structure study of 
diphenyliodonium halides. 50  In solid state, the iodine-halogen bonds held two 
diphenyliodonium salt molecules together to form an anion-bridged dimer 27. As shown in 
Figure 4, all I–C bonds are equally long (2.09 Å), and the I…Cl bond distance (3.09 Å) is 
much longer than the regular hypervalent I–Cl bond length of PhICl2 (2.45 Å).51 Because the 
halide is more electronegative than the aryl group, the electrons in the hypervalent bond are 
mostly concentrated on the halogen atom, and the hypervalent bond in this case tends to 









X = Cl: 








Bond length I−C(sp2): 2.09 Å27  





50 N. W. Alcock, R. M. Countryman, J. Chem. Soc., Dalton Trans. 1977, 217–219. 
51 E. M. Archer, T. G. D. Van Schalkwyk, Acta Cryst. 1953, 6, 88–92. 
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1.2.2.2 Transition Metal-Catalyzed Arylations of (Hetero)Arenes 
After Crabtree employed iodobenzene diacetate (28) to accomplish palladium-catalyzed 
acetoxylation of arenes 1 in 1996,52 a variety of highly efficient and site-selective catalytic 
methods for the oxidative C–H acetoxylation or hydroxylation has been developed.53,54 
Thereafter, the transition metal-catalyzed arylations of (hetero)arenes with diaryliodonium 
salts 26 has attracted increasing attention. In 2005, Sanford published a directing 
group-assisted palladium-catalyzed direct arylation of arenes 29 (Scheme 14).55a A range of 
directing groups proved to be viable for the ortho-monophenylations. And the 
diphenyliodonium salt (26a) was regarded as the best phenylating reagent in comparison to 
PhI or PhOTf, which both failed to provide desired product 30 under the same reaction 
conditions. Notably, the addition of 500 equiv. of mercury, a potent poison for heterogeneous 
catalysis,56 did not decrease the catalyst activity, indicating this reaction to proceed more 
likely via a homogenous palladium(II)/palladium(IV) catalytic cycle rather than through a 
traditional palladium(0) nanoparticle/palladium(II) one. Furthermore, the introduction of 
radical scavengers like hydroquinone monomethyl ester (MEHQ) or free radical galvinoxyl 
did not affect the reaction progress, suggesting that the reactions proceeded without 
participation of free radical intermediates. 
52 T. Yoneyama, R. H. Crabtree, J. Mol. Catal. A 1996, 108, 35–40. 
53 (a) T. W. Lyons, M. S. Sanford, Chem. Rev. 2010, 110, 1147–1169; (b) S. Enthaler, A. 
Company, Chem. Soc. Rev. 2011, 40, 4912–4924; (c) V. S. Thirunavukkarasu, S. I. Kozhushkov, 
L. Ackermann, Chem. Commun. 2014, 50, 29–39. 
54 (a) V. S. Thirunavukkarasu, J. Hubrich, L. Ackermann, Org. Lett. 2012, 14, 4210–4213; (b) V. 
S. Thirunavukkarasu, L. Ackermann, Org. Lett. 2012, 14, 6206–6209; (c) F. Yang, L. 
Ackermann, Org. Lett. 2013, 15, 718–720; (d) W. Liu, Ackermann, Org. Lett. 2013, 15, 
3484–3486; (e) F. Yang, K. Rauch, K. Kettelhoit, L. Ackermann, Angew. Chem. Int. Ed. 2014, 
53, 11285–11288. 
55 (a) D. Kalyani, N. R. Deprez, L. V. Desai, M. S. Sanford, J. Am. Chem. Soc. 2005, 127, 
7330–7331. For selected recent communications, see: (b) L. Y. Chan, L. Cheong, S. Kim, Org. 
Lett. 2013, 15, 2186–2189; (c) T. E. Storr, M. F. Greaney, Org. Lett. 2013, 15, 1410–1413; (d) Z. 
Wu, S. Chen, C. Hu, Z. Li, H. Xiang, X. Zhou, ChemCatChem 2013, 5, 2839–2842. 
56 M. R. Eberhard, Org. Lett. 2004, 6, 2125–2128. 
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Scheme 14: palladium-catalyzed arylations with diaryliodonium tetrafluoroborates (26a). 
Based on in-depth mechanistic studies, a palladium(II)/palladium(IV) catalytic cycle was 














































Scheme 15: Proposed mechanism for C–H arylation via binuclear palladium complex 32. 
After the insertion into the C–H bond, palladium forms the monomeric palladium(II) complex 
31, which is in equilibrium with the active binuclear species 32. Subsequently, a phenyl group 
from the unsymmetrical diaryliodonium salt 26b oxidatively adds to the palladium species 32 
to form the complex 33. The following reductive elimination in 33 and the final ligand 
57 N. R. Deprez, M. S. Sanford, J. Am. Chem. Soc. 2009, 131, 11234–11241. 
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exchange with participation of 29 provided the desired product 30, thus finishing this catalytic 
cycle. Notably, the authors observed that within this pathway the diaryliodonium salt 26b 
readily and reversible reacts with the 2-phenylpyridine (29) to form a λ3-iodane compound 35 
possessing an I–N bond.58 
The same palladium(II)/palladium(IV) catalytic mechanism can be assumed for the direct 
C–H bond arylation of indoles 17 with diaryliodonium salts 26. 59 Due to the highly 
nucleophilic property of electron-rich indoles, the reactions can smoothly proceed at ambient 




 (5 mol %)
AcOH, 25 °C
15 − 24 hR2 R2
R1 R1[Ar2I]BF4
yields up to 90%
17 2026
 
Scheme 16: Palladium-catalyzed direct C2-arylation of indoles 5. 
While palladium catalysts were broadly used in the arylation of (hetero)arenes,4f,55b–e the 
value of copper catalysts, which offer an economic advantage, was rarely appreciated.60,61 
Gaunt proposed of the copper(III) as a highly electrophilic d8-configured metal, which would 
enable the C–H functionalizaitons.60a Cu(OTf)2 was combined with hypervalent iodine(III) 
compounds 26 to provide arylated indoles 20 or 24 with two kinds of site-selectivities, 
depending on the nature of the protecting groups on the indole nitrogen (Scheme 17).  
58 (a) R. Weiss, J. Seubert, Angew. Chem. Int. Ed. 1994, 33, 891–893; (b) V. V. Zhdankin, A. Y. 
Koposov, N. V. Yashin, Tetrahedron Lett. 2002, 43, 5735–5737; (c) M. Ochiai, T. Suefuji,K. 
Miyamoto, M. Shiro, Chem. Commun. 2003, 1438–1439. 
59 N. R. Deprez, D. Kalyani, A. Krause, M. S. Sanford, J. Am. Chem. Soc. 2006, 128, 4972–4973. 
60 (a) R. J. Phipps, N. P. Grimster, M. J. Gaunt, J. Am. Chem. Soc. 2008, 130, 8172–8174. For the 
selected recent communications, see: (b) N. Gigant, L. Chausset-Boissarie, M.-C. Belhomme, T. 
Poisson, X. Pannecoucke, I. Gillaizeau, Org. Lett. 2013, 15, 278–281; (c) M. Prakash, S. 
Muthusamy, V. Kesavan, J. Org. Chem. 2014, 79, 7836–7843; (d) C. Liu, W. Zhang, L.-X. Dai, 
S.-L. You, Chem. Asian J. 2014, 9, 2113–2118; (e) D. Kumar, M. Pilania, V. Arun, S. Pooniya, 
Org. Biomol. Chem. 2014, 12, 6340–6344.  
61 For the recent examples of iron-catalyzed C–H functionalizations with diaryliodonium salts, see: 
(a) B. R. Vaddula, A. Saha, J. Leazer, R. S. Varma, Green Chem. 2012, 14, 2133–2136; (b) Z. 
Shu, W. Ji, X. Wang, Y. Zhou, Y. Zhang, J. Wang, Angew. Chem. Int. Ed. 2014, 53, 2186–2189. 
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Scheme 17: Copper-catalyzed direct arylations of indoles 17. 
In terms of the reaction mechanism, the correlation between the protecting group and the 































































Scheme 18: Proposed catalytic cycles for copper-catalyzed arylations. 
As shown in Scheme 18a, in the initial step of reaction the diaryliodonium salt 26 oxidatively 
adds to Cu(OTf)2. Subsequently, the highly electrophilic aryl-copper(III) species 37 attacks 
the indole 17c at the C3 position to form the intermediate 38. If the indole nitrogen is 
protected with an alkyl group as in 5d, the intermediate 38 undergoes rearomatization and 
then reductive elimination to provide 3-arylindole 24. On the contrary, an N-acetyl group on 
the nitrogen in 40 interacts with copper(III) species and renders 1,2-migration (Scheme 18b). 
This reorganization affords the C2-regioisomer 20. 
17 
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1.2.2.3 Metal-Free Direct C–H Arylations of (Hetero)Arenes 
While the transition metal-catalyzed methods discussed above have found widespread 
applications, alternatives need to be developed taking into consideration the toxicity and costs 
of transition metals. In recent years, more efforts focused on metal-free arylations of arenes 
and heterocycles with hypervalent iodine(III) compounds like diaryliodonium salts, which are 
also of relevance for the discussion of the mechanism for the metal-catalyzed transformation.  
Inspired by the studies of Barton,62 in which the electrophilic pentavalent organobismuth(V) 
reagent Ph4BiOTs reacted with 3-methylindole 17f affording the C3-substituted indolenine 41, 
Baran employed diaryliodonium salts 26 and 2-tert-butyl-1,1,3,3-tetramethylguanidine 
(BTMG) for the synthesis of the instable indolenine 41 and the more stable indoline 42 
(Scheme 19).63 It was assumed that the reaction proceeded via electrophilic addition of the 























rt, N241 4217f 26
 
Scheme 19: Arylation of 3-methylindole (17f) with [Ar2I]BF4 (26) furnishing indolenine 41. 
In 2011, an efficient regioselective direct C3-arylation of indoles 17 in the absence of any 
transition metal and base was reported by Ackermann (Scheme 20).64 It was observed that the 
counteranions of λ3-iodanes had a remarkable influence on the arylation, with tosylate 26 
providing the best results. Notably, competition experiments demonstrated that the more 
electron-deficient aryl groups in unsymmetrical diaryliodonium salts were preferentially 
transferred to the indole substrate,65 and the more electron-rich indoles were predominantly 
62 D. H. R. Barton, J.-P. Finet, C. Giannotti, F. Halley, J. Chem. Soc., Perkin Trans. 1 1987, 
241–245. 
63 K. Eastman, P. S. Baran, Tetrahedron 2009, 65, 3149–3154. 
64 L. Ackermann, M. Dell’Acqua, S. Fenner, R. Vicente, R. Sandmann, Org. Lett. 2011, 13, 
2358–2360. 
65 J. Malmgren, S. Santoro, N. Jalalian, F. Himo, B. Olofsson, Chem. Eur. J. 2013, 19, 
10334–10342. 
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Scheme 20: Direct C3-arylation of indoles 5 as reported by Ackermann. 
In addition to the indole 17, the pyrrole 43a was also a viable substrate under this metal-free 
condition, delivering the diarylated product 44ac (Scheme 21). 
DMF
 100 °C, 22 h
Ar = 4-MeC6H4
[Mes−I−Ar]OTf+







Scheme 21: Direct arylation of pyrrole 43a. 
Later, Yu published a base-mediated C2-arylation of pyrroles 43, in which an excess of 
pyrrole was required (Scheme 22).66 The positive radical trapping tests indicated that the 
mechanism of the arylation involved the participation of an aryl radical. 
yields up to 78%











Scheme 22: Base-mediated arylations of pyrroles 43 with diaryliodonium triflates 26. 
Moreover, Chatani disclosed that the arylation of pyrroles 43b can take place even at ambient 
temperature, when the reaction was irradiated by visible light from a white light-emitting 
diode (LED) (Scheme 23).67,68 Basing on the UV-Vis spectroscopic analysis of the reaction 
mixture, Chatani proposed that a charge-transfer (CT) complex 45 was in situ generated. 
Under the LED irradiation, the CT complex 45 is activated to provide the pyrrole radical 
cation 46 and the aryl radical 47, both of which are subsequently recombined to afford the 
66 J. Wen, R.-Y. Zhang, S.-Y. Chen, J. Zhang, X.-Q. Yu, J. Org. Chem. 2012, 77, 766–771. 
67 M. Tobisu, T. Furukawa, N. Chatani, Chem. Lett. 2013, 42, 1203–1205. 
68 For selected recent communications on visible light-mediated arylations of (hetero)arenes, see: 
(a) D. Kalyani, K. B. McMurtrey, S. R. Neufeldt, M. S. Sanford, J. Am. Chem. Soc. 2011, 133, 
18566–18569; (b) D. P. Hari, P. Schroll, B. König, J. Am. Chem. Soc. 2012, 134, 2958–2961; 
(c) S. R. Neufeldt, M. S. Sanford, Adv. Synth. Cat. 2012, 354, 3517–3522; (d) Y.-X. Liu, D. Xue, 
J.-D. Wang, C.-J. Zhao, Q.-Z. Zou, C. Wang, J. Xiao, Synlett 2013, 24, 507–513. 
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cationic intermediate 48. The final deprotonation led to the product 44b. 
rt, 16 h
white LED
































Scheme 23: Visible light-mediated direct arylations of pyrroles 43b. 
Besides, Rodríguez developed a microwave-assisted base- and metal-free C–H bond arylation 
of such inactivated arenes as naphthalene (49) (Scheme 24).69a In terms of site-selectivity, 
α-arylated naphthalene 50 was found to be the major product. Moreover, based on the fact 
that the addition of a radical scavenger TEMPO inhibited the reaction entirely, a radical 
mechanism was proposed. 





2649 50  
Scheme 24: Base- and metal-free C–H arylation of naphthalene (49). 
1.2.2.4 Mechanisms for Metal-Free Arylations with Diaryliodonium Salts 
Two kinds of reaction pathways via radical or ionic mechanisms could be envisioned for 
metal-free arylations of (hetero)arenes with diaryliodonium salts.  
Investigating the TMSOTf-promoted oxidative coupling of electron-rich arene 51 with 
phenylthienyliodonium bromide (26d) (Scheme 25),70 Kita has found hexafluoroisopropanol 
69 (a) S. Castro, J. J. Fernández, R. Vicente, F. J. Fañanás, F. Rodríguez, Chem. Commun. 2012, 
48, 9089–9091. For the transition metal-free direct C–H functionalization of quinones and 
naphthoquinones with diaryliodonium salts, see: (b) D.Wang, B. Ge, L. Li, J. Shan, Y. Ding, J. 
Org. Chem. 2014, 79, 8607–8613. 
70 (a) T. Dohi, M. Ito, K. Morimoto, M. Iwata, Y. Kita, Angew. Chem. Int. Ed. 2008, 47, 
1301–1304; (b) Y. Kita, K. Morimoto, M. Ito, C. Ogawa, A. Goto, T. Dohi, J. Am. Chem. Soc. 
2009, 131, 1668–1669; (c) T. Dohi, M. Ito, N. Yamaoka, K. Morimoto, H. Fujioka, Y. Kita, 
Angew. Chem. Int. Ed. 2010, 49, 3334–3337; (d) K. Morimoto, N. Yamaoka, C. Ogawa, T. 
Nakae, H. Fujioka, T. Dohi, Y. Kita, Org. Lett. 2010, 12, 3804–3807. 
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(HFIP) as the solvent to be crucial for the reaction, because of its good stabilizing properties. 
Moreover, the radical species formed from electron-rich arene 51 was detected by ESR 
spectroscopy.70c Hence, the reaction presumably proceeded via a radical mechanism involving 
a step of single-electron-transfer (SET)71 from the charge transfer complex 52 affording 
the radical anion/radical cation pair 53. Then, the electron-rich heteroaryl group was 













































Scheme 25: SET reaction pathway for λ3-iodine(III) mediated oxidative couplings of arenes. 
On the contrary, Gaunt regarded the arylation of electron-rich arenes as a Friedel-Crafts-type 
reaction. 72  Two possible pathways may render the biaryl formation (Scheme 26). An 
electron-rich arene 55 might attack the electrophilic diphenyliodonium salt 26e to form the 
trivalent iodine 56 via ligand exchange, which is unstable and quickly decomposes to the 
biaryl 58 via ligand coupling (pathway a), or through ipso-substitution on aniline 55 with a 
phenyl group from the diphenyliodonium salt 26e (pathway b). 
71 E. C. Ashby, Acc. Chem. Res. 1988, 21, 414–421. 
72 (a) C.-L. Ciana, R. J. Phipps, J. R. Brandt, F.-M. Meyer, M. J. Gaunt, Angew. Chem. Int. Ed. 
2011, 50, 458–462; (b) H. A. Duong, R. E. Gilligan, M. L. Cooke, R. J. Phipps, M. J. Gaunt, 
Angew. Chem. Int. Ed. 2011, 50, 463–466. 
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Scheme 26: Ionic Friedel-Crafts-type mechanism. 
To gain insight into the mechanism for mono- and diarylations of 1,3-dicarbonyl compounds 
with diaryliodonium salts,73 Ochiai examined an arylation of β-keto ester enolates 61 with 
[(o-allyloxy)phenyl](phenyl)iodonium tetrafluoroborate (26f).74 If a radical mechanism was 
operative in this reaction, the hypervalent iodine(III) compound 26f would easily decompose 
to (o-allyloxy)phenyl radical (59). The latter should undergo an intramolecular radical 
cyclization affording (2,3-dihydrobenzofuran-3-yl)methyl radical (60), which further reacts 
















Scheme 27: Potential cyclization of substrate 57. 
However, as shown in Scheme 28, this reaction afforded only α-phenylated and 
α-(o-allyloxy)phenylated products 63 and 64, respectively, in a ratio of 9:1, and no evidence 
for the formation of 3-substituted dihydrobenzofuran derivative 62 was obtained. Hence, an 
73 F. M. Beringer, P. S. Forgione, M. D. Yudis, Tetrahedron 1960, 8, 49–63. 
74 (a) D.-W. Chen, M. Ochiai, J. Org. Chem. 1999, 64, 6804–6814; (b) M. Ochiai, Y. Kitagawa, 
M. Toyonari, ARKIVOC 2003, vi, 43–48. 
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Scheme 28: Arylation of 2-(methoxycarbonyl)-1-indanone. 
It should be noted that the exact mechanism for any given example depends not only on the 
nature of the hypervalent iodine(III) compounds, but also on the substrate, solvent, additive 
and reaction temperature.75 
1.3 Transition Metal-Catalyzed Synthesis of Aryl Pyrroloindolines 
Pyrroloindoline represents an important scaffold of many nitrogen-containing alkaloids.76 Its 
tricyclic moiety delivers a diverse range of possibilities for post-synthetic modifications, 
affording natural products with compelling biological activities, such as asperazine,77a 











































gliocladine C  
Figure 5: Representative naturally occurring pyrroloindolines. 
As a result, a variety of new synthetic methods were investigated to synthesize the key 
75 A. Sreenithya, R. B. Sunoj, Org. Lett. 2014, 16, 6224–6227. 
76 U. Anthoni, C. Christophersen, P. H. Nielsen, Naturally Occurring Cyclotryptophans and 
Cyclotryptamines, in Alkaloids: Chemical & Biological Perspectives; S. W. Pelletier, Ed.; 
Pergamon: Oxford, 1999, vol. 13, pp. 163 ff. 
77 (a) M. Varoglu, T. H. Corbett, F. A. Valeriote, P. Crews, J. Org. Chem. 1997, 62, 7078–7079; 
(b) R. Raju, A. M. Piggott, M. Conte, W. G. L. Aalbersberg, K. Feussner, R. J. Capon, Org. Lett. 
2009, 11, 3862–3865; (c) J.-Y. Dong, H.-P. He, Y.-M. Shen, K.-Q. Zhang, J. Nat. Prod. 2005, 
68, 1510–1513. 
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pyrroloindoline core.78 Among them, the strategy, in which an electrophile first reacts with a 
tryptophan or a tryptamine through SEAr attack followed by a subsequent iminium 














Scheme 29: Electrophilic cyclization to pyrroloindoline. 
Up to now, various electrophiles were recognized as appropriate reaction partners. Among 
them are diazoacetate for cyclopropanation/ring-opening/iminium cyclization reactions, 79 
selectfluor for fluorocyclizations,80 NBS or Br2 for bromination-cyclizations,81 aniline with 
NCS as oxidant, or o-iodoaniline with NIS as oxidant for electrophilic 
amination-cyclizations, 82 N-phenylselenophthalimide (N-PSP) for selenocyclizations, 83  
dimethyldioxirane (DMDO) for cyclizations via epoxidation/nucleophilic ring opening,84 and 
α,β-unsaturated ketones for Michael addition-cyclizations (MIRC reactions).85 
 
78 For selected reviews on this topic, see: (a) D. Crich, A. Banerjee, Acc. Chem. Res. 2007, 40, 
151–161; (b) A. Steven, L. E. Overman, Angew. Chem. Int. Ed. 2007, 46, 5488–5508; (c) J. 
Kim, M. Movassaghi, Chem. Soc. Rev. 2009, 38, 3035–3050; (d) P. Ruiz-Sanchis, S. A. Savina, 
F. Albericio, M. Álvarez, Chem. Eur. J. 2011, 17, 1388–1408; (e) L. M. Repka, S. E. Reisman, 
J. Org. Chem. 2013, 78, 12314–12320. 
79 (a) H. Song, J. Yang, W. Chen, Y. Qin, Org. Lett. 2006, 8, 6011–6014; (b) B. He, H. Song, Y. 
Du, Y. Qin, J. Org. Chem. 2009, 74, 298–304; (c) D. Zhang, H. Song, Y. Qin, Acc. Chem. Res. 
2011, 44, 447–457. 
80 N. Shibata, T. Tarui, Y. Doi, K. L. Kirk, Angew. Chem. Int. Ed. 2001, 40, 4461–4463. 
81 (a) C. S. López, C. Pérez-Balado, P. Rodríguez-Graña, A. R. De Lera, Org. Lett. 2008, 10, 
77–80; (b) P. Ventosa-Andrés, J. A. González-Vera, Á. M. Valdivielso, M. T. García-López, R. 
Herranz, Bioorg. Med. Chem. 2008, 16, 9313–9322; (c) J. Kim, M. Movassaghi, J. Am. Chem. 
Soc. 2010, 132, 14376–14378. 
82 (a) T. Newhouse, P. S. Baran, J. Am. Chem. Soc. 2008, 130, 10886–10887; (b) T. Newhouse, C. 
A. Lewis, K. J. Eastman, P. S. Baran, J. Am. Chem. Soc. 2010, 132, 7119–7137. 
83 (a) S. P. Marsden,K. M. Depew, S. J. Danishefsky, J. Am. Chem. Soc. 1994, 116, 11143–11144; 
(b) M. K. Depew, S. P. Marsden, D. Zatorska, A. Zatorski, W. G. Bornmann, S. J. Danishefsky, 
J. Am. Chem. Soc. 1999, 121, 11953–11963; (c) D. Crich, X. Huang, J. Org. Chem. 1999, 64, 
7218–7223; (d) S. V. Ley, E. Cleator, P. R. Hewitt, Org. Biomol. Chem. 2003, 1, 3492–3494; (e) 
P. R. Hewitt, E. Cleator, S. V. Ley, Org. Biomol. Chem. 2004, 2, 2415–2417. 
84 T. M. Kamenecka; S. J. Danishefsky, Angew. Chem. Int. Ed. 1998, 37, 2995–2998. 
85 (a) J. F. Austin, S.-G. Kim, C. J. Sinz, W.-J. Xiao, D. W. C. MacMillan, Proc. Natl. Acad. Sci. 
USA 2004, 101, 5482–5487; (b) Q. Cai, C. Liu, X.-W. Liang, S.-L. You, Org. Lett. 2012, 14, 
4588–4590. 
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1.3.1 Synthesis of C3-Arylated Pyrroloindolines 
Despite the great progress in the oxidative as well as in the organo- or 
transitionmetal-catalyzed cyclization, the synthesis of C3-arylpyrroloindolines has remained a 
challenging work until recently.  
In 2011, Movassaghi reported a two-step synthesis of C3-arylated pyrroloindoline 68 from the 
corresponding tryptophan derivative 65, in which a bromocyclization affording 66 occurred 
first, followed by a electrophilic substitution with an electron-rich arene 1 or a potassium 











2. Ar–H (1) or ArBF3K (69)
    AgSbF6 






































Scheme 30: Two steps-approach to C3-arylated pyrroloindolines 68. 
More recently, the aryldiazonium salt 70 was utilized to enable the synthesis of the racemic 
C3-diazenated pyrroloindoline (±)-72. This unsymmetrical azo-intermediate (±)-72 was then 
irradiated to afford the racemic C3-arylpyrroloindoline (±)-73 (Scheme 31).87 
86 (a) J. Kim, M. Movassaghi, J. Am. Chem. Soc. 2011, 133, 14940–14943; (b) N. Boyer, M. 
Movassaghi, Chem. Sci. 2012, 3, 1798–1803. 
87 D. E. Stephens, O. V. Larionov, Eur. J. Org. Chem. 2014, 3, 662–3670. 
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Scheme 31: Assembly of C3-arylated pyrroloindoline (±)-73a through diazenation and 
nitrogen extrusion by photoirradiation. 
Interestingly, the employment of a catalytic amount of a chiral phosphoric acid, such as 
(R)-STRIP 74, resulted in a highly enantioselective formation of the C3-diazenated 
intermediate and the corresponding C3-arylated product 73 with high ee values (Scheme 
32).88 This outstanding property was attributed to a chiral anion phase transfer (CAPT), in 
which the chiral phosphoric acid 74 interacted with the insoluble aryldiazonium compound to 
form a soluble chiral ion pair. 
N
H
1. (R)-STRIP (74, 5 mol %) 
    PhN2BF4 
    Na3PO4
    MTBE, 23 °C
2. hn , cyclohexane























Scheme 32: Enantioselective synthesis of C3-phenylated pyrroloindolines 73. 
Since Zen published a selective and efficient photocatalytic oxidation of sulfides in the 
presence of a ruthenium photocatalyst in 2003,89 visible light photoredox catalysis has 
experienced a renaissance in organic synthesis.90 This strategy was recently applied to the 
88 H. M. Nelson, S. H. Reisberg, H. P. Shunatona, J. S. Patel, F. D. Toste, Angew. Chem. Int. Ed. 
2014, 53, 5600–5603. 
89 J. M. Zen, S. L. Liou, A. S. Kumar, M. S. Hsia, Angew. Chem. Int. Ed. 2003, 42, 577–579. 
90 For selected reviews on visible light photoredox catalysis, see: (a) J. M. R. Narayanam, C. R. J. 
Stephenson, Chem. Soc. Rev. 2011, 40, 102–113; (b) J. Xuan, W.-J. Xiao, Angew. Chem. Int. Ed. 
2012, 51, 6828–6838; (c) Y. Xi, H. Yi, A. Lei, Org. Biomol. Chem. 2013, 11, 2387–2403; (d) D. 
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[Ru(bpy)3Cl2]-catalyzed reductive debromination of C3-bromopyrroloindolines 76 under 
irradiation with a fluorescent bulb. In the meantime, a pyrroloindoline radical 77 was first 
produced and then reacted with indole-2-carboxaldehyde (78) to form 
C3-(3-indolyl)pyrroloindoline 79 (Scheme 33).91 Employing this key step, the (+)-gliocladin 
can subsequently be synthesized in moderate yield. 
1. NBS, PPTS, DCM, 23 °C









































Scheme 33: Visible light-mediated C3-heteroarylation. 
Although the above mentioned three procedures were concise and promising, the low yields 
after two separated steps prompted chemists to seek an alternative direct reaction. In 2012, 
MacMillan reported on a copper-catalyzed arylation-cyclization cascade of indolylacetamide 
80a with diaryliodonium salts 26 in the presence of a tailor-made chiral copper-ligand 
complex 81, affording pyrroloindolones 82 with high ee values (Scheme 34).92 Compounds 
82a can simply be converted to the desired pyrroloindoline through a reduction with LiAlH4. 
P. Hari, B. König, Angew. Chem. Int. Ed. 2013, 52, 2–12. 
91 (a) J. M. R. Narayanam, J. W. Tucker, C. R. J. Stephenson, J. Am. Chem. Soc. 2009, 131, 
8756–8757; (b) L. Furst, J. M. R. Narayanam, C. R. J. Stephenson, Angew. Chem. Int. Ed. 2011, 
50, 9655–9659. 
92 S. Zhu, D. W. C. MacMillan, J. Am. Chem. Soc. 2012, 134, 10815–10818. 
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Scheme 34: Copper-catalyzed enantioselective arylation-cyclization cascade. 
At the same time, a similar copper-catalyzed reaction of tryptamine 71a was developed by 
Reisman, delivering a racemic C3-arylated pyrroloindoline (±)-73a (Scheme 
35a).93a Unfortunately, employing the chiral copper catalyst 81 used in MacMillan's reaction, 
no further improvement of enantioselectivity was observed. Alternatively, enantioselectivity 
could be achieved by transmission of the stereochemical information from the α-carbon of 
enantiomerically pure starting material to the newly formed quaternary center. Thus, the 
arylation-cyclization of diketopiperazine 65 in the presence of the copper complex 83 
provided the diastereomer 68 with a high dr value, which were subsequently employed to 

















































Scheme 35: Copper-catalyzed direct construction of C3-arylated pyrroloindolines. 
 
 
93 (a) M. E. Kieffer, K. V. Chuang, S. E. Reisman, Chem. Sci. 2012, 3, 3170–3174; (b) M. E. 
Kieffer, K. V. Chuang, S. E. Reisman, J. Am. Chem. Soc. 2013, 135, 5557–5560. 
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1.3.2 Stereoselectivity of the Pyrroloindoline Synthesis 
The problem of stereoselectivity constantly accompanies the synthesis of pyrroloindolines. 
For the reaction of substrates without any chiral center such as tryptamine 71, the 
enantioselectivity could be introduced through the utilization of a chiral organocatalyst 
(Scheme 32) or a chiral metal-ligand complex (Scheme 34). As to (L)-tryptophan derivative 
75 bearing an innate chiral center, the exo configuration is remarkably favored compared to 
the endo-form, when the electrophile and the substituent on the N- or C-terminus are sterically 
demanding.82b 
In the electrophilic addition/cyclization reaction sequence, two kinds of intermediates could 
be imagined (Scheme 36). The pre-endo ensemble 84 possesses a steric clash between the 
carboxylate functionality and the indole nuclei, leading to a kinetic instability. On the 
contrary, the pre-exo ensemble 85 is free of this kind of steric restraint and smoothly affords 














































1.4 Late-Stage Diversification of Peptides by Direct C–H Arylations 
Over decades, peptides have found a broad spectrum of applications in pharmaceutical 
industry and asymmetric catalysis. Compared to small molecular drugs, peptides have 
gradually gained more market share owing to their more diversity, selectivity and low 
toxicity.94 Moreover, peptides as competitive chiral building blocks, chiral ligands or chiral 
catalysts have been employed in the total synthesis and ligand elaboration.95 
Within the exploration of methods enabling a rapid derivatization of peptides to a panel of 
closely related analogues and streamline the synthesis, late-stage modifications have become 
a useful tool.96 Chemo- and site-selective chemical transformations of peptides have so far 
mostly relied on prefunctionalized unnatural amino acids embedded within the peptides in 
advance. These strategies can be defined as "Tag-and-Modify" approaches (Scheme 37).97 
After the preparation of Tag-containing peptides, the corresponding modification can be 
site-selectively performed via palladium-catalyzed Suzuki-Miyaura cross-coupling reactions 
(Scheme 37a, b),98 copper-catalyzed azide-alkyne [3+2] Huisgen-cycloadditions (Scheme 37c, 
d),99 or ruthenium-catalyzed olefin metathesis (Scheme 37e).100 
94 (a) F. Albericio, H. G. Kruger, Future Med. Chem. 2012, 4, 1527–1531; (b) A. A. Kaspar, J. M. 
Reichert, Drug Discovery Today 2013, 18, 807–817; (c) D. J. Craik, D. P. Fairlie, S. Liras, D. 
Price, Chem. Biol. Drug Des. 2013, 81, 136–147. 
95 (a) E. A. C. Davie, S. M. Mennen, Y. Xu, S. J. Miller, Chem. Rev. 2007, 107, 5759–5812; (b) H. 
Wennemers, Chem. Commun. 2011, 47, 12036–12041. 
96 (a) J. Wencel-Delord, F. Glorius, Nature Chem. 2013, 5, 369–375; (b) A. F. M. Noisier, M. A. 
Brimble, Chem. Rev. 2014, 114, 8775–8806. 
97 J. M. Chalker, G. J. L. Bernardes, B. G. Davis, Acc. Chem. Res. 2011, 44, 730–741. 
98 (a) E. Brustad, M. L. Bushey, J. W. Lee, D. Groff, W. Liu, P. G. Schultz, Angew. Chem. Int. Ed. 
2008, 47, 8220–8223; (b) Z. Gao, V. Gouverneur, B. G. Davis, J. Am. Chem. Soc. 2013, 135, 
13612–13615. 
99 (a) C. W. Tornøe, C. Christensen, M. Meldal, J. Org. Chem. 2002, 67, 3057–3064; (b) Q. 
Wang, T. R. Chan, R. Hilgraf, V. V. Fokin, K. B. Sharpless, M. G. Finn, J. Am. Chem. Soc. 
2003, 125, 3192–3193; (c) S. I. van Kasteren, H. B. Kramer, H. H. Jensen, S. J. Campbell, J. 
Kirkpatrick, N. J. Oldham, D. C. Anthony, B. G. Davis, Nature 2007, 446, 105–1109. 
100 Y. A. Lin, J. M. Chalker, B. G. Davis, ChemBioChem 2009, 10, 959–969. 
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Scheme 37: The “Tag-and-Modify” approach to peptide modification. 
In addition, an alternative strategy could be adopted by exploiting ubiquitous C(sp2)–H bonds 
as a latent functional group and an ideal point of diversification.101 
Among native α-amino acids, tryptophan possesses a heteroaromatic side chain, which is a 
favorable fluorescent probe with a relatively high fluorescence quantum yield.102a Because of 
its large dipole moment of the excited state, the spectroscopic properties are highly sensitive 
to the specific conditions.102b By changing its surroundings, the fluorescence quantum yield 
and emission maximum vary significantly. Furthermore, tryptophan is found in relatively low 
abundance in proteins or peptides. These properties render tryptophan widely exploited for 
protein quantifications and explorations of protein dynamics, folding, binding and 
protein-protein interactions. 103  Hence, these appealing advantages of tryptophan have 
prompted chemists to seek general and site-selective chemical methods to modify and 
intensify the tryptophan's fluorescence. 
Based on a number of transition metal-catalyzed direct C–H arylations of simple indoles with 
excellent regioselectivities (see Chapter 1.2), similar strategies were applied to the 
101 J. Yamaguchi, A. D. Yamaguchi, K. Itami, Angew. Chem. Int. Ed. 2012, 51, 8960–9009. 
102 (a) J. A. Ross, D. M. Jameson, Photochem. Photobiol. Sci. 2008, 7, 1301–1312; (b) D. W. 
Pierce, S. G. Boxer, Biophys J. 1995, 68, 1583–1591. 
103 R. W. Sinkeldam, N. J. Greco, Y. Tor, Chem. Rev. 2010, 110, 2579–2619. 
31 
                                                 
Introduction 
tryptophan-containing peptides to provide biaryl moieties. 
Following Larrosa's reaction conditions, Lavilla developed a microwave-assisted direct C–H 
arylation of tryptophan-containing peptides 87 with a 10-fold excess of aryl iodide 3 in a 
phosphate buffer (pH = 6.0) at 80 °C, which afforded the arylated peptide 88 with 68% 
conversion (Scheme 38). 104a This approach displayed a high regioselectivity and good 
tolerance to other unprotected amino acid moieties, such as phenylalanine, tyrosine, arginine, 
histidine, lysine, serine, glutamine. The position of the tryptophan within the peptide 
sequence has no impact on the efficiency of this chemical transformation. More importantly, 
chiral HPLC studies indicated that no racemization occurred during the reaction, which makes 
the arylation reaction more attractive. Later, Lavilla found an alternative method to obtain 
modified peptides through the initial arylation of Fmoc-protected tryptophan and subsequent 
solid phase-supported peptide synthesis.104b 
Pd(OAc)2 (5 mol %)
AgBF4 (1.0 equiv)
2-NO2-C6H4CO2H (1.5 equiv)
PhI (3, 10.0 equiv)
phosphate buffer (pH 6.0)
















Scheme 38: Palladium-catalyzed arylation of tryptophan-containing peptides 87 with aryl 
iodides 3. 
Phenylboronic acid (90) could be an alternative arylating reagent to modify the 
tryptophan-containing hexapeptide 89 in the presence of Cu(OAc)2 and O2 as oxidants, 
delivering the product with 86% conversion, albeit with high loading of palladium catalyst 
and copper oxidant (Scheme 39). 105 Interestingly, Fairlamb observed and verified that 
Palladium0 nanoparticles (PdNPs) were formed in situ in the early stages of the reaction, and 
the pre-synthesized encapsulated PdNPs catalyzed the transformation of tryptophan as well. 
Therefore, Fairlamb assumed heterogeneous catalysis with a palladium(0)/palladium(II) 
catalytic cycle for the reactions.The active palladium(0) species is generated by the reduction 
104 (a) J. Ruiz-Rodríguez, F. Albericio, R. Lavilla, Chem. Eur. J. 2010, 16, 1124–1127; (b) S. 
Preciado, L. Mendive-Tapia, F. Albericio, R. Lavilla, J. Org. Chem. 2013, 78, 8129–8135. 
105 T. J. Williams, A. J. Reay, A. C. Whitwood, I. J. S. Fairlamb, Chem. Commun. 2014, 50, 
3052–3054. 
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of the precatalyst Pd(OAc)2. The palladium(0)/palladium(II) reduction potential can be 
lowered by the coordination of two acetamide moieties within peptides to Pd(OAc)2. 
Pd(OAc)2 (30 mol %)
Cu(OAc)2 (60 mol %)
AcOH, air




















Scheme 39: Palladium-catalyzed arylation of peptide 89 with phenylboronic acid (90). 
Despite the increasing pharmaceutical values of peptides, there are still some negative factors 
limiting their advance, such as poor pharmacokinetic properties. One possible method to 
overcome this hurdle is to generate more stable macrocyclic peptides mimicking the structure 
of peptides.106 For this purpose, James synthesized a series of linear peptides 92 containing a 
tryptophan at the C-terminus and a para-/meta-iodinated phenylalanine at the N-terminus. 
The subsequent palladium-catalyzed C–H bond arylation of tryptophans accomplished the 
intramolecular cyclization, providing 15- to 25-membered peptide rings 93 (Scheme 40).107 




























92 93  
Scheme 40: Peptide macrocyclization via palladium-catalyzed C–H arylations of tryptophans. 
 
106 E. M. Driggers, S. P. Hale, J. J. Lee, N. K. Terrett, Nat. Rev. Drug Discovery 2008, 7, 
608–624. 
107  H. Dong, C. Limberakis, S. Liras, S. Price, K. James, Chem. Commun. 2012, 48, 
11644–11646. 
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2 Objectives 
Due to the importance of the highly functionalized N-heterocycles, the development of 
sustainable strategies for their syntheses have sustained required. Ongoing researches by the 
group of Prof. Ackermann and others showed that the transition metal-catalyzed C–H 
functionalization is a powerful synthetic tool to meet this challenge. Besides, metal-free 
methodologies have also attracted high attentions, with which the employment of toxic 
transition metals could be avoided. The works presented within this thesis are focused on the 
efficient synthesis of heterocyclic molecules in the presence or absence of the transition 
metals.  
In light of the demand for a convenient synthesis of unsymmetrical acetylenes 9, several 
successful preparations were recently achieved by Piguel via copper-catalyzed direct 
alkynylations of heteroarenes with bromoacetylenes 622 or gem-dibromoalkenes 10. The 
utilization of more economical but less reactive gem-dichloroalkenes 94, however, remained a 
challenging work. On the basis of optimized reaction conditions by Kornhaaß,108 which 
involved a palladium catalyst combined with a DPE-Phos ligand, the first project presented 
within this thesis was the extension of the scope of oxazoles 8 and gem-dichloroalkenes 94 
(Scheme 41). 
 
Scheme 41: Palladium-catalyzed alkynylation of oxazoles 8 with gem-dichloroalkenes 94. 
The C2-arylated indole is a ubiquitous moiety in natural products and synthetic 
molecules.29 Besides the common well-known traditional methods,32 the recently developed 
methodologies employ C–H arylations in the presence of transition metal catalysts, such as 
palladium or copper. On the basis of the ongoing research directed towards the convenient 
and efficient C–H functionalization of (hetero)arenes, a metal-free direct arylation of indoles 
108 C. Kornhaaß, Dissertation, Universität Göttingen, 2014. 
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with symmetrical diaryliodonium tosylates 26, occurring regioselectively at the C3 position of 
the indoles 17, was reported by the group of Ackermann (Scheme 20). Thereafter, we were 
interested in developing direct C2-arylations of indoles 95 with a directing group at the 
C3-position in the absence of any transition metal catalyst (Scheme 42). Moreover, 
mechanistic studies should be carried out to gain deeper insight into the working mode of 

















Scheme 42: Metal-free C2-arylation of indoles 95 with hypervalent λ3-iodanes 26. 
For the arylation-cyclization cascade reaction of tryptamine-derived substrates 97 with 
diaryliodonium salts 26, a transition metal catalyst is generally necessary. Taking into account 
the success in the metal-free C2 arylations of 2-substituted indoles 95, the metal-free 
synthesis of C3-arylated pyrroloindolones 98 utilizing the diaryliodonium salts 26 should also 
be feasible (Scheme 43).  
 
Scheme 43: Metal-free arylation-cyclization cascade reactions. 
With regard to the attractive potential of the direct regioselective labeling of bioactive 
peptides or proteins and the biological understanding as well as the targeted medical imaging, 
a variety of late-stage functionalizations of peptides or proteins were discovered over last 
decades.96–107 Based on the above developed strategy for the metal-free arylation of simple 

















Scheme 44: Metal-free late-stage arylation of peptide-containing indolylacetamides 99. 
The amino acid tryptophan is an ideal target for chemical modifications, due to its inherent 
indole moiety and distinct spectroscopic properties. Lavilla and Fairlamb successively 
developed two methods to achieve transition metal-catalyzed arylation of 
tryptophan-containing peptides. In order to maintain the high reactivities, however, a high 
amount of the catalyst loading and the arylating agent as well as an elevated reaction 
temperature were required. Hence, diaryliodonium salts 26 as highly electrophilic arylating 
reagents should be employed with a purpose to make reactions more efficient and to perform 
mild late-stage arylations of tryptophan-containing peptides 101 at ambient reaction 


















Scheme 45: Transition metal-catalyzed arylation of tryptophan-containing peptides 101. 
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3 Results and Discussion 
3.1 Palladium-Catalyzed C–H Alkynylations of Oxazoles 
Due to versatile applications of the acetylene moiety in organic chemistry, chemical biology 
and materials sciences,109 a variety of powerful and convenient approaches for the synthesis 
of unsymmetrical acetylenes was developed over the past decades.110 
Since Zapata employed gem-dibromoalkenes 10 to synthesize enynes via the Stille reactions 
with 1-propenyltributyltin in the presence of palladium and copper catalysts for the first 
time,111 gem-dihaloalkenes have been used to accomplish direct alkynylations of unreactive 
arenes. Meanwhile, because gem-dihaloalkenes can readily be synthesized from aldehydes by 
dihalomethylenations, 112  the present strategy has opened a general and convenient 
transformation of aldehydes to unsymmetrical alkynes.  
While direct alkynylations of oxazoles 8 with bromoacetylenes 6 or gem-dibromoalkenes 10 
smoothly proceeded in moderate to good yields, the utilization of more economical but less 
reactive gem-dichloroalkenes 94 remains a challenging task. Within the program on 
streamlining of organic synthesis through sustainable metal-catalyzed direct C–H bond 
functionalizations, the gem-dichloroalkene's 94 reactivity was explored in our group.  
After the optimization of reaction conditions by Kornhaaß, the desired C2-alkynylated 
benzoxazole 9aa was afforded in the presence of Pd(OAc)2, DPEPhos and LiOtBu in good 
yield (Scheme 46). Notably, the catalyst CuBr·SMe2, which was utilized in Piguel's work, 
proved to be inefficient for the alkynylation reaction with the challenging gem-dichloroalkene 
94a. 
With these optimized conditions in hand, we set out to explore the alkynylation of 
5-heteroaryloxazoles 8b–d.  
109 (a) I.-T. Trotuş, T. Zimmermann, F. Schüth, Chem. Rev. 2014, 114, 1761–1782; (b) Y. 
Yamamoto, Chem. Soc. Rev. 2014, 43, 1575–1600; (c) R. Chinchilla, C. Nájera, Chem. Rev. 
2014, 114, 1783–1826. 
110 (a) E.-I. Negishi, L. Anastasia, Chem. Rev. 2003, 103, 1979–2017; (e) A. Orita, J. Otera, 
Chem. Rev. 2006, 106, 5387–5412. 
111 A. J. Zapata, J. Ruíz, J. Organomet. Chem. 1994, 479, C6–C8. 
112 (a) F. Ramirez, N. B. Desai, N. McKelvie, J. Am. Chem. Soc. 1962, 84, 1745–1747; (b) E. J. 
Corey, P. L. Fuchs, Tetrahedron Lett. 1972, 13, 3769–3772. 
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Cl
Pd(OAc)2    (5.0 mol %)
DPEPhos   (6.0 mol %)
LiOtBu        (5.0 equiv)
1,4-dioxane











Scheme 46: Optimized reaction conditions for direct alkynylations of benzoxazole 8a with 
gem-dichloroalkene 94a. 
3.1.1 Scope of Alkynylations of Oxazoles 
As shown in Table 1, reactions of 5-(pyridin-2-yl)oxazole (8b) with gem-dichloroalkenes 94 
bearing phenyl 94b, naphthalene-1-yl 94a or even tricyclic anthracen-9-yl 94c substituents 
smoothly proceeded affording 9ba–bc in moderate to good yields (entries 1–3). Sterically 
congested ortho-substituted arene moieties in gem-dichloroalkenes turned out to be well 
tolerated in these transformations. ortho-Tolyl-9d and mesityl-substituted 9be alkynes were 
obtained in 70% and 67% yield, respectively. However, electron-donating substituents at the 
para-position, such as methyl 94f and methoxy 94g, led to relatively low yields. As to 
electron-withdrawing substituents, halides afforded satisfactory results (entries 8–10), but 
substrates 94k or 94l with a trifluoromethyl and a nitro group, respectively, were not able to 
undergo the alkynylation reactions (entries 11 and 12). 









Pd(OAc)2   (5.0 mol %)
DPEPhos  (6.0 mol %)
LiOtBu       (5.0 equiv)
1,4-dioxane





Entry gem-Dichloroalkene Product Yield [%] 
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[a] Reaction conditions: 8b (0.50 mmol), 94 (0.75 mmol), Pd(OAc)2 (5.0 mol %), DPEPhos 
(6.0 mol %), LiOtBu (2.50 mmol), 1,4-dioxane (2.0 mL), 120 °C, 14 h; yield of the isolated 
product. 
Oxazoles 8 without a pyridyl substituent, but with other heteroaryl groups (Table 19), such as 
furyl (entries 1, 3, 5) or thienyl groups (entries 2, 4, 6, 7) appeared to be good candidates for 
the direct alkynylations. Notably, among aryl groups in gem-dichloroalkenes 94, compound 
94a with a naphthyl group always showed a comparably high reactivity (entries 3 and 4). 
Interestingly, this approach was also compatible with 2-(2,2-dichlorovinyl)thiophene (94m), 
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8c: Z = O




Pd(OAc)2   (5.0 mol %)
DPEPhos  (6.0 mol %)
LiOtBu       (5.0 equiv)
1,4-dioxane
120 °C, 14 h
 
Entry gem-Dichloroalkene Product Yield [%] 



























































[a] Reaction conditions: 8 (0.50 mmol), 94 (0.75 mmol), Pd(OAc)2 (5.0 mol %), DPEPhos 




Results and Discussion 
3.1.2 Proposed Catalytic Cycle 
Analogously to the mechanism proposed by Piguel, two possible reaction pathways could be 
envisioned (Scheme 6). Since Piguel did not observe the potential intermediate 
alkenyloxazole 14, she considered the one by initial formation of alkynyl bromides 6 by 
dehydrobromination to be most reasonable (Scheme 6, path B). However, under our reaction 
conditions, the intermediate alkenyloxazole 106 was clearly detected in GC/MS, and this 
indicated that another pathway seemed to be more likely involved. Thereby, the alternative 
catalytic cycle for the palladium-catalyzed C–H alkynylation with the gem-dichloroalkene 94 
is proposed (Scheme 47). The presence of two geminal chlorine atoms in the 
gem-dichloroalkene 94 renders the alkene reactive towards oxidative addition to palladium(0) 
complex 103. After the C–H metalation,113 oxazole replaces the chloride via ligand-exchange 
to give the palladium(II) species 105. A subsequent reductive elimination leads to the 
intermediate 106 and regenerates the catalytically active palladium(0) complex 103. The final 







































Scheme 47: Mechanistic proposal for palladium-catalyzed C–H alkynylations of oxazoles 8.
113 (a) B. Liégault, I. Petrov, S. I. Gorelsky, K. Fagnou, J. Org. Chem. 2010, 75, 1047–1060; (b) 
L. Théveau, C. Verrier, P. Lassalas, T. Martin, G. Dupas, O. Querolle, L. V. Hijfte, F. Marsais, 
C. Hoarau, Chem. Eur. J. 2011, 17, 14450–14463. 
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3.2 Metal-Free Direct Arylations of Indoles with Diaryliodonium Salts 
Significant progress was accomplished in transition metal-catalyzed direct arylations of 
indoles utilizing diaryliodonium salts 26 as arylating reagents. Moreover, some efforts were 
recently made to elaborate efficient direct arylations of electron-rich nitrogen heterocycles in 
the absence of transition metal catalysts.63–66 
Over the past decade, Ackermann's group devoted much effort to develop the novel indole 
syntheses via intermolecular annulation or palladium-catalyzed direct arylation. More 
recently, a convenient metal-free C3-arylation of indoles 17 with diaryliodonium tosylates 26 
was established. In this work, the authors observed that in several cases a small amount of 
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Solvent    24cg (Yield [%])    20cg (Yield [%])
 
Table 3: Regioselectivity of metal-free direct arylations. 
Hence, it was considered whether the C2-arylation of indoles can be promoted with the 
assistance of a directing group at the C3 position of the substrates. With this in mind, we set 
out to develop a metal-free carboxamide-directed C2-arylation of indoles 95 with 
diaryliodonium salts 26. 
3.2.1 Optimization Studies 
At the outset of our studies, we chose carboxamide as the directing group and treated 
2-(1-methyl-1H-indol-3-yl)acetamide (95a) with [Ph2I]OTs (26h) (Table 4). The reaction was 
highly dependent on the reaction temperature (entries 1–6). We were pleased to discover that 
the C2-arylated indole 96ah was provided in 90% yield at a reaction temperature of 100 °C 
(entry 4). Subsequently, a range of counteranions in diphenyliodonium salts was explored. 
While the counteranions triflate and tetrafluoroborate afforded 2-phenylindole 96ah in 
moderate yields (entries 7 and 8), the relatively more basic trifluoroacetate as the 
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counteranion provided only traces of the product 96ah (entry 9). After probing several 
solvents, DMF was found to be optimal for arylations (entries 10 and 11). Further increasing 
of the amount of diphenyliodonium tosylates (26h) raised the reaction yield to 96% (entry 
13). 





















Entry X Solvent Temp. [°C] Yield [%] 
1 OTs DMF 23 0 
2 OTs DMF 40 18[b] 
3 OTs DMF 60 25[b] 
4 OTs DMF 80 70 
5 OTs DMF 100 90 
6 OTs DMF 120 75 
7 OTf DMF 100 70 
8 BF4 DMF 100 71 
9 TFA DMF 100 11[b] 
10 OTs DCE 100 78 
11 OTs toluene 100 71 
12[c] OTs DMF 100 95 
13[d] OTs DMF 100 96 
[a] Reaction conditions: 95a (0.50 mmol), 26 (0.55 mmol), solvent (2.0 mL), 17 h, yield of 
isolated product. [b] GC conversion. [c] 26 (0.65 mmol). [d] 26 (0.75 mmol).  
3.2.2 Effect of C3-Substitutents on C2-Arylations of Indoles 
Furthermore, the effect of the substituents at the C3 position on the C2-arylations of indoles 
95 was examined (Table 5). While the indolylacetamide 95c was efficiently converted to the 
desired C2-arylated product 96ch, the homologues 95b or 95d displayed a significantly 
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reduced reactivity. A comparable observation was made with the corresponding ester 95e or 
simple the 3-methyl derivative 95f, thereby highlighting a considerable assistance exerted by 
the amide functionality. 
































n = 2: 96bh 
n = 1: 96ch 































[a] Reaction conditions: 95 (0.50 mmol), 26h (0.75 mmol), DMF (2.0 mL), 100 °C, 17 h; 
yield of isolated product.  
3.2.3 Scope of Metal-Free C–H Arylations of Indolylacetamides 
With the optimized reaction conditions in hand, we examined the scope of the diaryliodonium 
tosylates 26 (Table 6). Both electron-rich and electron-deficient arenes were found to be 
suitable coupling partners for this reaction (entries 1–5). In particular, halogen-containing 
motifs were well tolerated, which provided the potential for further cross-coupling 
transformations. The steric hindrances caused by an ortho-methyl group in tosylate 26m 
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reduced the yield of 96am to 63% (entry 6), and the additional steric obstacles in more bulky 
arylating reagent 26n suppressed the reaction completely (entry 7). Notably, this arylation 
protocol was also compatible with the heteroaromatic dithienyliodonium tosylate (26o) (entry 
8). 
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[a] Reaction conditions: 95a (0.50 mmol), 26 (0.75 mmol), DMF (2.0 mL), 100 °C, 17 h; 
yield of the isolated product. 
We next turned our attention to the introduction of diverse substituents onto the indole core 
(Table 7). Initial examinations of substitutions on the benzene ring of the indole motif 
demonstrated that the electron-donating groups were beneficial for the C2-arylation. 
Electron-withdrawing substituents decreased the yield of 96gh and 96hh (entries 1 and 2). In 
contrast, methyl and methoxyl groups facilitated the C–H functionalization (entries 3 and 4). 
With respect to the alkyl groups on the indole nitrogen, the N-benzyl-, N-butyl- and 
N-octylindole-3-acetamides 95k–m delivered the 2-arylindole 96kh–mh in good to excellent 
yields (entries 5–7). The 1-tosylindole 95n was completely inert under the reaction condition 
(entry 8), thus indicating the importance of the high electron density in the indole ring. 
Furthermore, the examination of substituents in the directing group revealed that the primary, 
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secondary and tertiary acetamides 95o–q enabled the C2-arylation in moderate to excellent 
yields (entries 9–11). Notably, when a pyridinyl group was embedded into a potential 
bidentate directing group, no desired product was observed (entry 12). 
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[a] Reaction conditions: 95 (0.50 mmol), 26h (0.75 mmol), DMF (2.0 mL), 100 °C, 17 h; 
yield of the isolated product. 
According to these results, it can be estimated that the high reactivity towards arylation was 
crucially dependent on four factors, namely the reaction temperature, the assistance of an 
acetamide functionality, the electronic nature of the indole and the steric hindrance of the 
arylating reagent. 
3.2.4 Mechanistic Studies 
3.2.4.1 Reactions with Radical Inhibitors and Radical Clock 
In consideration of the unique selectivity and the outstanding efficacy of our metal-free 
arylation, we became interested in delineating its mode of action. In order to examine the 
possibility of a radical mechanism, radical inhibition tests were carried out utilizing the 
2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) 114  and 2,6-di-tert-butyl-4-methylphenol 
(BHT),115 both of which are well known to be effective radical scavengers. A reaction in the 
presence of the former smoothly afforded the C2-arylated product 96ah in 56% yield, along 
with 34% of the reisolated starting material 95a (Scheme 48). Furthermore, BHT actually 
114 (a) P. S. Fier, J. F. Hartwig, J. Am. Chem. Soc. 2012, 134, 10795–10798; (b) X. Wang, Y. Xu, 
F. Mo, G. Ji, D. Qiu, J. Feng, Y. Ye, S. Zhang, Y. Zhang, J. Wang, J. Am. Chem. Soc. 2013, 135, 
10330–10333. 
115 S. H. Cho, J. Yoon, S. Chang, J. Am. Chem. Soc. 2011, 133, 5996–6005. 
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displayed no negative effect on the reaction course. These findings indicated that a SET-type 




















1.5 equiv TEMPO:                     53         34 
1.5 equiv BHT:                           96           0
Radical scavenger     Yield of 96ah      95a [%]
 
Scheme 48: Effects of radical inhibitors on the reaction efficiency. 
Moreover, additional data obtained by utilizing a "radical clock" test were also indicative of 
the absence of a radical mechanism. An unsymmetrical diaryliodonium tosylate 26p 
containing an O-allyl moiety as a potential radical clock precursor74,116 was employed for 
arylation of indolylacetamide 95s. If the reaction proceeded via a radical pathway, the 
intermediate (2,3-dihydrobenzofuran-3-yl)-methyl radical (60) may react with the 






















Scheme 49: Possible byproduct of arylation with λ3-iodane 26p via radical reaction pathway. 
Indeed, no corresponding byproduct 107 was formed, as determined by 1H NMR of the crude 
reaction mixture after completion of the reaction. On the contrary, the usual C2-arylated 
indole 96sp was obtained in 14% yield (Scheme 50). Another part of 26p decomposed, 
thereby furnishing o-(allyloxy)iodobenzene (109) and tosyloxymesitylene (110).117 
116 I. Sokolovs, D. Lubriks, E. Suna, J. Am. Chem. Soc. 2014, 136, 6920–6928. 
117 A mixture of 109 and 110 was isolated in 30% yield after flash chromatography; the ratio of 
the products was estimated by GC to be 1:1. 
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Scheme 50: Arylation with the potential radical clock precursor 26p. 
3.2.4.2 Probing α-Substituted Indolylacetamides 
Koser's118 or Quideau's119 studies demonstrated that a ligand exchange step, namely replacing 
the counteranion with the enolate fragment, took place in a phenylation reaction of a 
α-carbonyl compound with a hypervalent iodine (III) salt. Hence, α-substituted 
indolylacetamides were synthesized to get insight into the feasibility of a SN2-type 
replacement of a tosylate anion in the diphenyliodonium tosylate (26h) by the enol moiety of 





















Scheme 51: Possible coordination of enol 95a' to the diaryliodonium salt 26h. 
As shown in Scheme 52, the yields of arylated indoles 96 decreased dramatically along with 
the consecutive incorporation of methyl groups at the α-position of the acetamide. However, 
the arylated product from α,α-dimethyl-indolylacetamide 95u was still provided in 20% yield, 
which renders a substitution by an enol less likely to be operative. 
118 K. Chen, G. F. Koser, J. Org. Chem. 1991, 56, 5764–5767. 
119 A. Ozanne-Beaudenon, S. Quideau, Angew. Chem. Int. Ed. 2005, 44, 7065–7069. 
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95t:   53%
96uh: 20%
95u:   70%  
Scheme 52: Arylation of α-substituted indolylacetamides 95a,t,u. 
3.2.4.3 H/D Exchange Study 
The arylation reaction of deuterated indolylacetamide [D]3-95a in twofold excess with 
[Ph2I]OTs (26h) in DMF afforded starting material [D]n-95a as well as the product [D]2-96aa 
(Scheme 53). Isolation of the former compound revealed a reversible H/D-exchange reaction 
at the C2 position of the indole moiety. Meanwhile, the retention of deuterium at the 
α-position in both [D]n-95a and [D]2-96ah indicated that a keto-enol-tautomerism did not 
occur during the course of the reaction, and thus disproved a mechanism with initial 



































Scheme 53: H/D exchange study. 
3.2.4.4 Kinetic Isotope Effect 
The intermolecular competition experiment between substrates 95a and [D]3-95a indicated a 
rather low kinetic isotope effect (KIE) of kH/kD ≈ 1.22 (Scheme 54). This finding highlighted 
that the cleavage of the C–H bond was not involved in the rate-limiting step.  
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Scheme 54: KIE study of arylation reaction with substrates 95a and [D]3-95a. 
3.2.4.5 Proposed Mechanism 
Based on the mechanistic studies, a directing group-assisted SEAr-type mechanism was 
proposed to account for the site-selective metal-free direct arylation of indolylacetamide with 

































[Ph2I]  +  OTs
 
Scheme 55: Proposed mechanism. 
Initially, a thermally induced dissociation of the hypervalent iodine(III) salt 26 likely takes 
place, providing an electrophilic diaryliodonium cation and a counteranion. Thereafter, the 
diaryliodonium cation is attacked by the C3 position of indole 95 to form iminium tosylate 
112. Because of the steric hindrance stemming from the C3-substituent as well as of the 
temporary loss of aromaticity, the intermediate 112 would reversibly be converted back to the 
starting materials. Meanwhile, this steric effect forces the intermediate 112 to undergo an 
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acetamide moiety-assisted C3→C2 migration of the diphenyliodinyl substituent, affording the 
intermediate 113. After the abstraction of a proton by the tosylate, an instable 
tris(hetero)aryliodane species 114 is formed, which decomposes to the final product 96 via a 
reductive elimination. 
The 1,2-migration step of the λ3-iodane is supported by the experimental data published from 
other groups. Based on kinetic studies for the C2-azo-coupling reaction of 3-methylindole 
with p-nitrobenzenediazonium tetrafluoroborate, which is also an excellent electrophile. 
Jackson postulated an initial addition of the electrophile at the C3-position of 3-methylindole 
with subsequent migration to the C2 atom.120 More recently, Lera's computational studies 
demonstrated the migratory pathway in the construction of hexahydropyrrolo[2,3-b]indoles 
via the phenylselenation-cyclization cascade reaction of tryptophans.121 
  
120 A. H. Jackson, P. P. Lynch, J. Chem. Soc. Perkin Trans. 2 1987, 12, 1483–1487. 
121 C. S. López, C. Pérez-Balado, P. Rodríguez-Graña, Á. R. de Lera, Org. Lett. 2008, 10, 77–80. 
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3.3 Metal-Free Synthesis of Aryl Pyrroloindolines 
Our previous studies (Chapter 3.2.4) indicated that the diphenyliodonium salt 26 as the 
reactive electrophile should undergo the functionalization at the C3 position of 
indolylacetamide 95 affording the iminium salt 112, the diphenyliodinyl(III) substituent of 
which could migrate from C3 to C2 (Scheme 55). According to this mechanism, it can be 
assumed that a substitution at the C2 position of indole could prevent such a C3→C2 
migration in the iminium intermediate 115, as outlined in Scheme 56. After the formation of 
the trivalent iodine intermediate 115, the amide functionality should attack the iminium ion 
within an intramolecular cyclization. The final reductive elimination should afford the 
cyclization product pyrroloindolone 98. Given the architectural constraint of the intermediate 
116, it can be expected that the functional group R2 in the final product 98 should be 




































Scheme 56: Proposed reaction pathway of the arylation-cyclization cascade. 
Finally, the pyrroloindolone 98 can easily be converted to the pyrroloindoline 117 through a 


















Scheme 57: Reduction of pyrroloindolone 98 to pyrroloindoline 117. 
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3.3.1 Optimization Studies 
The feasibility of the proposed arylation-cyclization cascade was examined by testing 
reactions of indolylacetamide 97a with diphenyliodonium tosylate 26h at different reaction 
temperatures and in various solvents. As shown in Table 8, the temperature of 100 °C was 
revealed to be optimal for this metal-free arylation-cyclization cascade reaction (entries 1–4). 
Further experiments (entries 3, 5–8) indicated DMF as the optimal reaction solvent, in which 
the desired product 98ah was obtained in 89% yield (entry 3). 

















26h 98ah  
Entry Solvent Temp. (°C) Yield [%] 
1 DMF 23 0 
2 DMF 80 55 
3 DMF 100 89 
4 DMF 120 79 
5 DCE 100 32 
6 1,4-dioxane 100 42 
7 toluene 100 55 
8 NMP 100 73 
[a] Reaction conditions: 97a (0.50 mmol), 26h (0.75 mmol), solvent (2.0 mL), 17 h; yield of 
the isolated product. 
3.3.2 Scope and Limitations 
Under the optimized reaction conditions, a broad range of diaryliodonium salts 26 was tested 
and exhibited satisfactory to very good results (Table 9). Thus, the electrophilicity of the 
arylating agent 26 appeared to exert only a minimal influence on the cyclization-arylation 
cascade reaction. Iodonium salts with both electron-rich and electron-deficient aryl groups 
afforded pyrroloindolones 98 in good yields (entries 1–5). 
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[a] Reaction conditions: 97a (0.50 mmol), 26 (0.75 mmol), DMF (2.0 mL), 17 h; yield of the 
isolated product. 
Subsequently, different substituent patterns in the acetamide functionality were examined 
(Table 10). The arylation-cyclization cascade involving either a monoalkylated or a primary 
acetamide proceeded with good yields of the desired products (entries 1–3). On the contrary, 
N-phenylacetamide 97e afforded product 98eh in only 53% yield, presumably due to the 
lower nucleophilicity of the acetamide nitrogen atom (entry 4). 
Generally, alkyl substituents on the nitrogen atom of the indole core exerted no influence on 
the synthesis of pyrroloindolones 98 (entries 5 and 6). The benzyl group, however, appeared 
to be less suitable for the reaction, what could presumably be attributed to its de steric effect 
(entry 7). Meanwhile, it was also found that the metal-free arylation-cyclization cascade was 
not restricted to the N-protected substrate, but also could be applied to the free 
(NH)-indolylacetamide 97i (entry 8). 
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[a] Reaction conditions: 97 (0.50 mmol), 26h (0.75 mmol), DMF (2.0 mL), 17 h; yield of the 
isolated product. 
As the next important step, the methyl group at the C2 position was replaced by other 
substituents (Table 11). n-Butyl-, phenylethyl-, cyclopropylmethyl- or 4-ethoxy- 
4-oxobutan-1-yl groups were well tolerated with this reaction protocol (entries 1–5). The 
reaction of (2-phenyl-1H-indol-3-yl)acetamide (96sh), which was obtained by metal-free 
C2-arylation of the corresponding indolylacetamide 95s (Chapter 3.2), did not provide the 
desired product 98oh (entry 6). This result is consistent with those obtained in arylation 
reactions of indolylacetamides 95 with diaryliodonium salts 26, in which only the C2-arylated 
products 96 were obtained (Table 4), whereas the products of their further transformation 
were not isolated. 
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[a] Reaction conditions: 97 (0.50 mmol), 26h (0.75 mmol), DMF (2.0 mL), 17 h; yield of the 
isolated product. 
The 2D-NOESY spectrum of the pyrroloindolone 98dh, as shown in Scheme 58, 
demonstrated that it existed an interaction between the methyl group (marked with the 
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number 11) and the phenyl group (marked with the number 4), which confirmed these two 







Scheme 58: 2D-NOESY spectrum of the pyrroloindolone 98dh. 
The efficacy of the arylation-cyclization cascade is also dependent on the substituent at the 
C3 position. When in substrate 97p the acetamide moiety was replaced by the 
(N-acetylamino)ethylene group, no corresponding cyclization product 98ph was obtained 
















100 °C, 17 h
 
Scheme 59: Failed arylation-cyclization cascade of 97p. 
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applied to alkenylation-cyclization reactions. For instance, reaction with the unsymmetrical 
(phenyl)(phenylvinyl)iodonium triflate (26q) furnished the alkenylated product 98cq in 63% 
isolated yield (Scheme 60). Meanwhile, only traces of the phenylated pyrroloindolone 98ch 
































Scheme 60: Alkenylation-cyclization cascade reaction. 
Finally, the pyrroloindolone 98ah was treated with LiAlH4, delivering the desired reduction 
















70 °C, 30 min
LiAlH4
 
Scheme 61: Reduction of pyrroloindolone 98ah to pyrroloindoline 117ah. 
Overall, although this approach for the pyrroloindolone synthesis required an elevated 
reaction temperature, it displayed its high efficacy and avoided to use any transition metals. 
Meanwhile, it was found that a variety of alkyl substituents at the C2 position of the indole 
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3.4 Metal-Free Arylations of Peptide-Containing Indolylacetamides 
The late-stage functionalization of bioactive small molecules and synthetic biopolymers bears 
great potential for the direct labeling of specific structural motifs and is, for instance, 
attractive for the site-selective modification of peptides or proteins.96–107 
The newly developed efficient methodology for the site-selective metal-free C–H arylation of 
indoles 95 enabled the straightforward functionalization of more fragile indole substrates, 
such as peptide-containing indolylacetamides 99. Through the pre-attachment of an 
indolylacetyl group to the N-terminus of an amino acid or a peptide, the chemo- and 
site-selective late-stage modification of peptides could be expected, and the use of expensive, 
toxic and difficult to remove metal catalysts could be avoided. 
3.4.1 Optimization Studies 
Initial experiments showed the optimal conditions to be highly dependent on the reaction 
solvent and the counteranion of the diaryliodonium salt 26 (Table 12). The arylation of the 
dipeptide ethyl [2-(1H-indol-3-yl)acetyl-L-phenylalanyl-glycinate (99a) with hypervalent 
iodine(III) compound 26 regioselectively delivered the desired product 100aa, with best 
results being accomplished in DMF as the solvent (entries 1–6). Conversely, the 
corresponding trifluoroacetate ([Ph2I]TFA) and bromide ([Ph2I]Br) proved to be ineffective, 
while the trifluoromethylsulfonate ([Ph2I]OTf) and the tetrafluoroborate ([Ph2I]BF4) gave 
reduced yields of the desired indole (entries 7–10). Notably, the metal-free C–H bond 
functionalization of dipeptide 99a did not require inert reaction conditions, but readily 
proceeded with a comparable efficiency under an atmosphere of ambient air, again 
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Entry X Solvent Yield [%][b] 
1 OTs DCE 72 
2 OTs toluene 47 
3 OTs 1,4-dioxane 11 
4 OTs DMSO 0 
5 OTs tAmOH 38 
6 OTs DMF 85, 83[c] 
7 OTf DMF 42 
8 BF4 DMF 54 
9 TFA DMF 17 
10 Br DMF 0 
11 OTs DMF 68[c,d] 
[a] Reaction conditions: 99a (0.250 mmol), 26 (0.375 mmol), solvent (2.0 mL), 100 °C, 17 h. 
[b] 1H NMR conversion with 1,3,5-trimethoxybenzene as the internal standard. [c] Yield of 
the isolated product. [d] Under an atmosphere of ambient air. 
3.4.2 Substrate Scope of Arylation Reactions 
In consideration of the importance of applications to the site-specific peptide labeling, we 
next tested the versatility of the optimized reaction conditions for the direct C–H bond 
functionalization of the dipeptide 99a with variously substituted diaryliodonium tosylates 26 
(Table 13). Notably, a variety of arylating agents was found to be suitable partners in this 
metal-free C–H bond arylation reaction. Meanwhile, the halogen-containing motifs were also 
well tolerated (entries 1–3). Electron-rich hypervalent iodine(III) compounds afforded the 
C2-arylated products 100al and 100ag in excellent yields (entries 4 and 5). Not surprisingly, 
the sterically demanding arylating reagent 26m lowered the arylation efficacy (entry 6). 
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[a] Reaction conditions: 99a (0.250 mmol), 26 (0.375 mmol), DMF (2.0 mL), 100 °C, 17 h; 
yield of the isolated product. 
Subsequently, we turned our attention to the desired late-stage diversification of 
enantiomerically pure peptides 99 (Scheme 62). Several peptides derived from various amino 
acids were functionalized exclusively at the C2 position of the indole moiety in moderate to 
excellent yields. The protocol proved to be tolerant of valuable functionalities. Most notably, 
the arylation of tryptophan-containing substrates 99d and 99g displayed an outstanding 
chemoselectivity, in that the arylation only took place at the indole-3-acetamide moiety rather 
than the indole in the tryptophan fragment. Intriguingly, this metal-free arylation strategy was 
also well compatible with a more complicated hexapeptide 99g without any decrease in 
reactivity. Notably, under these reaction conditions, no noticeable racemization of peptides 
68 
Results and Discussion 




















































































Scheme 62: Metal-free C–H arylations of peptides 99. 
In order to confirm the site-selectivity in the arylation of the tryptophan-containing peptide 99, 
a 2D-HMBC spectrum of the arylated product 100dh was measured in CDCl3. As shown in 
Scheme 63, the first peak at 27 ppm in 13C-NMR sprectrum (marked with a number 1) 
accounts for the carbon of methylene group in tryptophan. It interacts with a proton at 6.2 
ppm (marked with a number 5), which is assigned to the C(2)–H of the indole motif. Thus, it 
122 For the exploration of racemization-prone peptides, see: J. Ploog, Master thesis, Universität 
Göttingen, 2013. 
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can be concluded that the aryl group substituted at the C2 position of the indoleacetamide 

























5 3 2 6 1 4 
C(2)–H of the indole motif 
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3.5 Palladium-Catalyzed Direct Arylations of Tryptophan-Containing Peptides 
Due to the bioactivities and structural diversity, peptides consisting of natural α-amino acids 
or of non-proteinogenic amino acids find major applications in the pharmaceutical industry 
and catalytic asymmetric reactions.94,95 
In order to conveniently obtain a range of modified tryptophan-containing peptides, 
Lavilla104 and Fairlamb105 successively developed two methods to realize palladium-catalyzed 
arylations of tryptophans in moderate to good yields. To obtain high productivity of these 
catalytic reactions, however, the catalyst loading and the amount of arylating reagents as well 
as of oxidant must be rather high. Moreover, these reactions proceeded mostly at elevated 
reaction temperature. 
Within our research program on the modification of indoles and the application onto bioactive 
peptides, we set out to develop a convenient and mild protocol for the direct C–H bond 
arylation of tryptophan-containing peptides 101. 
3.5.1 Optimization Studies 
As discussed above in the Chapters 3.4, the peptide-containing indolylacetamides 99 can 
successfully be arylated in the absence of any transition metal catalysts. Unfortunately, 
according to the crude 1H NMR spectra, no desired arylated tripeptide 102ah was obtained, 
when this usually high yielding protocol was applied to the structurally analogous tryptophan, 
which was embedded in the tripeptide Ac-Ala-Trp-Gly-OEt 101a, at either ambient or 


















  23                0  
100                0
101a 102ah
Temp. [°C]   Yield [%]
26h
 
Table 14: Attempted metal-free arylation of tryptophan-containing tripeptide 101a. 
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Thereafter, transition metal catalysts were employed to enhance the arylation reactivity. 
Under Larrosa's reaction conditions, a palladium-catalyzed functionalization of the 
tryptophan-containing tripeptide 101a with iodobenzene (3b) at ambient temperature was 
tested. As shown in Scheme 64, the protocol appeared to be inefficient in this particular case. 
Instead of the desired product 102ah, only starting material 101a was reisolated from the 













23 °C, 17 h, N2
(2.0 equiv)




  to 1H NMR monitoring
H I
101a 102ah: 0%3b
+ 101a: 99%  
Scheme 64: Attempted palladium-catalyzed arylation of the tripeptide 101a under Larrosa's 
reaction condition. 
Besides this, arylation of the tripeptide 101a was tested in the presence of 10.0 mol % 
Cu(OTf)2 and diphenyliodonium triflate (26e) (Table 15). Among a range of solvents, DCE 
and CH2Cl2 turned out to be partially effective, delivering the arylated tripeptide 102ah in  
12% and 32% yield, respectively (entries 1 and 2). In comparison, other more polar solvents 
afforded no conversions completely (entries 3–6). Meanwhile, the further screening of copper 
catalysts gave rise to no significant improvement of the efficiency (entries 7–13). The best 
reaction conditions exploiting copper(I) chloride as the catalyst yielded 102ah in only 41% 
yield (entry 12). The moderate activity of the copper(I)/copper(III) catalytic system is in line 
with the previously reported conclusion60a that the copper catalyst favors C(3)–H bond 
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 [Cu] (10.0 mol %)
[Ph2I]OTf  26e
 
Entry [Cu] Solvent Yield [%][b] 
1 Cu(OTf)2 DCE 12 
2 Cu(OTf)2 CH2Cl2 32 
3 Cu(OTf)2 DMF 0 
4 Cu(OTf)2 1,4-dioxane 0 
5 Cu(OTf)2 MeOH 0 
6 Cu(OTf)2 AcOH 0 
7 Cu(OAc)2 CH2Cl2 30 
8 Cu(OAc)2·H2O CH2Cl2 18 
9 CuOAc CH2Cl2 34 
10 CuI CH2Cl2 5 
11 CuBr·Me2S CH2Cl2 35 
12 CuCl CH2Cl2 41 
13 CuCl CH2Cl2/DMF (10/1) 13 
[a] Reaction conditions: 101a (0.20 mmol), 26e (0.22 mmol), [Cu] (10.0 mol %), solvent 
(2.0 mL), 23 °C, 15 h. [b] 1H NMR conversion with 1,3,5-trimethoxybenzene as the internal 
standard. 
Fortunately, the reaction yields were considerably improved by replacing copper catalyst by 
palladium compounds. As shown in Table 16, the reaction solvent played a crucial role in the 
palladium-catalyzed transformations (entries 1–5). While solvents, such as DMF, toluene or 
DCE, afforded moderate to good yields, AcOH drove the reaction to an almost quantitative 
production of the arylated tripeptide 102ah. The acid CF3COOH however did not offer any 
benefit. This significant solvent effect can be rationalized in terms of complexing ability of 
the acetic acid as a ligand, which is coordinated to the palladium catalyst and thus involved 
into the catalytic cycle. Notably, the catalyst loading was also important for the 
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transformation. Thus, loading decrease of Pd(OAc)2 to 0.5 mol % lowered the catalytic 
competence, delivering 102ah in 61% yield (entry 6). Moreover, the comparative arylations 
employing other palladium catalyst sources highlighted the priority of AcOH over other 
solvents again (entries 7–9). 


















Entry [Pd] Solvent Yield [%] 
1 Pd(OAc)2 DMF 59 
2 Pd(OAc)2 toluene 66 
3 Pd(OAc)2 DCE 85 
4 Pd(OAc)2 AcOH 99 
5 Pd(OAc)2 CF3COOH 39 
6 Pd(OAc)2 AcOH 61[b] 
7 (MeCN)2PdCl2 AcOH 99 
8 Pd(TFA)2 AcOH 99 
9 Pd(TFA)2 CF3COOH 46 
[a] Reaction conditions: 101a (0.2 mmol), 26h (0.3 mmol), [Pd] (5.0 mol %) solvent (3.0 mL), 
23 °C, 17 h; yield of the isolated product. [b] 0.5 mol % Pd(OAc)2.3.5.2 Scope of 
Symmetrical Diaryliodonium Salts 
Encouraged by the efficiency and the high regioselectivity observed in the 
palladium-catalyzed direct C–H bond arylation of tryptophan-containing tripeptides 101 in 
AcOH, we examined its generality with respect to symmetrical diaryliodonium tosylates 26 
and peptides 101.  
As shown in Table 17, both electron-rich and electron-deficient aryl groups in hypervalent 
iodine(III) compounds 26 kept the reaction reactivity at a high level, accomplishing the 
biheteroaryl formation in good to excellent yields (entries 1–4). However, the sterically 
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demanding aryl groups in 26 were not well tolerated with this approach. Thus, 
bis(2,4-dimethylphenyl)iodonium tosylate (26g) afforded the arylated tripeptide 102am in 
only 51% yield (entry 5). 
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[a] Reaction conditions: 101a (0.2 mmol), 26 (0.3 mmol), Pd(OAc)2 (5.0 mol %), AcOH 
(3.0 mL), 23 °C, 17 h; yield of the isolated product. 
Thereafter, we explored the versatility of this method by testing several peptide sequences 
(Table 18). The arylations of the tripeptides 101b and 101c afforded the desired products 
102bh and 102ch in excellent yields (entries 1 and 2). The reaction yield decreased to 56% in 
the case of the tripeptide Ac-Gly-Trp-Glu(OMe)2 (101d) (entry 3). Unfortunately, wenn the 
sulfur-containing amino acids, such as methionine and cysteine, were embedded in the 
peptide sequences, the arylations did not proceed (entries 4 and 5). This result could 
presumably be attributed to the palladium-catalyzed selective hydrolysis of the peptide 





123 L. Zhu, L. Qin, T. N. Parac, N. M. Kostic, J. Am. Chem. Soc. 1994, 116, 5218–5224. 
124 (a) J. V. Crivello, J. H. W. Lam, J. Org. Chem. 1978, 43, 3055–3058; (b). L. Wang, Z.-C. 
Chen, Synth. Commun. 2001, 31, 1227–1232; (c) A. Krief, W. Dumont, M. Robert, Chem. 
Commun. 2005, 2167–2168. 
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Results and Discussion 
[a] Reaction conditions: 101 (0.2 mmol), 26h (0.3 mmol), Pd(OAc)2 (5.0 mol %), AcOH 
(3.0 mL), 23 °C, 17 h; yield of the isolated product. 
3.5.3 Scope of Unsymmetrical Diaryliodonium Salts 
Unsymmetrical diaryliodonium salts, which are favored due to their potentially improved 
atom economy and relative ease of preparation, are also potential candidates for site-selective 
arylations of tryptophan-containing tripeptides. In arylation reactions employing 
unsymmetrical diaryliodonium salts, the problem of chemoselectivity between two different 
aryl groups appears inevitably. In order to discriminate one of the two aryl group, the bulky 
mesityl group can be introduced to the unsymmetrical salt. Under the optimized reaction 
conditions for the palladium-catalyzed C–H arylation, the sterically less hindered aryl group 
should be selectively transferred to the nucleophilic indole moiety. 
Various unsymmetrical diaryliodonium tosylates 26 bearing the mesityl group were 
synthesized and tested in the arylation reaction of the tripeptide 101a in the presence of 
AcOH. The results are summarized in Table 19. Thus, the (mesityl)(4-methoxyphenyl)- 
iodonium tosylate (26r) afforded the desired tripeptide 102ag in AcOH in 57% yield (entry 1). 
A slight modification utilizing a solvent mixture of AcOH and DCE in a ratio of 1:1, where 
DCE was used to improve the solubility of the unsymmetrical diaryliodonium salts 26, 
slightly meliorated the reaction yield to 64% (entry 2). However, in comparison with the 
reaction of symmetrical bis(4-methoxyphenyl)iodonium tosylate (26g) (Table 9, entry 4), the 
reactivity was remarkably lowered, presumably due to the steric hindrance with the bulky 
diaryliodonium salt.  
The electron-rich aryl groups of λ3-iodane 26 were easier transferred to the indole moiety of 
101a under the palladium catalysis than the electron-deficient aryl groups. Thus, whereas the 
(mesityl)(4-tolyl)iodonium tosylate (26s) provided the arylated tripeptide 102as in a moderate 
yield of 55% (entry 3), the desired product 102at was obtained employing 
(mesityl)(3-trifluorophenyl)iodonium tosylates (26t) in only 33% yield (entry 4).  
On the other hand, the (mesityl)(1-naphthalenyl)iodonium tosylate (26u) was well tolerated 
under these reaction conditions, delivering the arylated tripeptide 102au in 70% yield 
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(entry 5).  
Interestingly, unsymmetrical iodonium tosylates 26v and 26w bearing amino acid moieties 
became viable substrates as well (entries 6 and 7). These phenylalanine- and glycine-derived 
λ3-iodanes gave rise to new peptides 102av and 102aw in 53% and 36% yield, respectively. 
These reactions displayed a potential for the ligation of two non-natural peptides. 
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[a] Reaction conditions: 101a (0.2 mmol), 26 (0.3 mmol), Pd(OAc)2 (5.0 mol %), AcOH 
(1.5 mL), DCE (1.5 mL), 23 °C, 24 h; yield of the isolated product. [b] AcOH (3.0 mL) as the 
solvent.  
3.5.4 Water as the Reaction Medium 
Given that a wide range of in vivo syntheses of biological substrates, such as peptides, are 
carried out under aqueous conditions, water as an inexpensive, environmentally benign, 
nontoxic reaction medium has been gradually utilized to perform in vitro organic reactions.125 
Hence, the above developed palladium-catalyzed C–H bond functionalization was further 
explored employing water as the reaction medium (Table 12). Differing from organic solvents, 
water has a low dissolving capacity of organic compounds, such as the tripeptide 101 and the 
diaryliodonium tosylate (26). 
125 (a) C.-J. Li, Chem. Rev. 2005, 105, 3095–3165; (b) A. Chanda, V. V. Fokin, Chem. Rev. 2009, 
109, 725–748; (c) R. N. Butler, A. G. Coyne, Chem. Rev. 2010, 110, 6302–6337. 
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After a simple replacement of organic solvent with water, the reaction of the tripeptide 101a 
Ac-Ala-Trp-Gly-OEt with the diphenyliodonium tosylate (26h) afforded a satisfactory 
outcome with 70% yield (entry 1). Further exploration of other arylating reagents 26 showed 
good performance as well (entries 2–8). We were surprised to find that the sterically 
demanding 2,4-dimethylphenyl group afforded the arylated peptide 102am, which under 
acidic conditions was previously obtained in only 51% yield (Table 17, entry 5), in high yield 
of 71% (entry 8). Whereas the arylation reaction of 101b Ac-Ala-Trp-Ala-OMe with the 
aqueous medium still afforded the product 102bh with moderate efficacy (54% yield, entry 9), 
the arylated tripeptides 102dh can be synthesized from substrate Ac-Gly-Trp-Glu(OMe)2 
102d in only 23% yield (entry 10). 























































Results and Discussion 
(continued) 
































































    (continued) 
     
82 
Results and Discussion 
(continued) 

























































[a] Reaction conditions: 101 (0.2 mmol), 26 (0.3 mmol), Pd(OAc)2 (5.0 mol %), H2O 
(3.0 mL), 23 °C, 24 h; yield of the isolated product. 
Furthermore, the unsymmetrical (mesityl)(4-methoxyphenyl)iodonium tosylate (26r) was also 
employed to test its reactivity with water as the reaction medium (Table 21). Unfortunately, 
the optimized reaction conditions appeared to be less effective for arylations with 
unsymmetrical diaryliodonium tosylates 26r. 
H2O

























  5.0                     22
10.0                     34
102ar
H
[Pd] [mol %]   Yield [%]
 
Table 21: Palladium-catalyzed C–H arylation with 26r with H2O as the reaction medium. 
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To test the reaction potential of peptides bearing a free C-terminus, a simple acetylated 
tryptophan Ac-Trp-OH 101g was subjected to the catalytic arylation. When the symmetrical 
diphenyliodonium tosylate 26h was the arylating partner, 85% of the phenylated product 
102gh was obtained (Scheme 65).  
AcHN COOH
+ [Ph2I]OTs
 Pd(OAc)2 (5.0 mol %)
H2O










Scheme 65: Arylation of amino acid 101g with diphenyliodonium tosylate 26h. 
However, the unsymmetrical hypervalent iodine(III) compound 26r did not demonstrate the 
same high reactivity (Table 22). Under the typical reaction conditions, the arylated tryptophan 
102gg was obtained in only 39% yield (entry 1). Elevated temperature had a minor effect on 
the outcome (entry 2). Taking into consideration the capability of surfactants to improve 
reactions with water, 126  the surfactant PTS (polyoxyethanyl α-tocopherylsebacate) was 
examined as the additive (entry 3). Unfortunately, the reaction in the presence of a catalytic 
amount of the surfactant PTS did not provide improved yield in this case. Moreover, a 
palladium catalyst containing a water-soluble ligand guanidine also turned out to be 
inefficient for this biaryl synthesis (entry 4).127 





















126 (a) B. H. Lipshutz, B. R. Taft, Org. Lett. 2008, 10, 1329–1332; (b) B. H. Lipshutz, T. B. 
Petersen, A. R. Abela, Org. Lett. 2008, 10, 1333–1336. 
127 (a) Z. Gao, V. Gouverneur, B. G. Davis, J. Am. Chem. Soc. 2013, 135, 13612–13615; (b) A. 
Dumas, C. D. Spicer, Z. Gao, T. Takehana, Y. A. Lin, T. Yasukohchi, B. G. Davis, Angew. 
Chem. Int. Ed. 2013, 52, 3916–3921. 
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Entry [Pd] Additive Yield [%][b] 
1 Pd(OAc)2 --- 39 
2 Pd(OAc)2 --- 40[c] 







[a] Reaction conditions: 101g (0.2 mmol), 26r (0.3 mmol), [Pd] (5.0 mol %), additive 
(3.0 wt %), H2O (3.0 mL), 23 °C, 24 h. [b] 1H NMR conversion with 
1,3,5-trimethoxybenzene as the internal standard. [c] Reaction temperature of 37 °C. 
Overall, our results demonstrate that water is a very promising reaction medium for 
palladium-catalyzed C–H arylations of tryptophan-containing peptides 101. Compared to 
reactions under acidic conditions, however, transformations in the aqueous medium remain 
challenging, especially the reactions of sterically demanding substrates. 
3.5.5 UV-Vis and Fluorescence Studies 
The optical properties (absorption and fluorescence maxima, stoke shift and molar 
absorptivity) for the peptides 101a, 102ag–am and 102as–aw are presented in Table 23. All 
of these peptides showed an intense absorption band in the UV region (see Chapter 5.4.6). 
With the exception of the bromophenylated tripeptide 102ak, these chromophores were also 
fluorescent in the UV-Vis region. Moreover, the arylated peptides 102 exhibited a red-shifted 
absorption/emission wavelength relative to the free tripeptide 101a.  
By comparing the arylated peptides 102ag–am, 102as–at and 102av–aw, it could be 
apparently found that both electron-donating and electron-withdrawing groups at the meta- or 
para-position of the phenyl rings could affect the optical properties. Notably, the 3-CF3 group 
in the peptide 102at shifted the the absorption and fluorescence maxima from 308 nm for 
102ah to 312 nm in absorption and from 379 nm for 102ah to 416 nm in emission. 
Furthermore, the largest Stockes shift was generated, when the naphthalyl group in 102au 
substituted at the C2 position of the indole moiety. 
The arylated peptide with an electron-donating group generally displayed high fluorescence 
intensity (Figure 6). Among the arylated peptides, the largest fluorescence intensity was seen 
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for 102al. Notably, the heavy atom which could enhance spin-orbit coupling in the molecule 
can strongly decrease the fluorescence intensity,128 so that the peptide 102aj with a chloro 
group was weakly emissive and 102ak with a bromo group even non-fluorescent. 
Table 23: UV-Vis data and Stokes shifts for the tripeptide 101a and the arylated tripeptides 
102ag–an, 102hs–hw.[a] 
Compound Abs. λmax [nm] Em. λmax [nm] Stokes shift [nm] ε [dm3·mol-1·cm-1] 
101a 283 343 60 7036 
102ag 310 370 60 23505 
102ah 308 379 71 17408 
102ai 305 379 74 17027 
102aj 313 393 80 20028 
102ak 315 - - 22414 
102al 311 376 65 24701 
102am 295 377 82 18447 
102as 310 379 69 21822 
102at 312 416 104 22515 
102au 282 451 169 15798 
102av 311 380 69 19967 
102aw 310 380 70 13361 
[a] Solutions of peptides 101a, 102ag–am and 102as–aw in DMSO. 
 
Figure 6: Fluorescence spectra for arylated tripeptides. 
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4 Summary and Outlook 
The development of sustainable strategies for the synthesis of highly functionalized 
N-containing heterocycles is of great importance for the preparation of pharmaceuticals, 
agrochemicals and functional materials. Thus, the focus of the present work was set on the 
construction of a variety of heterocyclic frameworks through palladium-catalyzed or 
metal-free direct C−H functionalizations. 
In the first project, the substrate scope for the direct C–H bond alkynylation of oxazoles with 
gem-dichloroalkenes employing the catalytic system consisted of Pd(OAc)2, DPE-Phos and 
LiOtBu was explored (Scheme 66). Pyridyl, thienyl and furyl groups at the C5 position of 
oxazoles 8b−c were well tolerated. Furthermore, a variety of gem-dichloroalkenes 94 bearing 
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Scheme 66: Palladium-catalyzed alkynylation of oxazoles 8 with gem-dichloroalkenes 94. 
In recent decades, diaryliodonium salts 26 have emerged as a potent alternative to haloarenes 
as arylating reagents. The utilization of diaryliodonium salts allows C–H arylations of 
(hetero)arenes to take place at low reaction temperatures under transition metal catalysis or 
even in the absence of the transition metal catalyst.  
In the second project of this thesis, diaryliodonium tosylates 26 were used for metal-free 
C2-arylations of indoles 95 bearing the acetamide functionality at the C3 position (Scheme 
67). The reaction conditions showed good tolerance of electron-rich and electron-deficient 
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diaryliodonium salts. Mechanistic studies were indicative of a SEAr-type functionalization 










































Scheme 67: Metal-free arylation of indolylacetamides 95. 
Subsequently, the challenging metal-free arylation-cyclization cascade reaction was 
elaborated by blocking the C2 position of indoles (Scheme 68). A wide range of C2-alkyl 
rests was found to be viable for the assembly of pyrroloindolones. We were delighted to 
observe that the cascade reaction also smoothly proceeded with the utilization of 
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Scheme 68: Metal-free arylation-cyclization cascade reactions. 
Prospective endeavours for the metal-free arylation-cyclization cascade reactions could be 
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directed towards the employment of a chiral diaryliodonium salt or a suitable chiral catalyst, 
such as the chiral phosphoric acid 74, to achieve enantioselective formations of 
pyrroloindolones. 
The last two projects were focused on the late-stage diversification of peptides through the 
site-selective C−H arylation. The approach for the metal-free C−H arylations was further 
applied to the peptide 99 involving the indolylacetyl group as a tag. The more complicated 
substrates, including di-, tri- and even hexapeptides, were capable to furnish the arylated 
peptides 100 chemo- and site-selectively (Scheme 69). Interestingly, the arylation substrates 
with two indolyl moieties, one of which was part of a tryptophan residue, took only place at 









+ [Ar2I]OTs OHN ArH
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Scheme 69: Metal-free late-stage arylations of peptide-containing indolylacetamides 99. 
The post-synthetic modification of the tryptophan-containing peptides 101 was accomplished 
through the palladium-catalyzed C–H arylation (Scheme 70). The arylation of tripeptides 101 
proceeded at ambient temperature by utilizing symmetrical or unsymmetrical diaryliodonium 
salts 26 as the arylating reagents, respectively. With water as an environmentally benign 
reaction medium, the arylation reactions still displayed satisfactory performances. Importantly, 
the amino acid tryptophan with free C-terminus proved to be a viable substrate for this 
chemical transformation. 
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Scheme 70: Palladium-catalyzed arylations of tryptophan-containing peptides 101. 
Future development of the palladium-catalyzed C–H arylations of tripeptides should be 
focused on testing the robustness of these reaction conditions by extending substrate scope to 
include peptides containing different amino acids. And the introduction of a fluorescent aryl 





5 Experimental Section 
5.1 General Remarks 
Unless otherwise noticed, all reactions were carried out under a N2 atmosphere using 
pre-dried glassware and standard Schlenk techniques. As to metal-free reactions, new 
glassware and new stirring bars were used for all reactions. 
5.1.1 Solvents 
The anhydrous solvents for reactions with moisture-sensitive reagents were dried, distilled 
and stored under inert atmosphere (argon or nitrogen) according to the following standard 
procedures: 
tert-Amyl alcohol was stirred over Na for 5 h at 120 °C and distilled under ambient pressure. 
1,2-Dichloroethane or N,N-dimethylformamide were stirred with CaH2 for 8 h, degassed 
and distilled under reduced pressure. 
Dichloromethane was purified using a M. Braun SPS-800 solvent purification system and 
was stored over molecular sieves. 
Dimethyl sulfoxide was stirred with CaH2 for 4 h, degassed and distilled under reduced 
pressure. 
Methanol was stirred over MgOMe for 3 h at 65 °C prior to distillation. 
N-Methyl-2-pyrrolidone was stirred for 4 h at 150 °C and subsequently distilled under 
reduced pressure. 
1,4-Dioxane was dried and distilled over Na/benzophenone ketyl. 
Toluene was pre-dried over KH and distilled over Na/benzophenone ketyl. 
Water was degassed for 2 h and ultrasonicated. 
Acetic acid was degassed before its use applying repeated Freeze-Pump-Thaw degassing 
procedure. 
5.1.2 Vacuum 
Following pressures were measured on the used vacuum pump and are not corrected: 




Analytical TLC was performed on 0.25 mm silica gel 60F plates (MACHEREY-NAGEL) 
with 254 nm fluorescent indicator from MERCK. Plates were visualized under ultraviolet 
light and developed by treatment with a KMnO4 solution or an acidic Cer(IV)-solution 
followed by careful warming with a heat gun. Chromatographic purification of products was 
accomplished by flash column chromatography on MERCK silica gel, grade 60 (0.040–0.063 
mm and 0.063–0.200 mm, 70–230 mesh ASTM). 
5.1.4 High-Performance Liquid Chromatography (HPLC) 
Preparative separations were performed on an HPLC-System from KNAUER (Smartline 
Pump 100, Dynamic Mixing Chamber, Injection- and Control-Valve, Smartline UV Detector 
2500). Separation column VP C18 ec (RP) (250 × 16 mm, Nucleodur, 100-10) from 
MACHEREY-NAGEL was used. Organic solvents of HPLC-grade and twice distilled H2O 
were employed. All samples were filtrated through Polytetrafluorethylen-(PTFE) -Filter from 
ROTH (Ø 25 mm, 0.2 μm), respectively VWR (Ø 13 mm, 0.2 μm) prior to separation. 
5.1.5 Gas Chromatography (GC) 
Monitoring of reaction processes via coupled gas chromatography-mass spectrometry was 
performed using G1800C GCD plus with mass detector HP 5971, 5890 Series II with mass 
detector HP 5972 from HEWLETT-PACKARD and 7890A GC-System with mass detector 
5975C (Triplex-Axis-Detector) from AGILENT TECHNOLOGIES. HP-5MS columns (30 m 
× 0.25 mm, film 0.25 μm) were used. 
5.1.6 Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectroscopy was performed at 300 or 600 MHz (1H 
NMR), 75 or 125 MHz (13C NMR, APT) and 283 MHz (19F NMR) on BRUKER AM 250, 
VARIAN Unity-300 and Inova 500 instruments. Chemical shifts are reported as δ-values in 
ppm relative to the residual proton peak of the deuterated solvent or its carbon atom, 
respectively, or the standard trimethylsilyl (TMS) peak. 
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 1H NMR 13C NMR 
CDCl3 7.26 ppm 77.0 ppm 
d6-DMSO 2.49 ppm 49.5 ppm 
For characterization of the observed resonance multiplicities the following abbrevations were 
applied: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), 
dt (doublet of triplet), or analogue representations. The coupling constants J are reported in 
Hertz (Hz). 
5.1.7 Infrared Spectroscopy (IR) 
Infrared spectra were recorded on a BRUKER Alpha-P ATR-spectrometer. Liquid probes 
were measured as film and solid probes neat. Analysis of the spectral data was performed 
using the OPUS 3.1 software from BRUKER, respectively OPUS 6. Absorption (ṽ) is given 
in wave numbers (cm–1). Spectra were recorded in the range of 4000 to 400 cm–1. 
5.1.8 Mass Spectroscopy (MS) 
EI- and EI-HRMS spectra were measured on a Time-of-Flight mass spectrometer AccuTOF 
from JOEL. ESI-mass spectra were recorded on an Ion-Trap mass spectrometer LCQ from 
FINNIGAN or on a Time-of-Flight mass spectrometer microTOF from BRUKER. 
ESI-HRMS spectra were recorded on a BRUKER APEX IV or a BRUKER DALTONIC (7T, 
Transform Ion Cyclotron Resonance (FTICR)) mass spectrometer. The ratios of mass to 
charge are indicated, intensities relative to the base peak (I = 100) are written in parentheses. 
5.1.9 Melting Points 
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 from 
BARLOWORLD SCIENTIFIC or BÜCHI 540 Melting Point Apparatus. Reported values are 
uncorrected. 
5.1.10 UV-Visible Spectroscopy 
UV-Visible Spectroscopy was performed on a Jasco® V-770 spectrophotometer. A baseline 
in the appropriate solvent was obtained prior to recording spectra. 
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5.1.11 Fluorescence Spectroscopy 
Fluorescence excitation and emission data in solution were recorded on a Jasco® FP-8500 
spectrofluorometer. The widths of excitation and emission slits were held constant at 2.5 and 
5 nm, respectively. The scan speed was adjusted to 200 nm/min. 
5.1.12 Reagents 
Chemicals obtained from commercial sources (purity > 95%) were used without further 
purification. 3-Chloroperoxybenzoic acid (mCPBA) was purchased from ACROS 
ORGANICS with a purity of 70–75% (rest: 3-chlorobenzoic acid and water) and was used 
after drying under vacuum at ambient temperature for 1h (calculated as 81% wt). 
5.2 Synthesis of Starting Materials 
The following starting materials were synthesized according to previously described methods:  
Oxazoles 8b–d,129gem-dichloroalkenes 94a–m,130 indolylacetamides 95a–e, 95g–j,13195k–s, 
α-substituted indolylacetamides 95t–u, 132  2-methylindolylacetamides 97a–i, 
2-alkylindolylacetamides 97j–n, 133  symmetrical diaryliodonium salts 26g–n, 134  26x, 135  
dithienyliodonium tosylate (26o), 136  (mesityl)(aryl)iodonium tosylates 26r–w, 
(phenyl)(vinyl)iodonium triflate (26q), 137  (2-allyloxyphenyl)(mesityl)iodonium tosylate 
129 A. M. van Leusen, B. E. Hoogenboom, H. Siderius, Tetrahedron Lett. 1972, 23, 2369–2372.  
130 S. G. Newman, C. S. Bryan, D. Perez, M. Lautens, Synthesis 2011, 342–346. 
131 S. Petit, Y. Duroc, V. Larue, C. Giglione, C. Léon, C. Soulama, A. Denis, F. Dardel, T. 
Meinnel, I. Artaud, ChemMedChem 2009, 4, 261–275. 
132 (a) Y.-F. Zhu, Z. Guo, T. D. Gross, Y. Gao, P. J. Connors, R. S. Struthers, Q. Xie, F. C. Tucci, 
G. J. Reinhart, D. Wu, J. Saunders, C. Chen, J. Med. Chem. 2003, 46, 1769–1772; (b) E. Kiuru, 
Z. Ahmed, H. Lönnberg, L. Beigelman, M. Ora, J. Org. Chem. 2013, 78, 950–959; (c) A. 
Tsotinis, M. Vlachou, D. P. Papahatjis, T. Calogeropoulou, S. P. Nikas, P. J. Garratt, V. Piccio, 
S. Vonhoff, K. Davidson, M.-T. Teh, D. Sugden, J. Med. Chem. 2006, 49, 3509–3519. 
133 L. Jiao, T. Bach, J. Am. Chem. Soc. 2011, 133, 12990–12993. After reaction, the crude 
products were at first purified by flash chromatography and then by "bulb-to-bulb" distillation in 
order to remove the palladium residue. 
134 (a) P. Kazmierczak, L. Skulski, Synthesis 1995, 1027–1032; (b) L. Kraszkiewicz, L. Skulski, 
Synthesis 2008, 2373–2389. 
135 (a) K. S. Daub, B. Habermann, T. Hahn, L. Teich, K. Eger, Eur. J. Org. Chem. 2004, 894–898; 
(b) N. Ichiishi, A. F. Brooks, J. J. Topczewski, M. E. Rodnick, M. S. Sanford, P. J. H. Scott, 
Org. Lett. 2014, 16, 3224–3227. 
136 M. Zhu, N. Jalalian, B. Olofsson, Synlett 2008, 4, 592–596. 
137 (a) G. W. Kabalka, E. E. Gooch, H. C. Hsu, Synth. Commun. 1981, 11, 247–251; (b) M. 
Ochiai, M. Toyonari, T. Nagaoka, D.-W. Chen, M. Kida, Tetrahedron Lett. 1997, 38, 
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(26p),,138 oligopeptides 99a–d,139 99f–g, 99i, 101a–c, 101e–f.  
The following compounds were obtained by the generous courtesy of the persons named 
below: 
M.Sc. Jasper Ploog: Peptide 99e, 99h. 
M.Sc. Michaela Bauer: Peptide 101e. 
5.3 General Procedures 
General procedure A for palladium-catalyzed C–H alkynylations of oxazoles with 
gem-dichloroalkenes: 
A mixture of oxazole 8 (0.50 mmol), gem-dichloroalkene 94 (0.75 mmol), Pd(OAc)2 
(5.0 mol %), DPE-Phos (6.0 mol %) and LiOtBu (2.5 mmol) in 1,4-dioxane (2.0 mL) was 
stirred at 120 °C for 14 h. At ambient temperature, H2O (5 mL) was added, and the aqueous 
layer was extracted with EtOAc (4 × 20 mL). The organic layers were combined, and the 
solvents were removed in vacuo. Purification of the residue by column chromatography on 
silica gel yielded the product 9. 
General procedure B for metal-free C–H arylations of indolylacetamides and metal-free 
synthesis of pyrroloindolones: 
A mixture of indolylacetamide 95 or 97 (0.50 mmol), diphenyliodonium tosylate 26 
(0.75 mmol) in DMF (2.00 mL) was stirred at 100 °C for 17 h. At ambient temperature, H2O 
(5 mL) was added, and the aqueous layer was extracted with EtOAc (2 × 20 mL). The organic 
layers were combined, and the solvents were removed in vacuo. The residue was purified by 
column chromatography on silica gel to yield the desired product 96 or 98. 
General procedure C for metal-free C–H arylations of peptide-containing 
indolylacetamides with diaryliodonium salts: 
A mixture of peptide 99 (0.250 mmol), diaryliodonium tosylate 26 (0.375 mmol) in DMF 
138 C. A. Ocasio, T. S. Scanlan, Bioorg. Med. Chem. 2008, 16, 762–770; (b) J. Morgan, J. T. 
Pinhey, J. Chem. Soc., Perkin. Trans. 1 1993, 1673–1676. 
139 (a) Z.-L. Shen, K. K. K. Goh, C. H. A. Wong, W.-Y. Loo, Y.-S. Yang, J. Lu, T.-P. Loh, Chem. 
Commun. 2012, 48, 5856–5858; (b) M. N. Kumara, D. C. Gowda, K. S. Rangappa, Int. J. Chem. 
Kinet. 2002, 34, 438–444; (c) S. M. Voshell, S. J. Lee, M. R. Gagné, J. Am. Chem. Soc. 2006, 
128, 12422–12423. 
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(2.00 mL) was stirred at 100 °C for 17 h. At ambient temperature, the crude reaction mixture 
was directly purified by column chromatography on silica gel to yield the desired product 
100. 
General procedure D1 for palladium-catalyzed C–H arylations of tryptophan- 
containing peptides with symmetrical diaryliodonium salts in AcOH: 
A mixture of tryptophan-containing peptide 101 (0.20 mmol), symmetrical diaryliodonium 
tosylate 26 (0.30 mmol) and Pd(OAc)2 (5.0 mol %) in AcOH (3.00 mL) was stirred at 23 °C 
for 17 h. At ambient temperature, H2O (5 mL) was added, and the aqueous layer was 
extracted with EtOAc (3 × 20 mL). The organic layers were combined, and the solvents were 
removed in vacuo. The crude product was purified by column chromatography on silica gel to 
yield the desired product 102. 
General procedure D2 for palladium-catalyzed C–H arylations of tryptophan- 
containing peptides with unsymmetrical diaryliodonium salts in AcOH/DCE: 
A mixture of tryptophan-containing peptide 101 (0.2 mmol), unsymmetrical diaryliodonium 
tosylate 26 (0.3 mmol) and Pd(OAc)2 (5.0 mol %) in mixture solvent of AcOH (1.5 mL) and 
DCE (1.5 mL) was stirred at 23 °C for 24 h. At ambient temperature, H2O (5 mL) was added, 
and the aqueous layer was extracted with EtOAc (3 × 20 mL). The organic layers were 
combined, and the solvents were removed in vacuo. The crude product was purified by 
column chromatography on silica gel to yield the desired product 102. 
General procedure D3 for palladium-catalyzed C–H arylations of tryptophan- 
containing peptides with water as the reaction medium: 
A mixture of tryptophan-containing peptide 101 (0.2 mmol), diaryliodonium tosylate 26 
(0.3 mmol) and Pd(OAc)2 (5.0 mol %) with water (3.0 mL) was stirred at 23 °C for 24 h. 
After the reaction was completed, MeOH (5.0 mL) was added, and the solvents were removed 
in vacuo. The residue was purified by column chromatography on silica gel to yield the 




5.4 Analytical Data 
5.4.1 Analytical Data for Alkynylated Oxazoles 
Synthesis of 2-(Naphthalen-1-ylethynyl)-5-(pyridin-2-yl)oxazole (9ba): 
The general procedure A was followed using 
5-(pyridin-2-yl)oxazole (8b) (73 mg, 0.50 mmol) and 
1-(2,2-dichlorovinyl)naphthalene (94a) (167 mg, 0.75 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 
10/1) yielded 9ba (130 mg, 88%) as a pale yellow solid (m. p. = 146–147 °C).  
1H NMR (300 MHz, CDCl3): δ = 8.67 (ddd, J = 4.7, 1.6, 0.9 Hz, 1H), 8.45 (d, J = 8.4 Hz, 
1H), 7.94 (d, J = 8.1 Hz, 1H), 7.90 (d, J = 7.3 Hz, 1H), 7.89 (d, J = 7.3 Hz, 1H), 7.82 (s, 1H), 
7.78 (ddd, J = 7.9, 7.4, 1.6 Hz, 1H), 7.75 (ddd, J = 7.9, 1.1, 0.9 Hz, 1H), 7.65 (dd, J = 8.4, 6.8 
Hz, 1H), 7.57 (dd, J = 7.3, 6.8 Hz, 1H), 7.49 (dd, J = 8.1, 7.3 Hz, 1H), 7.27 (ddd, J = 7.4, 4.7, 
1.1 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 151.5 (Cq), 150.0 (CH), 146.9 (Cq), 146.7 (Cq), 136.9 (CH), 
133.2 (Cq), 133.0 (Cq), 131.9 (CH), 130.6 (CH), 128.4 (CH), 127.5 (CH), 126.8 (CH), 126.7 
(CH), 125.9 (CH), 125.1 (CH), 123.3 (CH), 119.6 (CH), 118.1 (Cq), 90.8 (Cq), 81.8 (Cq).  
IR (ATR): 3093, 2210, 1600, 1333, 1217, 947, 785, 763, 741, 485 cm–1.  
MS (EI) m/z (relative intensity) 296 (100) [M]+, 268 (10), 163 (31), 119 (50), 91 (28).  
HR-MS (EI) m/z calcd for C20H12N2O+ 296.0950, found 290.0945 [M]+. 
Synthesis of 2-(Phenylethynyl)-5-(pyridin-2-yl)oxazole (9bb): 
The general procedure A was followed using 
5-(pyridin-2-yl)oxazole (8b) (73 mg, 0.50 mmol) and 
(2,2-dichlorovinyl)benzene (94b) (130 mg, 0.75 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 10/1) yielded 9bb (79 mg, 64%) 
as a pale yellow solid (m. p. = 86–87 °C).  
1H NMR (300 MHz, CDCl3): δ = 8.65 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H), 7.77 (ddd, J = 7.7, 7.4, 
1.6 Hz, 1H), 7.76 (s, 1H), 7.70 (ddd, J = 7.7, 1.1, 0.9 Hz, 1H), 7.73 (dd, J = 7.7, 1.6 Hz, 2H), 
7.44–7.34 (m, 3H), 7.25 (ddd, J = 7.4, 4.8, 1.1 Hz, 1H).  







132.2 (CH), 130.0 (CH), 128.5 (CH), 126.6 (CH), 123.2 (CH), 120.5 (Cq), 119.5 (CH), 92.3 
(Cq), 77.2 (Cq).  
IR (ATR): 3098, 2222, 1758, 1601, 1524, 1161, 1080, 785, 688, 398 cm–1.  
MS (EI) m/z (relative intensity) 246 (100) [M]+, 218 (13), 140 (10), 119 (62), 113 (30), 91 
(36).  
HR-MS (EI) m/z calcd for C16H10N2O+ 246.0793, found 246.0792 [M]+. 
Synthesis of 2-(Anthracen-9-ylethynyl)-5-(pyridin-2-yl)oxazole (9bc): 
The general procedure A was followed using 
5-(pyridin-2-yl)oxazole (8b) (73 mg, 0.50 mmol) and 
9-(2,2-dichlorovinyl)anthracene (94c) (204 mg, 0.75 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 
10/1) yielded 9bc (106 mg, 61%) as a pale yellow solid (m. p. = 183–184 °C).  
1H NMR (300 MHz, CDCl3): δ = 8.66 (dd, J = 4.8, 1.6 Hz, 1H), 8.61 (d, J = 8.6 Hz, 2H), 
8.48 (s, 1H), 8.00 (d, J = 7.9 Hz, 2H), 7.85 (s, 1H), 7.78–7.75 (m, 2H), 7.63 (dd, J = 8.6, 
6.5 Hz, 2H), 7.51 (dd, J = 7.9, 6.5 Hz, 2H), 7.25 (dd, J = 7.4, 4.8 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 151.5 (Cq), 150.0 (CH), 147.1 (Cq), 146.7 (Cq), 136.9 (CH), 
133.4 (Cq), 130.9 (Cq), 129.9 (CH), 128.8 (CH), 127.5 (CH), 127.0 (CH), 126.3 (CH), 125.9 
(CH), 123.3 (CH), 119.6 (CH), 113.9 (Cq), 89.9 (Cq), 88.0 (Cq).  
IR (ATR): 3090, 2213, 1597, 1520, 1114, 781, 735, 701, 619, 406 cm–1.  
MS (EI) m/z (relative intensity) 346 (100) [M]+, 213 (23), 119 (27), 91 (21).  
HR-MS (EI) m/z calcd for C24H14N2O+ 346.1106, found 346.1105 [M]+. 
Synthesis of 2-[(2-Methylphenyl)ethynyl]-5-(pyridin-2-yl)oxazole (9bd): 
The general procedure A was followed using 
5-(pyridin-2-yl)oxazole (8b) (73 mg, 0.50 mmol) and 
1-(2,2-dichlorovinyl)-2-methylbenzene (94d) (140 mg, 
0.75 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 10/1) yielded 9bd (91 mg, 70%) as a pale yellow solid (m. p. = 
114–116 °C).  








1.6 Hz, 1H), 7.75 (s, 1H), 7.69 (ddd, J = 7.7, 1.1, 0.9 Hz, 1H), 7.57 (d, J = 7.9 Hz, 1H), 7.30 
(dd, J = 7.7, 5.4 Hz, 1H), 7.18 (dd, J = 7.9, 5.4 Hz, 1H), 7.25 (ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 
7.22 (d, J = 7.7 Hz, 1H), 2.52 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 151.3 (Cq), 150.0 (CH), 146.9 (Cq), 146.7 (Cq), 141.4 (Cq), 
136.9 (CH), 132.7 (CH), 130.0 (CH), 129.7 (CH), 126.7 (CH), 125.7 (CH), 123.2 (CH), 120.3 
(Cq), 119.5 (CH), 91.4 (Cq), 80.8 (Cq), 20.7 (CH3).  
IR (ATR): 3097, 2213, 1719, 1603, 1576, 1469, 1337, 1198, 888, 791, 748, 455 cm–1.  
MS (EI) m/z (relative intensity) 260 (100) [M]+, 154 (14), 127 (25), 119 (56), 91 (43).  
HR-MS (EI) m/z calcd for C17H12N2O+ 260.0950, found 260.0946 [M]+. 
Synthesis of 2-[(2,4,6-Trimethylphenyl)ethynyl]-5-(pyridin-2-yl)oxazole (9be): 
The general procedure A was followed using 
5-(pyridin-2-yl)oxazole (8b) (73 mg, 0.50 mmol) and 
2-(2,2-dichlorovinyl)-1,3,5-trimethylbenzene (94e) 
(161 mg, 0.75 mmol). Purification by column 
chromatography (n-hexane/EtOAc: 10/1) yielded 9be (96 mg, 67%) as a pale yellow solid (m. 
p. = 128–129 °C).  
1H NMR (300 MHz, CDCl3): δ = 8.65 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H), 7.78 (ddd, J = 7.7, 7.4, 
1.6 Hz, 1H), 7.77 (s, 1H), 7.71 (ddd, J = 7.7, 1.1, 0.9 Hz, 1H), 7.25 (ddd, J = 7.4, 4.8, 1.1 Hz, 
1H), 6.91 (s, 2H), 2.49 (s, 6H), 2.29 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 151.2 (Cq), 150.0 (CH), 147.3 (Cq), 146.8 (Cq), 141.6 (Cq), 
139.9 (Cq), 136.9 (CH), 127.9 (CH), 126.7 (CH), 123.1 (CH), 119.5 (CH), 117.4 (Cq), 90.7 
(Cq), 84.4 (Cq), 21.4 (CH3), 20.9 (CH3).  
IR (ATR): 3100, 2914, 2207, 1604, 1519, 1280, 1153, 1075, 846, 778, 709, 401 cm–1.  
MS (EI) m/z (relative intensity) 288 (100) [M]+, 273 (10), 182 (11), 119 (25), 91 (20).  
HR-MS (EI) m/z calcd for C19H16N2O+ 288.1263, found 288.1264 [M]+.  
Synthesis of 2-[(4-Methylphenyl)ethynyl]5-(pyridin-2-yl)oxazole (9bf): 
The general procedure A was followed using 
5-(pyridin-2-yl)oxazole (8b) (73 mg, 0.50 mmol) and 











0.75 mmol). Purification by column chromatography (n-hexane/EtOAc: 30/1→5/1) yielded 
9bf (55 mg, 42%) as a pale yellow solid (m. p. = 135–137 °C).  
1H NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H), 7.78 (ddd, J = 7.7, 7.4, 
1.6 Hz, 1H), 7.74 (s, 1H), 7.70 (ddd, J = 7.7, 1.1, 0.9 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.24 
(ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 7.20 (d, J = 8.2 Hz, 2H), 2.38 (s, 3H). 
13C NMR(75 MHz, CDCl3): δ = 151.2 (Cq), 150.0 (CH), 146.9 (Cq), 146.7 (Cq), 140.5 (Cq), 
136.9 (CH), 132.1 (CH), 129.3 (CH), 126.6 (CH), 123.2 (CH), 119.5 (CH), 117.4 (Cq), 92.7 
(Cq), 76.8 (Cq), 21.6 (CH3). 
IR (ATR): 3086, 2913, 2215, 1601, 1528, 1279, 1160, 779, 742 cm–1.  
MS (EI) m/z (relative intensity) 260 (100) [M]+, 232 (10), 127 (23), 119 (43), 91 (20).  
HR-MS (EI) m/z calcd for C17H12N2O+ 260.0950, found 260.0950 [M]+. 
Synthesis of 2-[(4-Methoxyphenyl)ethynyl]-5-(pyridin-2-yl)oxazole (9bg): 
The general procedure A was followed using 
5-(pyridin-2-yl)oxazole (8b) (48 mg, 0.33 mmol) and 
1-(2,2-dichlorovinyl)-4-methoxybenzene (94g) 
(101 mg, 0.50 mmol). Purification by column chromatography (n-hexane/EtOAc: 30/1) 
yielded 9bg (35 mg, 38%) as a pale yellow solid (m. p. = 103–105 °C).  
1H NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H), 7.77 (ddd, J = 7.7, 7.4, 
1.6 Hz, 1H), 7.74 (s, 1H), 7.70 (ddd, J = 7.7, 1.1, 0.9 Hz, 1H), 7.57 (d, J = 8.7 Hz, 2H), 7.24 
(ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 6.91 (d, J = 8.7 Hz, 2H), 3.84 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 161.0 (Cq), 151.1 (Cq), 150.0 (CH), 147.1 (Cq), 146.8 (Cq), 
136.9 (CH), 133.9 (CH), 126.6 (CH), 123.2 (CH), 119.5 (CH), 114.3 (CH), 112.4 (Cq), 92.8 
(Cq), 76.4 (Cq), 55.4 (CH3). 
IR (ATR): 3113, 2938, 2214, 1608, 1533, 1296, 1112, 781, 740 cm–1.  
MS (EI) m/z (relative intensity) 276 (100) [M]+, 261 (9), 233 (10), 143 (26), 119 (54), 91 
(29).  








Synthesis of 2-[(4-Chlorophenyl)ethynyl]-5-(pyridin-2-yl)oxazole (9bh): 
The general procedure A was followed using 
5-(pyridin-2-yl)oxazole (8b) (73 mg, 0.50 mmol) and 
1-chloro-4-(2,2-dichlorovinyl)benzene (94h) (156 mg, 
0.75 mmol). Purification by column chromatography (n-hexane/EtOAc: 10/1) yielded 9bh 
(70 mg, 50%) as a pale yellow solid (m. p. = 137–138 °C).  
1H NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H), 7.77 (ddd, J = 7.7, 7.4, 
1.6 Hz, 1H), 7.75 (s, 1H), 7.70 (ddd, J = 7.7, 1.1, 0.9 Hz, 1H), 7.55 (d, J = 8.6 Hz, 2H), 7.38 
(d, J = 8.6 Hz, 2H), 7.25 (ddd, J = 7.4, 4.8, 1.1 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 151.5 (Cq), 150.0 (CH), 146.6 (Cq), 146.5 (Cq), 136.9 (CH), 
136.2 (CH), 133.4 (CH), 129.0 (CH), 126.7 (CH), 123.3 (CH), 119.6 (Cq), 119.0 (CH), 91.1 
(Cq), 78.1 (Cq).  
IR (ATR): 3090, 2217, 1673, 1522, 1158, 823, 777, 707, 521 cm–1.  
MS (EI) m/z (relative intensity) 282/280 (32/100) [M]+, 252 (12), 147 (25), 119 (75), 91 (41).  
HR-MS (EI) m/z calcd for C16H9ClN2O+ 280.0403, found 280.0412 [M]+.  
Synthesis of 2-[(2-Chlorophenyl)ethynyl]-5-(pyridin-2-yl)oxazole (9bi): 
The general procedure A was followed using 
5-(pyridin-2-yl)oxazole (8b) (73 mg, 0.50 mmol) and 
1-chloro-2-(2,2-dichlorovinyl)benzene (94i) (156 mg, 
0.75 mmol). Purification by column chromatography 
(n-hexane/EtOAc: 10/1) yielded 9bi (80 mg, 57%) as a pale yellow solid (m. p. = 
128–129 °C).  
1H NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H), 7.78 (s, 1H), 7.77 (ddd, 
J = 7.7, 7.4, 1.6 Hz, 1H), 7.74 (ddd, J = 7.7, 1.1, 0.9 Hz, 1H), 7.65 (d, J = 7.7 Hz, 1H), 7.50 (d, 
J = 8.0 Hz, 1H), 7.36 (dd, J = 8.0, 7.6 Hz, 1H), 7.28 (dd, J = 7.7, 7.6 Hz, 1H), 7.24 (ddd, J = 
7.4, 4.8, 1.1 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 151.6 (Cq), 150.0 (CH), 146.6 (Cq), 146.4 (Cq), 136.9 (CH), 
136.6 (Cq), 134.0 (CH), 130.9 (CH), 129.5 (CH), 126.8 (CH), 126.6 (CH), 123.3 (CH), 120.8 









IR (ATR): 3095, 2222, 1603, 1521, 1284, 1030, 830, 790, 747, 403 cm–1.  
MS (EI) m/z (relative intensity) 282/280 (33/100) [M]+, 252 (18), 147 (35), 119 (83), 91 (54).  
HR-MS (EI) m/z calcd for C16H9ClN2O+ 280.0403, found 280.0413 [M]+. 
Synthesis of 2-[(4-Fluorophenyl)ethynyl]-5-(pyridin-2-yl)oxazole (9bj): 
The general procedure A was followed using 
5-(pyridin-2-yl)oxazole (8b) (73 mg, 0.50 mmol) and 
1-(2,2-dichlorovinyl)-4-fluorobenzene (94j) (143 mg, 
0.75 mmol). Purification by column chromatography (n-hexane/EtOAc: 10/1) yielded 9bj 
(61 mg, 46%) as a pale white solid (m. p. = 106–108 °C).  
1H NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H), 7.76 (ddd, J = 7.7, 7.4, 
1.6 Hz, 1H), 7.74 (s, 1H), 7.68 (ddd, J = 7.7, 1.1, 0.9 Hz, 1H), 7.60 (dd, J = 8.9, 5.3 Hz, 2H), 
7.24 (ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 7.08 (dd, J = 8.9, 8.5 Hz, 2H). 
13C NMR(75 MHz, CDCl3): δ = 165.1 (Cq), 161.8 (Cq), 151.4 (Cq), 150.0 (CH), 146.5 (Cq), 
136.9 (CH), 134.3 (d, JC–F = 8.6 Hz, CH), 126.6 (CH), 123.3 (CH), 119.5 (CH), 116.6 (d, 
JC–F = 3.4 Hz, Cq), 116.0 (d, JC–F = 22.3 Hz, CH), 91.2 (Cq), 77.1 (Cq). 
IR (ATR): 3096, 2219, 1601, 1530, 1336, 834, 779, 707 cm–1.  
MS (EI) m/z (relative intensity) 264 (100) [M]+, 236 (10), 208 (8), 158 (11), 131 (32), 119 
(62), 91 (35).  
HR-MS (EI) m/z calcd for C16H9FN2O+ 264.0699, found 264.0699 [M]+.  
Synthesis of 5-(Furan-2-yl)-2-(phenylethynyl)oxazole (9cb): 
The general procedure A was followed using 
5-(furan-2-yl)oxazole (8c) (68 mg, 0.50 mmol) and 
(2,2-dichlorovinyl)benzene (94b) (130 mg, 0.75 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 10/1) yielded 9cb (54 mg, 46%) 
as a pale yellow solid (m. p. = 59–61 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.62 (dd, J = 8.1, 1.7 Hz, 2H), 7.49 (dd, J = 1.8, 0.7 Hz, 
1H), 7.44–7.38 (m, 3H), 7.31 (s, 1H), 6.72 (dd, J = 3.4, 0.7 Hz, 1H), 6.51 (dd, J = 3.4, 1.8 Hz, 
1H). 








129.9 (CH), 128.5 (CH), 123.0 (CH), 120.6 (Cq), 111.7 (CH), 108.3 (CH), 92.2 (Cq), 77.2 
(Cq). 
IR (ATR): 3128, 2218, 1639, 1620, 1066, 1011, 741, 686 cm–1.  
MS (EI) m/z (relative intensity) 235 (100) [M]+, 180 (44), 152 (58), 126 (39), 113 (19), 9 
(11). 
HR-MS (EI) m/z calcd for C15H9NO2+ 235.0633, found 235.0631 [M]+.  
Synthesis of 2-(Phenylethynyl)-5-(thiophen-2yl)oxazole (9db): 
The general procedure A was followed using 
5-(thiophen-2-yl)oxazole (8d) (76 mg, 0.50 mmol) and 
(2,2-dichlorovinyl)benzene (94b) (130 mg, 0.75 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 30/1) yielded 9db (65 mg, 52%) 
as a pale yellow solid (m. p. = 91–92 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.63 (dd, J = 7.5, 1.4 Hz, 2H), 7.45–7.35 (m, 5H), 7.27 (s, 
1H), 7.10 (dd, J = 4.8, 3.4 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 147.6 (Cq), 145.5 (Cq), 132.2 (CH), 129.9 (CH), 129.2 (Cq), 
128.5 (CH), 127.9 (CH), 126.3 (CH), 125.1 (CH), 122.9 (CH), 120.6 (Cq), 92.1 (Cq), 77.1 
(Cq).  
IR (ATR): 3107, 2216, 1530, 1164, 1017, 848, 759, 691, 524 cm–1.  
MS (EI) m/z (relative intensity) 251 (90) [M]+, 196 (100), 152 (35), 110 (25).  
HR-MS (EI) m/z calcd for C15H9NOS+ 251.0405, found 281.0400 [M]+. 
Synthesis of 5-(Furan-2-yl)-2-(103aphthalene-1-ylethynyl)oxazole (9ca): 
The general procedure A was followed using 
5-(furan-2-yl)oxazole (8c) (68 mg, 0.50 mmol) and 
1-(2,2-dichlorovinyl)naphthalene (94a) (167 mg, 0.75 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 
10/1) yielded 9ca (110 mg, 77%) as a pale yellow solid (m. p. = 78–79 °C).  
1H NMR (300 MHz, CDCl3): δ = 8.43 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.89 (d, 
J = 8.6 Hz, 1H), 7.88 (d, J = 7.3 Hz, 1H), 7.64 (dd, J = 8.0, 6.7 Hz, 1H), 7.57 (dd, J = 8.4, 







3.4 Hz, 1H), 6.54 (dd, J = 3.4, 1.9 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 145.6 (Cq), 144.4 (Cq), 143.3 (CH), 143.1 (Cq), 133.2 (Cq), 
133.0 (Cq), 131.8 (CH), 130.5 (CH), 128.4 (CH), 127.4 (CH), 126.8 (CH), 125.9 (CH), 125.1 
(CH), 123.2 (CH), 118.1 (Cq), 111.8 (CH), 108.4 (CH), 90.7 (Cq), 81.6 (Cq).  
IR (ATR): 3058, 2211, 1636, 1584, 1199, 1011, 885, 798, 772, 705 cm–1.  
MS (EI) m/z (relative intensity) 285 (100) [M]+, 230 (45), 202 (38), 176 (42), 163 (18).  
HR-MS (EI) m/z calcd for C19H11NO2+ 285.0790, found 285.0798 [M]+. 
Synthesis of 2-(Naphthalen-1-ylethynyl)-5-(thiophen-2-yl)oxazole (9da): 
The general procedure A was followed using 
5-(thiophen-2-yl)oxazole (8d) (76 mg, 0.50 mmol) and 
1-(2,2-dichlorovinyl)naphthalene (94a) (167 mg, 0.75 mmol). 
Purification by column chromatography (n-hexane/EtOAc: 
10/1) yielded 9da (100 mg, 66%) as a pale yellow solid (m. p. = 98–99 °C).  
1H NMR (300 MHz, CDCl3): δ = 8.44 (d, J = 8.1 Hz, 1H), 7.93 (d, J = 8.5 Hz, 1H), 7.88 (d, 
J = 7.7 Hz, 2H), 7.64 (dd, J = 8.5, 7.0 Hz, 1H), 7.56 (dd, J = 8.1, 7.0 Hz, 1H), 7.48 (dd, J = 
7.7 Hz, 1H), 7.41 (d, J = 3.8 Hz, 1H), 7.38 (d, J = 5.1 Hz, 1H), 7.32 (s, 1H), 7.11 (dd, J = 5.1, 
3.8 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 147.7 (Cq), 145.6 (Cq), 133.2 (Cq), 133.0 (Cq), 131.8 (CH), 
130.5 (CH), 129.2 (Cq), 128.4 (CH), 128.0 (CH), 127.4 (CH), 126.8 (CH), 126.4 (CH), 125.9 
(CH), 125.1 (CH), 123.0 (CH), 118.2 (Cq), 90.6 (Cq), 81.7 (Cq).  
IR (ATR): 3102, 2216, 1586, 1117, 911, 845, 796, 767, 705, 436 cm–1.  
MS (EI) m/z (relative intensity) 301 (92) [M]+, 245 (100), 163 (35), 111 (32).  
HR-MS (EI) m/z calcd for C19H11NOS+ 301.0561, found 301.0556 [M]+. 
Synthesis of 5-(Furan-2-yl)-2-[(4-methoxyphenyl)ethynyl]oxazole (9cg): 
The general procedure A was followed using 
5-(furan-2-yl)oxazole (8c) (68 mg, 0.50 mmol) and 
1-(2,2-dichlorovinyl)-4-methoxybenzene (94g) 
(152 mg, 0.75 mmol). Purification by column chromatography (n-hexane/EtOAc: 30/1) 









1H NMR (300 MHz, CDCl3): δ = 7.56 (d, J = 8.6, 2H), 7.48 (d, J = 1.8 Hz, 1H), 7.29 (s, 1H), 
6.90 (d, J = 8.6 Hz, 2H), 6.70 (d, J = 3.5 Hz, 1H), 6.51 (dd, J = 3.5, 1.8 Hz, 1H), 3.83 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 160.9 (Cq), 145.8 (Cq), 144.1 (Cq), 143.2 (Cq), 143.1 (CH), 
133.8 (CH), 123.0 (CH), 114.2 (CH), 112.5 (Cq), 111.7 (CH), 108.1 (CH), 92.6 (Cq), 76.1 
(Cq), 55.4 (CH3).  
IR (ATR): 3040, 2216, 1603, 1545, 1248, 1160, 1010, 963, 837, 744, 557 cm–1. 
MS (EI) m/z (relative intensity) 265 (100) [M]+, 210 (80), 182 (44), 156 (61), 143 (33), 95 
(38).  
HR-MS (EI) m/z calcd for C16H11NO3+ 265.0739, found 265.0735 [M]+. 
Synthesis of 2-[(4-Methoxyphenyl)ethynyl]-5-(thiophen-2-yl)oxazole (9dg): 
The general procedure A was followed using 
5-(thiophen-2-yl)oxazole (8d) (76 mg, 0.50 mmol) and 
1-(2,2-dichlorovinyl)-4-methoxybenzene (94g) 
(152 mg, 0.75 mmol). Purification by column chromatography (n-hexane/EtOAc: 30/1) 
yielded 9dg (80 mg, 57%) as a pale yellow solid (m. p. = 96–97 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.57 (d, J = 8.8 Hz, 2H), 7.34 (d, J = 5.0 Hz, 1H), 7.33 (d, 
J = 3.5 Hz, 1H), 7.26 (s, 1H), 7.10 (dd, J = 5.0, 3.5 Hz, 1H), 6.91 (d, J = 8.8 Hz, 2H), 3.82 (s. 
3H).  
13C NMR (75 MHz, CDCl3): δ = 160.9 (Cq), 147.3 (Cq), 145.8 (Cq), 133.8 (CH), 129.3 (Cq), 
127.9 (CH), 126.2 (CH), 124.9 (CH), 122.8 (CH), 114.2 (CH), 112.6 (Cq), 92.5 (Cq), 76.1 
(Cq), 55.4 (CH3).  
IR (ATR): 3078, 2214, 1602, 1535, 1248, 1175, 1016, 823, 704, 568 cm–1.  
MS (EI) m/z (relative intensity) 281 (90) [M]+, 226 (100), 211 (26), 183 (15), 111 (22).  
HR-MS (EI) m/z calcd for C16H11NO2S+ 281.0510, found 281.0511 [M]+. 
Synthesis of 5-(Thiophen-2-yl)-2-(thiophen-2-ylethynyl)oxazole (9dm): 
The general procedure A was followed using 
5-(thiophen-2-yl)oxazole (8d) (76 mg, 0.50 mmol) and 
2-(2,2-dichlorovinyl)thiophene (94m) (134 mg, 0.75 mmol). 








as a pale yellow solid (m. p. = 110–111 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.40 (d, J = 5.1 Hz, 1H), 7.44 (d, J = 3.6 Hz, 1H), 7.36 (d, 
J = 5.3 Hz, 1H), 7.35 (d, J = 3.4 Hz, 1H), 7.27 (s, 1H), 7.04 (d, J = 5.1, 3.6 Hz, 1H), 7.08 (dd, 
J = 5.3, 3.4 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 147.7 (Cq), 145.4 (Cq), 134.6 (CH), 129.6 (CH), 129.2 (Cq), 
127.9 (CH), 127.4 (CH), 126.4 (CH), 125.2 (CH), 123.1 (CH), 120.6 (Cq), 85.8 (Cq), 80.9 
(Cq).  
IR (ATR): 3075, 2203, 1589, 1410, 1211, 1019, 824, 715, 486 cm–1.  
MS (EI) m/z (relative intensity) 257 (88) [M]+, 202 (100), 158 (30), 119 (26), 110 (24), 69 
(41).  
HR-MS (EI) m/z calcd for C13H7NOS2+ 256.9969, found 256.9972 [M]+.  
5.4.2 Analytical Data for Arylated Indolylacetamides 
Synthesis of N-(4-Methoxybenzyl)-2-(1-methyl-2-phenyl-1H-indol-3-yl)acetamide 
(96ah): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)acetamide (95a) 
(154 mg, 0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 
0.75 mmol). After 17 h, purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 96ah (184 mg, 96%) as a pale white solid (m. p. = 
157–158 °C). 
1H NMR (300 MHz, CDCl3): δ = 7.59 (ddd, J = 7.8, 1.1, 0.9 Hz, 1H), 7.46 (d, J = 7.6 Hz, 
1H), 7.45 (d, J = 8.4 Hz, 2H), 7.37 (ddd, J = 8.2, 1.3, 0.9 Hz, 1H), 7.30 (ddd, J = 8.2, 6.9, 
1.1 Hz, 1H), 7.27 (dd, J = 8.4, 7.6 Hz, 2H), 7.19 (ddd, J = 7.8, 6.9, 1.3 Hz, 1H), 7.03 (d, J = 
8.8 Hz, 2H), 6.78 (d, J = 8.8 Hz, 2H), 5.98 (t, J = 5.9 Hz, 1H), 4.31 (d, J = 5.9 Hz, 2H), 3.77 
(s, 3H), 3.71 (s, 2H), 3.62 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 171.4 (Cq), 158.8 (Cq), 139.9 (Cq), 137.3 (Cq), 130.7 (Cq), 
130.4 (Cq), 130.3 (CH), 128.8 (CH), 128.7 (CH), 128.6 (CH), 127.3 (Cq), 122.4 (CH), 120.1 










IR (ATR): 3244, 1631, 1512, 1254, 1175, 747 cm–1. 
MS (EI) m/z (relative intensity) 384 (23) [M]+, 220 (100), 204 (22), 121 (14). 
HR-MS (EI): m/z calcd for C25H24N2O2+ 384.1838, found 384.1837 [M]+. 
Synthesis of N-(4-Methoxybenzyl)-3-(2-phenyl-1H-indol-3-yl)propanamide (96bh): 
The general procedure B was followed using 
3-(1H-indol-3-yl)-N-(4-methoxybenzyl)propanamide (95b) 
(154 mg, 0.50 mmol) and diphenyliodonium tosylate (26h) 
(339 mg, 0.75 mmol). After 17 h, purification by column 
chromatography (n-hexane/EtOAc: 2/1) yielded 96bh (42 mg, 22%) as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 8.26 (s, 1H), 7.64 (dd, J = 7.8, 1.2 Hz, 1H), 7.53 (d, J = 
8.5 Hz, 2H), 7.44 (dd,J = 8.5, 7.5 Hz, 2H), 7.38 (dd, J =8.1, 1.3 Hz, 1H), 7.36 (d, J =7.5 Hz, 
1H), 7.20 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.13 (ddd, J = 7.8, 7.0, 1.3 Hz, 1H), 6.97 (d, J = 
8.7 Hz, 2H), 6.77 (d, J = 8.7 Hz, 2H), 5.54 (t, J = 5.8 Hz, 1H), 4.23 (d, J = 5.8 Hz, 2H), 3.77 (s, 
3H), 3.28 (t, J = 8.6 Hz, 2H), 2.55 (t, J = 8.6 Hz, 2H). 
13C NMR (75 MHz, CDCl3): δ = 172.3 (Cq), 158.8(Cq), 135.8 (Cq), 134.6 (Cq), 132.8 (Cq), 
130.1 (Cq), 129.0 (CH), 128.9 (CH), 128.7 (Cq), 127.9 (CH), 127.7 (CH), 122.3 (CH), 119.7 
(CH), 119.0 (CH), 113.9 (CH), 111.5 (Cq), 110.9 (CH), 55.2 (CH3), 43.0 (CH2), 37.4 (CH2), 
20.7 (CH2). 
IR (ATR): 3279, 1644, 1510, 1242, 1174, 1029, 743, 695 cm–1.  
MS (EI) m/z (relative intensity) 384 (51) [M]+, 234 (19), 222 (30), 206 (100), 178 (23), 136 
(33), 121 (64).  
HR-MS (EI): m/z calcd for C25H24N2O2+ 384.1838, found 384.1825 [M]+. 
Synthesis of N-(4-Methoxybenzyl)-2-(2-phenyl-1H-indol-3-yl)acetamide (96ch): 
The general procedure B was followed using 
2-(1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (95c) (147 mg, 
0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 
0.75 mmol). After 17 h, purification by column chromatography 
















165–166 °C).  
1H NMR (300 MHz, d6-DMSO): δ = 11.2 (s, 1H), 8.42 (t, J = 5.9 Hz, 1H), 7.79 (d, J = 8.5 
Hz, 2H), 7.59 (dd, J = 7.8, 1.1 Hz, 1H), 7.48 (dd, J = 8.5, 7.5 Hz, 2H), 7.40 (dd, J = 8.1, 1.3 
Hz, 1H), 7.37 (d, J = 7.5 Hz, 1H), 7.17 (d, J = 8.6 Hz, 2H), 7.11 (ddd, J = 8.1, 7.0, 1.1 Hz, 
1H), 7.00 (ddd, J = 7.8, 7.0, 1.3 Hz, 1H), 6.85 (d, J = 8.6 Hz, 2H), 4.24 (d, J = 5.8 Hz, 2H), 
3.73 (s, 3H), 3.67 (s, 2H).  
13C NMR (75 MHz, d6-DMSO): δ = 170.6 (Cq), 158.1 (Cq), 135.9 (Cq), 135.8 (Cq), 132.5 
(Cq), 131.5 (Cq), 128.9 (Cq), 128.5 (CH), 128.4 (CH), 128.0 (CH), 127.4 (CH), 121.4 (CH), 
118.8 (CH), 118.6 (CH), 113.6 (CH), 111.0 (CH), 106.0 (Cq), 55.0 (CH3), 41.8 (CH2), 31.8 
(CH2).  
IR (ATR): 3385, 1638, 1508, 1240, 1175, 1028, 815, 746, 695 cm–1.  
MS (EI) m/z (relative intensity) 370 (31) [M]+, 206 (100), 193 (60), 121 (40).  
HR-MS (EI): m/z calcd for C24H22N2O2+ 370.1681, found 370.1682 [M]+. 
Synthesis of 2-[2-(4-Fluorophenyl)-1-methyl-1H-indol-3-yl)-N-(4-methoxybenzyl)-
acetamide (96ai): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)acetamide (95a) 
(154 mg, 0.50 mmol) and bis(4-fluorophenyl)iodonium tosylate 
(26i) (366 mg, 0.75 mmol). After 17 h, purification by column 
chromatography (n-hexane/EtOAc: 2/1) yielded 96ai (191 mg, 95%) as a pale white solid (m. 
p. = 150–151 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.57 (dd, J = 7.8, 1.1 Hz, 1H), 7.37 (dd, J = 8.2, 1.3 Hz, 
1H), 7.34–7.23 (m, 3H), 7.23–7.10 (m, 3H), 7.0 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 
5.98 (t, J = 5.9 Hz, 1H), 4.31 (d, J = 5.9 Hz, 2H), 3.78 (s, 3H), 3.67 (s, 2H), 3.60 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ= 171.2 (Cq), 162.9 (Cq, JC–F = 249.3 Hz), 158.8 (Cq), 138.7 
(Cq), 137.2 (Cq), 132.1 (CH, JC–F = 8.3 Hz), 130.4 (Cq), 128.8 (CH), 127.2 (Cq), 126.7 (Cq, 
JC–F = 3.2 Hz), 122.5 (CH), 120.2 (CH), 118.8 (CH), 115.8 (CH, JC–F = 22.2 Hz), 113.8 (CH), 
109.6 (CH), 105.9 (Cq), 55.2 (CH3), 42.8 (CH2), 32.8 (CH2), 30.9 (CH3).  









MS (EI) m/z (relative intensity) 402 (26) [M]+, 238 (100), 222 (21), 121 (14).  
HR-MS (EI): m/z calcd for C25H23FN2O2+ 402.1744, found 402.1744 [M]+. 
Synthesis of 2-[2-(4-Chlorophenyl)-1-methyl-1H-indol-3-yl]-N-(4-methoxybenzyl)-
acetamide (96aj): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)acetamide (95a) 
(154 mg, 0.50 mmol) and bis(4-chlorophenyl)iodonium tosylate 
(26j) (391 mg, 0.75 mmol). After 17 h, purification by column 
chromatography (n-hexane/EtOAc: 2/1) yielded 96aj (187 mg, 89%) as a pale white solid 
(m. p. = 167–168 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.63 (dd, J = 8.0, 1.1 Hz, 1H), 7.59 (d, J = 8.3 Hz, 2H), 
7.35 (dd, J = 8.3, 1.3 Hz, 1H), 7.31 (ddd, J = 8.3, 6.8, 1.1 Hz, 1H), 7.23 (d, J = 8.3 Hz, 2H), 
7.19 (ddd, J = 8.0, 6.8, 1.3 Hz, 1H), 7.03 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 5.95 (t, 
J = 5.9 Hz, 1H), 4.30 (d, J = 5.9 Hz, 2H), 3.79 (s, 3H), 3.68 (s, 2H), 3.61 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 171.1 (Cq), 158.8 (Cq), 138.5 (Cq), 137.3 (Cq), 134.8 (Cq), 
131.5 (CH), 130.3 (Cq), 129.1 (Cq), 129.0 (CH), 128.8 (CH), 127.2 (Cq), 122.7 (CH), 120.3 
(CH), 118.8 (CH), 113.8 (CH), 109.7 (CH), 106.1 (Cq), 55.3 (CH3), 42.8 (CH2), 32.8 (CH2), 
31.0 (CH3).  
IR (ATR): 3280, 1638, 1547, 1513, 1255, 1028, 741 cm–1.  
MS (EI) m/z (relative intensity) 420/418 (8/26) [M]+, 256/254 (32/100), 219 (67), 121 (34).  
HR-MS (EI): m/z calcd for C25H23ClN2O2+ 418.1448, found 418.1437 [M]+. 
Synthesis of 2-[2-(4-Bromophenyl)-1-methyl-1H-indol-3-yl]-N-(4-methoxybenzyl)-
acetamide (96ak): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)acetamide (95a) 
(154 mg, 0.50 mmol) and bis(4-bromophenyl)iodonium tosylate 
(26k) (458 mg, 0.75 mmol). After 17 h, purification by column 
chromatography (n-hexane/EtOAc: 2/1) yielded 96ak (215 mg, 93%) as a pale white solid (m. 















1H NMR (300 MHz, CDCl3): δ = 7.63 (d, J = 8.4 Hz, 2H), 7.59 (dd, J = 8.2, 1.1 Hz, 1H), 
7.36 (dd, J = 8.3, 1.3 Hz, 1H), 7.31 (ddd, J = 8.3, 6.7, 1.1 Hz, 1H), 7.19 (ddd, J = 8.2, 6.7, 
1.3 Hz, 1H), 7.17 (d, J = 8.4 Hz, 2H), 7.02 (d, J = 8.8 Hz, 2H), 6.79 (d, J = 8.8 Hz, 2H), 5.95 
(t, J = 5.9 Hz, 1H), 4.30 (d, J = 5.9 Hz, 2H), 3.79 (s, 3H), 3.68 (s, 2H), 3.61 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 171.1 (Cq), 158.8 (Cq), 138.5 (Cq), 137.3 (Cq), 132.0 (CH), 
131.8 (CH), 130.3 (Cq), 129.6 (Cq), 128.8 (CH), 127.2 (Cq), 123.0 (Cq), 122.7 (CH), 120.3 
(CH), 118.8 (CH), 113.8 (CH), 109.7 (CH), 106.1 (Cq), 55.3 (CH3), 42.8 (CH2), 32.8 (CH2), 
31.0 (CH3).  
IR (ATR): 3243, 1629, 1556, 1513, 1242, 1175, 834, 747 cm–1.  
MS (EI) m/z (relative intensity) 464/462 (29/28) [M]+, 300/298 (99/100), 219 (96), 204 (27), 
121 (49).  
HR-MS (EI): m/z calcd for C25H23BrN2O2+ 462.0943, found 462.0952 [M]+. 
Synthesis of 2-{2-[4-(tert-Butyl)phenyl]-1-methyl-1H-indol-3-yl}-N-(4-methoxyben-
zyl)acetamide (96al): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)acetamide 
(95a) (154 mg, 0.50 mmol) and bis(4-tert-butylphenyl)-
iodonium tosylate (26l) (423 mg, 0.75 mmol). After 17 h, 
purification by column chromatography (n-hexane/EtOAc: 2/1) yielded 96al (183 mg, 83%) 
as a pale white solid (m. p. = 139–140 °C).  
1H NMR(300 MHz, CDCl3): δ = 7.58 (dd, J = 8.0, 1.1 Hz, 1H), 7.46 (d, J = 8.7 Hz, 2H), 7.35 
(dd, J = 8.3, 1.3 Hz, 1H), 7.29 (ddd, J = 8.3, 6.7, 1.1 Hz, 1H), 7.22 (d, J = 8.7 Hz, 2H), 7.18 
(ddd, J = 8.0, 6.7, 1.3 Hz, 1H), 7.05 (d, J = 9.1 Hz, 2H), 6.78 (d, J = 9.1 Hz, 2H), 6.02 (t, J = 
6.0 Hz, 1H), 4.31 (d, J = 6.0 Hz, 2H), 3.78 (s, 3H), 3.71 (s, 2H), 3.63 (s, 3H), 1.39 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 171.6 (Cq), 158.8 (Cq), 151.6 (Cq), 140.1 (Cq), 137.2 (Cq), 
130.5 (Cq), 129.9 (CH), 128.8 (CH), 127.6 (Cq), 127.4 (Cq), 125.6 (CH), 122.2 (CH), 120.0 
(CH), 118.7 (CH), 113.8 (CH), 109.6 (CH), 105.5 (Cq), 55.2 (CH3), 42.8 (CH2), 34.7 (Cq), 
33.0 (CH2), 31.3 (CH3), 31.0 (CH3).  









MS (EI) m/z (relative intensity) 440 (34) [M]+, 276 (100), 220 (66), 121 (26).  
HR-MS (EI): m/z calcd for C29H32N2O2+ 440.2464, found 440.2471 [M]+. 
Synthesis of N-(4-Methoxybenzyl)-2-[2-(4-methoxyphenyl)-1-methyl-1H-indol-3-yl]-
acetamide (96ag): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)acetamide 
(95a) (154 mg, 0.50 mmol) and bis(4-methoxyphenyl)- 
iodonium tosylate (26g) (384 mg, 0.75 mmol). After 17 h, 
purification by column chromatography (n-hexane/EtOAc: 2/1) yielded 96ag (175 mg, 84%) 
as a pale white solid (m. p. = 153–154 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.57 (dd, J = 8.0, 1.1 Hz, 1H), 7.35 (dd, J = 8.3, 1.3 Hz, 
1H), 7.28 (ddd, J = 8.3, 6.7, 1.1 Hz, 1H), 7.21 (d, J = 9.0 Hz, 2H), 7.18 (ddd, J = 8.0, 6.7, 
1.3 Hz, 1H), 7.03 (d, J = 8.3 Hz, 2H), 6.98 (d, J = 9.0 Hz, 2H), 6.78 (d, J = 8.3 Hz, 2H), 6.01 
(t, J = 6.0 Hz, 1H), 4.31 (d, J = 6.0 Hz, 2H), 3.88 (s, 3H), 3.78 (s, 3H), 3.70 (s, 2H), 3.61 (s, 
3H).  
13C NMR (75 MHz, CDCl3): δ = 171.5 (Cq), 159.8 (Cq), 158.7 (Cq), 139.8 (Cq), 137.1 (Cq), 
131.5 (CH), 130.4 (Cq), 128.8 (CH), 127.3 (Cq), 122.8 (Cq), 122.2 (CH), 120.0 (CH), 118.6 
(CH), 114.2 (CH), 113.8 (CH), 109.5 (CH), 105.3 (Cq), 55.3 (CH3), 55.2 (CH3), 42.8 (CH2), 
32.9 (CH2), 30.8 (CH3). 
IR (ATR): 3258, 2935, 2836, 1626, 1611, 1507, 1243, 1029, 841, 746 cm–1.  
MS (EI) m/z (relative intensity) 414 (23) [M]+, 250 (100), 219 (17), 121 (16).  
HR-MS (EI): m/z calcd for C26H26N2O3+ 414.1943, found 414.1942 [M]+. 
Synthesis of 2-[2-(2,4-Dimethylphenyl)-1-methyl-1H-indol-3-yl]-N-(4-methoxyben-
zyl)acetamide (96am): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)acetamide (95a) 
(154 mg, 0.50 mmol) and bis(2,4-dimethylphenyl)iodonium 
















column chromatography (n-hexane/EtOAc: 2/1) yielded 96am (130 mg, 63%) as a pale white 
solid (m. p. = 160–161 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.61 (d, J = 8.0 Hz, 1H), 7.37 (d, J = 8.2 Hz, 1H), 7.29 (dd, 
J = 8.0, 6.7 Hz, 1H), 7.19 (dd, J = 8.2, 6.7 Hz, 1H), 7.14 (s, 1H), 7.05 (d, J = 7.6 Hz, 1H), 
7.03 (d, J = 8.0 Hz, 2H), 6.99 (d, J = 7.6 Hz, 1H), 6.79 (d, J = 8.0 Hz, 2H), 6.02 (t, J = 6.0 Hz, 
1H), 4.34 (dd, J = 14.7, 6.0 Hz, 1H), 4.25 (dd, J = 14.7, 6.0 Hz, 1H), 3.79 (s, 3H), 3.66 (d, J = 
17.4 Hz, 1H), 3.50 (d, J = 17.4 Hz, 1H), 3.47 (s, 3H), 2.41 (s, 3H), 1.98 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 171.3 (Cq), 158.7 (Cq), 139.6 (Cq), 139.1 (Cq), 138.0 (Cq), 
136.9 (Cq), 131.0 (CH), 130.9 (CH), 130.3 (Cq), 128.8 (CH), 127.3 (Cq), 127.2 (Cq), 126.6 
(CH), 121.9 (CH), 119.8 (CH), 118.7 (CH), 113.7 (CH), 109.4 (CH), 105.4 (Cq), 55.2 (CH3), 
42.7 (CH2), 32.7 (CH2), 30.2 (CH3), 21.2 (CH3), 19.4 (CH3).  
IR (ATR): 3251, 2923, 1633, 1513, 1256, 1032, 831, 747 cm–1.  
MS (EI) m/z (relative intensity) 412 (24) [M]+, 248 (100), 233 (26), 218 (25), 121 (15). 
HR-MS (EI): m/z calcd for C27H28N2O2+ 412.2151, found 412.2152 [M]+. 
Synthesis of N-(4-Methoxybenzyl)-2-[1-methyl-2-(thiophen-2-yl)-1H-indol-3-yl]-
acetamide (96ao): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)acetamide (95a) 
(154 mg, 0.50 mmol) and di(thiophen-2-yl)iodonium tosylate (26o) 
(348 mg, 0.75 mmol). After 17 h, purification by column 
chromatography (n-hexane/EtOAc: 2/1) yielded 96ao (127 mg, 65%) as a pale white solid (m. 
p. = 158–160 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.59 (dd, J = 7.9, 1.0 Hz, 1H), 7.50 (dd, J = 5.2, 1.2 Hz, 
1H), 7.36 (dd, J = 8.2, 1.3 Hz, 1H), 7.30 (ddd, J = 8.2, 6.7, 1.0 Hz, 1H), 7.19 (ddd, J = 7.9, 
6.7, 1.3 Hz, 1H), 7.16 (dd, J = 5.2, 3.8 Hz, 1H), 7.06 (dd, J = 3.8, 1.2 Hz, 1H), 7.05 (d, J = 
8.5 Hz, 2H), 6.78 (d, J = 8.5 Hz, 2H), 5.96 (t, J = 5.9 Hz, 1H), 4.32 (d, J = 5.9 Hz, 2H), 3.79 
(s, 2H), 3.77 (s, 3H), 3.70 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 171.1 (Cq), 158.7 (Cq), 137.4 (Cq), 132.2 (Cq), 130.8 (Cq), 









(CH), 118.9 (CH), 113.8 (CH), 109.7 (CH), 108.0 (Cq), 55.2 (CH2), 42.8 (CH2), 33.1 (CH2), 
30.9 (CH3).  
IR (ATR): 3240, 3071, 1628, 1513, 1463, 1255, 1229, 1032, 816, 747, 705 cm–1.  
MS (EI) m/z (relative intensity) 390 (29) [M]+, 226 (100), 213 (15), 210 (11), 121 (19). 
HR-MS (EI): m/z calcd for C23H22N2O2S+ 390.1402, found 390.1402 [M]+. 
Synthesis of 2-(5-Chloro-1-methyl-2-phenyl-1H-indol-3-yl)-N-(4-methoxybenzyl)-
acetamide (96gh): 
The general procedure B was followed using 
2-(5-chloro-1-methyl-1H-indol-3-yl)-N-(4-methoxybenzyl)- 
acetamide (95g) (172 mg, 0.50 mmol) and diphenyliodonium 
tosylate (26h) (339 mg, 0.75 mmol). After 17 h, purification by 
column chromatography (n-hexane/EtOAc: 2/1) yielded 96gh (101 mg, 48%) as a pale white 
solid (m. p. = 156–157 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.55 (d, J = 1.9 Hz, 1H), 7.50–7.46 (m, 3H), 7.33–7.28 (m, 
2H), 7.25–7.23 (m, 2H), 7.06 (d, J = 8.5 Hz, 2H), 6.81 (d, J = 8.5 Hz, 2H), 5.92 (t, J = 5.8 Hz, 
1H), 4.32 (d, J = 5.8 Hz, 2H), 3.78 (s, 3H), 3.63 (s, 2H), 3.59 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 170.9 (Cq), 158.8 (Cq), 141.1 (Cq), 135.6 (Cq), 130.3 (Cq), 
130.3 (Cq), 130.2 (CH), 128.8 (CH), 128.8 (CH), 128.7 (CH), 128.3 (Cq), 125.8 (Cq), 122.6 
(CH), 118.3 (CH), 113.9 (CH), 110.7 (CH), 105.5 (Cq), 55.2 (CH3), 42.9 (CH2), 32.8 (CH2), 
31.2 (CH3).  
IR (ATR): 3283, 1645, 1512, 1469, 1253, 1226, 1110, 853, 784, 707 cm–1.  
MS (EI) m/z (relative intensity) 420/418 (7/23) [M]+, 256/254 (32/100), 220/218 (10/32), 121 
(21).  
HR-MS (EI): m/z calcd for C25H23ClN2O2+ 418.1448, found 418.1438 [M]+. 
Synthesis of 2-(5-Bromo-1-methyl-2-phenyl-1H-indol-3-yl)-N-(4-methoxybenzyl)-
acetamide (96hh): 
The general procedure B was followed using 
2-(5-bromo-1-methyl-1H-indol-3-yl)-N-(4-methoxybenzyl)- 

















tosylate (26h) (339 mg, 0.75 mmol). After 17 h, purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 96hh (130 mg, 56%) as a pale white solid (m. p. = 
157–158 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.71 (d, J = 1.9 Hz, 1H), 7.48–7.43(m, 3H), 7.35 (dd, J = 
8.7, 1.9 Hz, 1H), 7.28 (dd, J = 7.6, 3.5 Hz, 2H), 7.22 (d, J = 8.7 Hz, 1H), 7.06 (d, J = 8.9 Hz, 
2H), 6.82 (d, J = 8.9 Hz, 2H), 5.91 (t, J = 5.8 Hz, 1H), 4.33 (d, J = 5.8 Hz, 2H), 3.78 (s, 3H), 
3.63 (s, 2H), 3.59 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 170.9 (Cq), 158.8 (Cq), 141.0 (Cq), 135.9 (Cq), 130.2 (CH), 
130.2 (Cq), 128.9 (Cq), 128.9 (Cq), 128.9 (Cq), 128.8 (CH), 128.8 (CH), 125.2 (CH), 121.4 
(CH), 113.9 (CH), 113.3 (CH), 111.2 (CH), 105.3 (Cq), 55.26 (CH3), 42.87 (CH2), 32.73 
(CH2), 31.13 (CH3).  
IR (ATR): 3272, 1647, 1543, 1467, 1246, 1225, 1028, 789, 709 cm–1.  
MS (EI) m/z (relative intensity) 464/462 (22/23) [M]+, 330/298 (99/100), 220/218 (75/75), 
204 (29), 121 (45).  
HR-MS (EI): m/z calcd for C25H23BrN2O2+ 462.0943, found 462.0950 [M]+. 
Synthesis of 2-(1,5-Dimethyl-2-phenyl-1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide 
(96ih): 
The general procedure B was followed using 2-(1,5-di-
methyl-1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (95i) 
(161 mg, 0.50 mmol) and diphenyliodonium tosylate (26h) 
(339 mg, 0.75 mmol). After 17 h, purification by column 
chromatography (n-hexane/EtOAc: 2/1) yielded 96ih (181 mg, 91%) as a pale white solid (m. 
p. = 180–181 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.46 (d, J = 7.4 Hz, 1H), 7.44 (d, J = 8.5 Hz, 2H), 7.35 (s, 
1H), 7.27 (dd, J = 8.5, 7.4 Hz, 2H), 7.25 (d, J = 8.4 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 7.04 (d, 
J = 8.6 Hz, 2H), 6.80 (d, J = 8.6 Hz, 2H), 6.04 (t, J = 6.0 Hz, 1H), 4.32 (d, J = 6.0 Hz, 2H), 
3.78 (s, 3H), 3.68 (s, 2H), 3.59 (s, 3H), 2.47 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 171.5 (Cq), 158.7 (Cq), 139.9 (Cq), 135.7 (Cq), 130.8 (Cq), 










(CH), 118.5 (CH), 113.8 (CH), 109.3 (CH), 105.0 (Cq), 55.2 (CH3), 42.7 (CH2), 32.9 (CH2), 
31.0 (CH3), 21.4 (CH3).  
IR (ATR): 3261, 2912, 1630, 1512, 1253, 1176, 1031, 796, 698 cm–1.  
MS (EI) m/z (relative intensity) 398 (22) [M]+, 234 (100), 218 (23), 121 (15).  
HR-MS (EI): m/z calcd for C26H26N2O2+ 398.1994, found 398.1985 [M]+. 
Synthesis of 2-(5-Methoxy-1-methyl-2-phenyl-1H-indol-3-yl)-N-(4-methoxybenzyl)-
acetamide (96jh): 
The general procedure B was followed using 2-(5-methoxy- 
1-methyl-1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (95j) 
(169 mg, 0.50 mmol) and diphenyliodonium tosylate (26h) 
(339 mg, 0.75 mmol). After 17 h, purification by column 
chromatography (n-hexane/EtOAc: 2/1) yielded 96jh (180 mg, 87%) as a pale white solid (m. 
p. = 178–179 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.48 (d, J = 7.6 Hz, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.29 (dd, 
J = 8.5, 7.6 Hz, 2H), 7.27 (d, J = 8.3 Hz, 1H), 7.06 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 2.3 Hz, 
1H), 6.95 (dd, J = 8.3, 2.3 Hz, 1H), 6.80 (d, J = 8.8 Hz, 2H), 6.10 (t, J = 6.0 Hz, 1H), 4.33 (d, 
J = 6.0 Hz, 2H), 3.83 (s, 3H), 3.78 (s, 3H), 3.69 (s, 2H), 3.60 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 171.4 (Cq), 158.8 (Cq), 154.6 (Cq), 140.4 (Cq), 132.5 (Cq), 
130.8 (Cq), 130.4 (Cq), 130.2 (CH), 128.7 (CH), 128.6 (CH), 128.5 (CH), 127.6 (Cq), 113.8 
(CH), 112.8 (CH), 110.5 (CH), 105.2 (Cq), 100.1 (CH), 55.8 (CH3), 55.2 (CH3), 42.7 (CH2), 
32.9 (CH2), 31.1 (CH3).  
IR (ATR): 3267, 1631, 1513, 1482, 1235, 1164, 1027, 703 cm–1.  
MS (EI) m/z (relative intensity) 414 (25) [M]+, 250 (100), 235 (10), 206 (17), 121 (15). 
HR-MS (EI): m/z calcd for C26H26N2O3+ 414.1943, found 414.1948 [M]+. 
Synthesis of 2-(1-Benzyl-2-phenyl-1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (96kh): 
The general procedure B was followed using 
2-(1-benzyl-1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (95k) 
(192 mg, 0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 
















(n-hexane/EtOAc: 2/1) yielded 96kh (198 mg, 86%) as a pale white solid (m. p. = 
178–179 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.66–7.59 (m, 1H), 7.42–7.32 (m, 3H), 7.24–7.16 (m, 8H), 
7.04 (d, J = 8.6 Hz, 2H), 6.91–6.87 (m, 2H), 7.79 (d, J = 8.6 Hz, 2H), 5.97 (t, J = 5.8 Hz, 1H), 
5.23 (s, 2H), 4.32 (d, J = 5.8 Hz, 2H), 3.78 (s, 3H), 3.73 (s, 2H).  
13C NMR (75 MHz, CDCl3): δ = 171.3 (Cq), 158.8 (Cq), 140.0 (Cq), 137.8 (Cq), 136.9 (Cq), 
130.6 (Cq), 130.4 (Cq), 130.2 (CH), 128.8 (CH), 128.7 (CH), 128.7 (CH), 128.6 (CH), 127.6 
(Cq), 127.2 (CH), 125.9 (CH), 122.6 (CH), 120.4 (CH), 118.9 (CH), 113.9 (CH), 110.6 (CH), 
106.4 (Cq), 55.2 (CH3), 47.7 (CH2), 42.9 (CH2), 32.9 (CH2).  
IR (ATR): 3309, 1637, 1511, 1240, 1032, 811, 744 cm–1.  
MS (EI) m/z (relative intensity) 460 (31) [M]+, 296 (100), 204 (19), 91 (89).  
HR-MS (EI): m/z calcd for C31H28N2O2+ 460.2151, found 460.2146 [M]+. 
Synthesis of 2-(1-n-Butyl-2-phenyl-1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (96lh): 
The general procedure B was followed using 
2-(1-n-butyl-1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (95l) 
(175 mg, 0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 
0.75 mmol). After 17 h, purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 96lh (199 mg, 93%) as a pale white solid (m. p. = 94–95 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.59 (dd, J = 7.8, 1.1 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 
7.44 (d, J = 8.4 Hz, 2H), 7.39 (dd, J = 8.2, 1.3 Hz, 1H), 7.29 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 
7.26 (dd, J = 8.4, 7.6 Hz, 2H), 7.18 (ddd, J = 7.8, 7.0, 1.3 Hz, 1H), 7.01 (d, J = 8.6 Hz, 2H), 
6.78 (d, J = 8.6 Hz, 2H), 5.93 (t, J = 5.9 Hz, 1H), 4.29 (d, J = 5.9 Hz, 2H), 4.01 (t, J = 7.3 Hz, 
2H), 3.78 (s, 3H), 3.67 (s, 2H), 1.60 (tt, J = 7.3, 7.3 Hz, 2H), 1.11 (tq, J = 7.3, 7.3 Hz, 2H), 
0.74 (t, J = 7.3 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 171.4 (Cq), 158.8 (Cq), 139.7 (Cq), 136.4 (Cq), 131.1 (Cq), 
130.5 (Cq), 130.3 (CH), 128.7 (CH), 128.7 (CH), 128.6 (CH), 127.4 (Cq), 122.2 (CH), 120.0 
(CH), 118.9 (CH), 95.8 (CH), 110.1 (CH), 105.9 (Cq), 55.3 (CH3), 43.8 (CH2), 42.8 (CH2), 
32.8 (CH2), 32.0 (CH2), 19.9 (CH2), 13.5 (CH3).  









MS (EI) m/z (relative intensity) 426 (54) [M]+, 262 (100), 206 (25), 121 (16).  
HR-MS (EI): m/z calcd for C28H30N2O2+ 426.2307, found 426.2312 [M]+. 
Synthesis of N-(4-Methoxybenzyl)-2-(1-n-octyl-2-phenyl-1H-indol-3-yl)acetamide 
(96mh): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-(1-n-octyl-1H-indol-3-yl)acetamide (95m) 
(203 mg, 0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 
0.75 mmol). After 17 h, purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 96mh (176 mg, 73%) as a pale white solid (m. p. = 
100–101 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.59 (dd, J = 7.9, 0.9 Hz), 7.49–7.42 (m, 3H), 7.38 (dd, J = 
8.3, 1.2 Hz, 1H), 7.29–7.23 (m, 3H), 7.18 (ddd, J = 7.9, 6.9, 1.2 Hz, 1H), 7.01 (d, J = 8.6 Hz, 
2H), 6.78 (d, J = 8.6 Hz, 2H), 5.95 (t, J = 5.9 Hz, 1H), 4.29 (d, J = 5.9 Hz, 2H), 3.99 (t, J = 
7.4 Hz, 2H), 3.78 (s, 3H), 3.67 (s, 2H), 1.62 (tt, J = 7.4 Hz, 2H), 1.30–1.03 (m, 10H), 0.85 (t, 
J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ = 171.4 (Cq), 158.8 (Cq), 139.7 (Cq), 136.3 (Cq), 131.1 (Cq), 
130.4 (Cq), 130.3 (CH), 128.7 (CH), 128.6 (CH), 128.6 (CH), 127.4 (Cq), 122.2 (CH), 120.0 
(CH), 118.9 (CH), 113.8 (CH), 110.0 (CH), 105.8 (Cq), 55.2 (CH3), 44.0 (CH2), 42.8 (CH2), 
32.8 (CH2), 31.7 (CH2), 29.8 (CH2), 29.0 (CH2), 28.9 (CH2), 26.7 (CH2), 22.5 (CH2), 14.0 
(CH3).  
IR (ATR): 3285, 2922, 2850, 1644, 1545, 1354, 1254, 1174, 1027, 814, 726, 707 cm–1.  
MS (EI) m/z (relative intensity) 482 (24) [M]+, 318 (100), 206 (20), 121 (23).  
HR-MS (EI): m/z calcd for C32H38N2O2+ 482.2933, found 482.2938 [M]+. 
Synthesis of 2-(1-Methyl-2-phenyl-1H-indol-3-yl)acetamide (96oh): 
The general procedure B was followed using 
2-(1-methyl-1H-indol-3-yl)acetamide (95o) (94 mg, 0.50 mmol) and 
diphenyliodonium tosylate (26h) (339 mg, 0.75 mmol). After 17 h, 
purification by column chromatography (n-hexane/EtOAc: 1/2) yielded 














1H NMR (300 MHz, CDCl3): δ = 7.62 (dd, J = 7.8, 1.2 Hz, 1H), 7.54–7.46 (m, 3H), 
7.40–7.37 (m, 3H), 7.31 (ddd, J = 7.8, 6.9, 1.0 Hz, 1H), 7.21 (ddd, J = 7.5, 6.9, 1.2 Hz, 1H), 
5.71 (s, 2H), 3.65 (s, 3H), 3.64 (s, 2H).  
13C NMR (75 MHz, CDCl3): δ = 174.4 (Cq), 139.7 (Cq), 137.3 (Cq), 130.7 (Cq), 130.3 (CH), 
128.7 (CH), 128.6 (CH), 127.2 (Cq), 122.4 (CH), 120.1 (CH), 118.7 (CH), 109.6 (CH), 106.1 
(Cq), 32.5 (CH2), 31.0 (CH3).  
IR (ATR): 3378, 3191, 1651, 1461, 1399, 1235, 733, 615 cm–1.  
MS (EI) m/z (relative intensity) 264 (25) [M]+, 220 (100), 204 (29), 178 (10).  
HR-MS (EI): m/z calcd for C17H16N2O+ 264.1263, found 264.1255 [M]+. 
Synthesis of N-Cyclopropyl-2-(1-methyl-2-phenyl-1H-indol-3-yl)acetamide (96ph): 
The general procedure B was followed using 
N-cyclopropyl-(1-methyl-1H-indol-3-yl)acetamide (113p) (96 mg, 
0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 
0.75 mmol). After 17 h, purification by column chromatography 
(n-hexane/EtOAc: 1/4) yielded 96ph (150 mg, 98%) as a pale white solid (m. p. = 
182–183 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.55 (dd, J = 7.9, 1.0 Hz, 1H), 7.53–7.44 (m, 3H), 7.39 (dd, 
J = 8.2, 1.2 Hz, 1H), 7.37–7.33 (m, 2H), 7.30 (ddd, J = 8.2, 6.9, 1.0 Hz, 1H), 7.19 (ddd, J = 
7.9, 6.9, 1.2 Hz, 1H), 5.83 (s, 1H), 3.65 (s, 3H), 3.63 (s, 2H), 2.61 (tt, J = 7.0, 4.0 Hz, 1H), 
0.68 (ddd, J = 8.1, 7.0, 5.6 Hz, 2H), 0.29 (ddd, J = 7.6, 5.6, 4.0 Hz, 2H).  
13C NMR (75 MHz, CDCl3): δ = 172.9 (Cq) , 139.7 (Cq), 137.2 (Cq), 130.7 (Cq), 130.2 (CH), 
128.7 (CH), 128.6 (CH), 127.2 (Cq), 122.3 (CH), 120.1 (CH), 118.6 (CH), 109.6 (CH), 105.8 
(Cq), 32.8 (CH2), 31.0 (CH3), 22.5 (CH), 6.5 (CH2).  
IR (ATR): 3291, 1639, 1533, 1470, 1231, 765, 737, 707 cm–1.  
MS (EI) m/z (relative intensity) 304 (23) [M]+, 220 (100), 204 (27), 178 (11).  










Synthesis of N,N-Dimethyl-2-(1-methyl-2-phenyl-1H-indol-3-yl)acetamide (96qh): 
The general procedure B was followed using 
N,N-dimethyl-(1-methyl-1H-indol-3-yl)acetamide (95q) (108 mg, 
0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 0.75 mmol). 
After 17 h, purification by column chromatography (n-hexane/EtOAc: 
1/4) yielded 96qh (141 mg, 96%) as a pale yellow solid (m. p. = 136–137 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.75 (dd, J = 7.8, 1.0 Hz, 1H), 7.58–7.39 (m, 5H), 7.35 (dd, 
J = 8.2, 1.2 Hz, 1H), 7.27 (ddd, J = 8.2, 6.9, 1.0 Hz, 1H), 7.17 (ddd, J = 7.8, 6.9, 1.2 Hz, 1H), 
3.77 (s, 2H), 3.62 (s, 3H), 2.89 (s, 3H), 2.77 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 171.3 (Cq), 138.4 (Cq), 137.2 (Cq), 131.4 (Cq), 130.5 (CH), 
128.4 (CH), 128.2 (CH), 127.6 (Cq), 121.8 (CH), 119.6 (CH), 119.5 (CH), 109.2 (CH), 106.5 
(Cq), 37.3 (CH3), 35.5 (CH3), 31.0 (CH2), 30.8 (CH3).  
IR (ATR): 3010, 2938, 1650, 1469, 1131, 742, 713, 608 cm–1.  
MS (EI) m/z (relative intensity) 292 (20) [M]+, 220 (100), 204 (25), 178 (14).  
HR-MS (EI): m/z calcd for C19H20N2O+ 292.1576, found 292.1568 [M]+. 
Synthesis of 2-{2-[2-(Allyloxy)phenyl]-1H-indol-3-yl}-N-methylacetamide (96sp): 
The general procedure B was followed using 2-(1H-indol-3-yl)-N-methylacetamide (95s) 
(47 mg, 0.25 mmol) and [2-(allyloxy)phenyl](mesityl)iodonium tosylate (26p) (138 mg, 
0.25 mmol). After 17 h, purification by column chromatography (n-hexane/EtOAc: 1/1) 
yielded 96sp (11 mg, 14%) as a yellow solid (m. p. = 67–69 °C), 2-iodo-1,3,5- 
trimethylbenzene (108) (7 mg, 11%) as a yellow oil and a mixture (21 mg, 30%) of 
2-(allyloxy)iodobenzene (109) and 2-tosyloxy-1,3,5-trimethylbenzene (110), the ratio of 
which was estimated by GC to be 1:1. 
1H NMR (500 MHz, CDCl3): δ = 8.84 (s, 1H), 7.57 (ddd, J = 7.9, 0.9, 
0.7 Hz, 1H), 7.42 (ddd, J = 8.3, 1.2, 0.7 Hz, 1H), 7.39 (ddd, J = 7.8, 
7.6, 1.6 Hz, 1H), 7.35 (dd, J = 8.0, 1.6 Hz, 1H), 7.26 (ddd, J = 8.3, 
7.0, 1.0 Hz, 1H), 7.17 (ddd, J = 7.9, 7.0, 1.2 Hz, 1H), 7.08 (ddd, J = 
8.0, 7.6, 1.1 Hz, 1H), 7.03 (dd, J = 7.8, 1.1 Hz, 1H), 5.99 (ddt, J = 













3.0, 1.7 Hz, 1H), 5.26 (ddt, J = 10.5, 3.0, 1.5 Hz, 1H), 4.59 (ddd, J = 5.2, 1.7, 1.5 Hz, 2H), 
3.77 (s, 2H), 2.70 (d, J = 4.9 Hz, 3H).  
13C NMR (126 MHz, CDCl3): δ = 172.1 (Cq), 155.7 (Cq), 135.6 (Cq), 133.6 (Cq), 132.6 (CH), 
130.9 (CH), 129.8 (CH), 128.0 (Cq), 122.5 (CH), 121.4 (CH), 120.6 (Cq), 120.0 (CH), 118.6 
(CH), 117.9 (Cq), 113.0 (CH), 110.8 (CH), 106.5 (CH2), 69.4 (CH2), 33.2 (CH2), 26.4 (CH3).  
IR (ATR): 3385, 2167, 2018, 1651, 1488, 1456, 1221, 993, 740 cm–1.  
MS (ESI) m/z (relative intensity) 663 (38) [2M+Na]+, 641 (40) [2M+H]+, 343 (33) [M+Na]+, 
321 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C20H21N2O2+ 321.1603, found 321.1601 [M+H]+. 
Synthesis of N-(4-Methoxybenzyl)-2-(1-methyl-2-phenyl-1H-indol-3-yl)propanamide 
(96th): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)propanamide (95t) 
(81 mg, 0.250 mmol) and diphenyliodonium tosylate (26h) (170 mg, 
0.375 mmol). After 17 h, purification by column chromatography 
(n-hexane/EtOAc: 3/2) yielded 96th (46 mg, 46%) as a yellow solid (m. p. = 137–138 °C).  
1H NMR (500 MHz, CDCl3): δ = 7.65 (ddd, J = 8.1, 1.0, 0.9 Hz, 1H), 7.51–7.45 (m, 3H), 
7.36 (ddd, J = 8.2, 1.2, 0.9 Hz, 1H), 7.33–7.30 (m, 2H), 7.28 (ddd, J = 8.2, 7.1, 1.0 Hz, 1H), 
7.15 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 7.02 (d, J = 8.7 Hz, 2H), 6.75 (d, J = 8.7 Hz, 2H), 5.97 (t, 
J = 5.4 Hz, 1H), 4.30 (qd, J = 14.8, 5.4 Hz, 2H), 3.77 (s, 3H), 3.74 (t, J = 7.4 Hz, 1H), 3.57 (s, 
3H), 1.63 (d, J = 7.4 Hz, 3H).  
13C NMR (126 MHz, CDCl3): δ = 174.3 (Cq), 158.6 (Cq), 139.0 (Cq), 137.3 (Cq), 131.0 (Cq), 
130.6 (Cq), 130.4 (CH), 128.7 (CH), 128.6 (CH), 128.6 (CH), 125.5 (Cq), 122.0 (CH), 120.2 
(CH), 119.7 (CH), 113.7 (CH), 112.1 (Cq), 109.6 (CH), 55.3 (CH3), 43.0 (CH2), 38.2 (CH), 
30.9 (CH3), 17.7 (CH3).  
IR (ATR): 3385, 3128, 2790, 1644, 1509, 1467, 1242, 1035, 736, 701 cm–1.  
MS (ESI) m/z (relative intensity) 819 (50) [2M+Na]+, 797 (41) [2M+H]+, 421 (19) [M+Na]+, 
399 (100) [M+H]+. 










Synthesis of N-(4-Methoxybenzyl)-2-methyl-2-(1-methyl-2-phenyl-1H-indol-3-yl)- 
propionamide (96uh): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-methyl-2-(1-methyl-1H-indol-3-yl)- 
propanamide (95u) (50 mg, 0.15 mmol) and diphenyliodonium 
tosylate (26h) (101 mg, 0.22 mmol). After 17 h, purification by 
column chromatography (n-hexane/EtOAc: 2/1) yielded 96uh (12 mg, 20%) as a yellow solid 
(m. p. = 152–153 °C).  
1H NMR (500 MHz, CDCl3): δ = 7.55 (d, J = 8.1 Hz, 1H), 7.49–7.41 (m, 3H), 7.32–7.28 (m, 
3H), 7.25 (ddd, J = 8.2, 6.9, 0.9 Hz, 1H), 7.10 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 6.98 (d, J = 
8.7 Hz, 2H), 6.74 (d, J = 8.7 Hz, 2H), 5.93 (t, J = 5.3 Hz, 1H), 4.29 (d, J = 5.3 Hz, 2H), 3.76 
(s, 3H), 3.34 (s, 3H), 1.41 (s, 6H). 
13C NMR (126 MHz, CDCl3): δ = 178.3 (Cq), 158.6 (Cq), 137.8 (Cq), 136.6 (Cq), 133.7 (Cq), 
131.0 (CH), 130.7 (Cq), 128.8 (CH), 128.7 (CH), 128.0 (CH), 126.0 (Cq), 121.9 (CH), 120.8 
(CH), 119.5 (CH), 115.6 (Cq), 113.7 (CH), 109.3 (CH), 55.3 (CH3), 44.1 (CH2), 43.2 (Cq), 
30.2 (CH3), 28.5 (CH3).  
IR (ATR): 3385, 3200, 1648, 1511, 1463, 1361, 1245, 1178, 1031, 744, 723 cm–1.  
MS (ESI) m/z (relative intensity) 847 (50) [2M+Na]+, 825 (41) [2M+H]+, 435 (23) [M+Na]+, 
413 (100) [M+H]+. 
HR-MS (ESI): m/z calcd for C27H29N2O2+ 413.2229, found 413.2227 [M+H]+. 
Synthesis of 2,2-Dideutero-N-(4-methoxybenzyl)-2-(2-deutero-1-methyl-1H-indol-3-
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A flame-dried flask was charged with N-(4-methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)- 
acetamide (95a) (1.54 g, 5.0 mmol) and anhydrous THF (10 mL) under a N2 atmosphere. The 











0 °C, and a 2.67 M n-BuLi solution in hexane (3.75 mL, 10.0 mmol) was added dropwise. 
The resulting solution was allowed to warm up to ambient temperature and stirred for an 
additional 20 minutes. Very slowly, 0.5 mL of D2O was added dropwise. The solution was 
extracted with n-hexane (3 × 5 mL). The organic layers were combined and dried over 
Na2SO4, and the solvents were removed in vacuo. The resulting crude product was 
transferred to the flame-dried flask, and the above described deuteration procedure was 
repeated again. The final purification by column chromatography (n-hexane/EtOAc: 2/1) 
yielded [D]3-95a (996 mg, 64%) as a pale white solid (m. p. = 96–97 °C). 
1H NMR (300 MHz, CDCl3): δ = 7.50 (dd, J = 8.1, 1.0 Hz, 1H), 7.30 
(dd, J = 8.3, 1.2 Hz, 1H), 7.24 (ddd, J = 8.3, 6.7, 1.0 Hz, 1H), 7.15 
(ddd, J = 8.1, 6.7, 1.2 Hz, 1H), 7.06 (d, J = 8.8 Hz, 2H), 6.77 (d, J = 
8.8 Hz, 2H), 5.99 (t, J = 5.9 Hz, 1H), 4.32 (d, J = 5.9 Hz, 2H), 3.77 (s, 
3H), 3.75 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 171.4 (Cq), 158.8 (Cq), 137.1 (Cq), 130.4 (Cq), 128.8 (CH), 
128.0 (t, JC–D = 27.8 Hz, CD), 127.5 (Cq), 122.2 (CH), 119.6 (CH), 118.9 (CH), 113.9 (CH), 
109.5 (CH), 107.1 (Cq), 55.3 (CH3), 42.8 (CH2), 33.0 (quintet, JC–D = 19.3 Hz, CD2), 32.7 
(CH3).  
IR (ATR): 3254, 2937, 1626, 1510, 1494, 1249, 1029, 747 cm–1. 
MS (ESI) m/z (relative intensity) 623 (38) [2M+H]+, 357 (16) [M+2Na]+, 312 (100) [M+H]+. 
HR-MS (EI): m/z calcd for C19H18D3N2O2+ 312.1791, found 312.1789 [M+H]+. 



































A mixture of 2,2-dideutero-N-(4-methoxybenzyl)-2-(2-deutero-1-methyl-1H-indol-3-yl)- 
acetamide [D]3-95a (156 mg, 0.50 mmol) and diphenyliodonium tosylate (26h) (113 mg, 










(5 mL) was added, and the aqueous layer was extracted with EtOAc (2 × 20 mL). The organic 
layers were combined, and the solvents were removed in vacuo. Purification of the residue by 
column chromatography (n-hexane/EtOAc: 2/1) yielded [D]2-96aa (75 mg, 78% on the basis 
of 26a) as a pale white solid (m. p. = 165–166 °C) and [D]n-95a (61 mg, 39%). The 
deuterium incorporation was estimated by 1H NMR spectroscopy. 
2,2-Dideutero-N-(4-methoxybenzyl)-2-(2-deutero-1-methyl-2-phenyl-1H-indol-3-yl)- 
acetamide ([D]2-96ah): 
1H NMR (300 MHz, CDCl3): δ = 7.60 (dd, J = 8.0, 1.0 Hz, 1H), 
7.46–7.41 (m, 3H), 7.36 (dd, J = 8.2, 1.2 Hz, 1H), 7.33–7.25 (m, 3H), 
7.25 (ddd, J = 8.1, 6.7, 1.3 Hz, 1H), 7.02 (d, J = 8.9 Hz, 2H), 6.76 (d, 
J = 8.9 Hz, 2H), 6.00 (t, J = 5.9 Hz, 1H), 4.29 (d, J = 5.9 Hz, 2H), 3.76 
(s, 3H), 3.60 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ= 171.4(Cq), 158.7 (Cq), 139.9 (Cq), 137.3(Cq), 130.7 (Cq), 
130.4 (Cq), 130.2 (CH), 128.8 (CH), 128.7 (CH), 128.6 (CH), 127.3 (Cq), 122.4 (CH), 120.1 
(CH), 118.8 (CH), 113.8 (CH), 109.6 (CH), 105.6 (Cq), 55.2 (CH3), 42.8 (CH2), 32.5 (quintet, 
JC–D = 17.6 Hz, CD2), 31.0 (CH3).  
IR (ATR): 3248, 2937, 1625, 1510, 1494, 1251, 1026, 747 cm–1.  
MS (ESI) m/z (relative intensity) 1181 (23) [3M+Na]+, 795 (81) [2M+Na]+, 409 (100) 
[M+Na]+. 
HR-MS (ESI): m/z calcd for C25H22D2N2NaO2+ 409.1861, found 409.1857 [M+Na]+. 






















































A mixture of N-(4-methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)acetamide (95a) (154 mg, 
0.50 mmol), 2,2-dideutero-N-(4-methoxybenzyl)-2-(2-deutero-1-methyl-1H-indol-3-yl)- 
acetamide ([D]3-95a) (156 mg, 0.50 mmol) and diphenyliodonium tosylate (26h) (226 mg, 
0.50 mmol) in DMF (2.00 mL) was stirred at 100 °C for 30 min. At ambient temperature, 
H2O (5 mL) was added, and the aqueous layer was extracted with EtOAc (2 × 20 mL). The 
organic layers were combined, and the solvents were removed in vacuo. Purification of the 
residue by column chromatography (n-hexane/EtOAc: 2/1) yielded a mixture of 96ah and 
[D]2-96ah as a pale white solid (116 mg, 30%). The kinetic isotope effect of this reaction was 
determined to be kH/kD = 1.22, as estimated by 1H NMR spectroscopy. 
5.4.3 Analytical Data for Pyrroloindolones 
Synthesis of 8,8a-Dimethyl-1-(4-methoxybenzyl)-3a-phenyl-3,3a,8,8a-tetrahydro-
pyrrolo[2,3-b]indol-2(1H)-one (98ah): 
The general procedure B was followed using 2-(1,2-dimethyl-
1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (97a) (161 mg, 
0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 
0.75 mmol). After 17 h, purification by column chromatography (n-hexane/EtOAc: 1/1) 
yielded 98ah (177 mg, 89%) as a pale white solid (m. p. = 145–146 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.29–7.21 (m, 3H), 7.16 (ddd, J = 7.8, 7.6, 1.3 Hz, 1H), 7.05 
(dd, J = 8.0, 1.8 Hz, 2H), 6.97 (dd, J = 7.5, 1.3 Hz, 1H), 6.90 (d, J = 8.6 Hz, 2H), 6.75 (ddd, J = 
7.6, 7.5, 1.1 Hz, 1H), 6.72 (d, J = 8.6 Hz, 2H), 6.28 (dd, J = 7.8, 1.1 Hz, 1H), 4.58 (d, J = 
16.0 Hz, 1H), 4.31 (d, J = 16.0 Hz, 1H), 3.76 (s, 3H), 3.50 (d, J = 16.7 Hz, 1H), 3.14 (d, J = 
16.7 Hz, 1H), 2.69 (s, 3H), 1.06 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 172.4 (Cq), 158.4 (Cq), 149.0 (Cq), 139.6 (Cq), 134.4 (Cq), 
129.4 (Cq), 128.9 (CH), 128.3 (CH), 127.8 (CH), 127.4 (CH), 127.2 (CH), 124.2 (CH), 118.8 
(CH), 113.7 (CH), 106.9 (CH), 91.5 (Cq), 58.2 (Cq), 55.2 (CH3), 43.0 (CH2), 39.2 (CH2), 29.3 
(CH3), 18.4 (CH3).  
IR (ATR): 2912, 1681, 1488, 1246, 1034, 749, 701, 621 cm–1.  
MS (EI) m/z (relative intensity) 398 (39) [M]+, 236 (65), 221 (76), 121 (100).  










Synthesis of 8,8a-Dimethyl-3a-(4-fluorophenyl)-1-(4-methoxybenzyl)-3,3a,8,8a- 
tetrahydropyrrolo[2,3-b]indol-2(1H)-one (98ai): 
The general procedure B was followed using 2-(1,2-dimethyl-
1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (97a) (161 mg, 
0.50 mmol) and bis(4-fluorophenyl)iodonium (26i) tosylate (366 mg, 
0.75 mmol). After 17 h, purification by column chromatography 
(n-hexane/EtOAc: 1/1) yielded 98ai (168 mg, 81%) as a pale white 
solid (m. p. = 166–167 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.17 (ddd, J = 7.6, 7,6, 1.3 Hz, 1H), 7.09–6.82 (m, 7H), 6.73 
(ddd, J = 7.6, 7,6, 0.9 Hz, 1H), 6.71 (d, J = 8.7 Hz, 2H), 6.28 (d, J = 7.6 Hz, 1H), 4.57 (d, J = 
16.0  Hz, 1H), 4.30 (d, J = 16.0 Hz, 1H), 3.76 (s, 3H), 3.43 (d, J = 16.6 Hz, 1H), 3.13 (d, J = 
16.6 Hz, 1H), 2.69 (s, 3H), 1.05 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 172.1 (Cq), 163.4 (Cq, JC–F = 245.7 Hz), 158.5 (Cq), 148.8 
(Cq), 135.4 (Cq, JC–F = 3.2 Hz), 134.2 (Cq), 129.3 (Cq), 129.2 (CH), 129.1 (CH, JC–F = 3.2 
Hz), 127.8 (CH), 124.1 (CH), 118.9 (CH), 115.2 (CH, JC–F = 21.2 Hz), 113.7 (CH), 107.1 
(CH), 91.4 (Cq), 57.7 (Cq), 55.2 (CH3), 43.0 (CH2), 39.3 (CH2), 29.3 (CH3), 18.4 (CH3).  
IR (ATR): 3011, 1694, 1604, 1509, 1489, 1294, 755, 519 cm–1.  
MS (EI) m/z (relative intensity) 416 (31) [M]+, 254 (42), 239 (71), 121 (100).  
HR-MS (EI): m/z calcd for C26H25FN2O2+ 416.1900, found 416.1900 [M]+. 
Synthesis of 3a-(4-Chlorophenyl)-8,8a-dimethyl-1-(4-methoxybenzyl)-3,3a,8,8a- 
tetrahydropyrrolo[2,3-b]indol-2(1H)-one (98aj): 
The general procedure B was followed using 2-(1,2-dimethyl-
1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (97a) (161 mg, 
0.50 mmol) and bis(4-chlorophenyl)iodonium tosylate (26j) (391 mg, 
0.75 mmol). After 17 h, purification by column chromatography 
(n-hexane/EtOAc: 1/1) yielded 98aj (179 mg, 83%) as a pale light 
yellow solid (m. p. = 182–183 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.22 (d, J = 8.6 Hz, 2H), 7.17 (ddd, J = 7.7, 7,7, 1.3 Hz, 1H), 

















7.7, 7.7, 1.0 Hz, 1H), 6.71 (d, J = 8.8 Hz, 2H), 6.27 (d, J = 7.7 Hz, 1H), 4.57 (d, J = 16.0 Hz, 
1H), 4.29 (d, J = 16.0 Hz, 1H), 3.76 (s, 3H), 3.41 (d, J = 16.6 Hz, 1H), 3.12 (d, J = 16.6 Hz, 1H), 
2.69 (s, 3H), 1.06 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 172.0 (Cq), 158.5 (Cq), 148.8 (Cq), 138.2 (Cq), 133.9 (Cq), 
133.2 (Cq), 129.3 (Cq), 129.1 (CH), 128.9 (CH), 128.5 (CH), 127.8 (CH), 124.1 (CH), 119.0 
(CH), 113.7 (CH), 107.1 (CH), 91.3 (Cq), 57.8(Cq), 55.2 (CH3), 43.0 (CH2), 39.0 (CH2), 29.3 
(CH3), 18.4 (CH3).  
IR (ATR): 3011, 1692, 1606, 1512, 1490, 1293, 746, 509 cm–1.  
MS (EI) m/z (relative intensity) 434/432 (7/21) [M]+, 272/270 (11/33), 257/255 (17/52), 121 
(100).  
HR-MS (EI): m/z calcd for C26H25ClN2O2+ 432.1605, found 432.1605 [M]+. 
Synthesis of 3a-(4-Bromophenyl)-8,8a-dimethyl-1-(4-methoxybenzyl)-3,3a,8,8a- 
tetrahydropyrrolo[2,3-b]indol-2(1H)-one (98ak): 
The general procedure B was followed using 2-(1,2-dimethyl-
1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (97a) (161 mg, 
0.50 mmol) and bis(4-bromophenyl)iodonium tosylate (26k) (458 mg, 
0.75 mmol). After 17 h, purification by column chromatography 
(n-hexane/EtOAc: 1/1) yielded 98ak (188 mg, 79%) as a pale white 
solid (m. p. = 160–161 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.37 (d, J = 8.7 Hz, 2H), 7.17 (ddd, J = 7.6, 7.6, 1.3 Hz, 1H), 
6.98–6.89 (m, 3H), 6.87 (d, J = 8.7 Hz, 2H), 6.75 (dd, J = 7.6, 1.0 Hz, 1H), 6.71 (d, J = 8.7 Hz, 
2H), 6.27 (dd, J = 7.6, 1.0 Hz, 1H), 4.57 (d, J = 16.0 Hz, 1H), 4.29 (d, J = 16.0 Hz, 1H), 3.76 (s, 
3H), 3.41 (d, J = 16.5 Hz, 1H), 3.12 (d, J = 16.5 Hz, 1H), 2.69 (s, 3H), 1.06 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 172.0 (Cq), 158.6 (Cq), 148.9 (Cq), 138.8 (Cq), 133.9 (Cq), 
131.5 (CH), 129.3 (Cq), 129.3 (CH), 129.2 (CH), 127.8 (CH), 124.1 (CH), 121.5 (Cq), 119.0 
(CH), 113.8 (CH), 107.2 (CH), 91.3 (Cq), 57.9 (Cq), 55.3 (CH3), 43.1 (CH2), 39.0 (CH2), 
29.3 (CH3), 18.5 (CH3).  










MS (EI) m/z (relative intensity) 478/476 (14/14) [M]+,316/314 (24/24), 301/299 (31/31), 158 
(19), 121 (100).  
HR-MS (EI): m/z calcd for C26H25BrN2O2+ 476.1099, found 476.1097 [M]+. 
Synthesis of 3a-(4-tert-Butylphenyl)-8,8a-dimethyl-1-(4-methoxybenzyl)-3,3a,8,8a- 
tetrahydropyrrolo[2,3-b]indol-2(1H)-one (98al): 
The general procedure B was followed using 2-(1,2-dimethyl-
1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (97a) (161 mg, 
0.50 mmol) and bis(4-tert-butylphenyl)iodonium tosylate (26l) 
(423 mg, 0.75 mmol). After 17 h, purification by column 
chromatography (n-hexane/EtOAc: 1/1) yielded 98al (193 mg, 85%) 
as a pale white solid (m. p. = 83–85 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.26 (d, J = 8.7 Hz, 2H), 7.16 (ddd, J = 7.6, 7.6, 1.3 Hz, 1H), 
7.00–6.94 (m, 3H), 6.88 (d, J = 8.6 Hz, 2H), 6.76 (ddd, J = 7.6, 7.6, 1.0 Hz, 1H), 6.71 (d, J = 
8.6 Hz, 2H), 6.26 (dd, J = 7.6, 0.6 Hz, 1H), 4.58 (d, J = 16.1 Hz, 1H), 4.28 (d, J = 16.1 Hz, 1H), 
3.76 (s, 3H), 3.48 (d, J = 16.6 Hz, 1H), 3.12 (d, J = 16.6 Hz, 1H), 2.68 (s, 3H), 1.26 (s, 9H), 1.06 
(s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 172.5 (Cq), 158.5 (Cq), 150.1 (Cq), 149.0 (Cq), 136.5 (Cq), 
134.5 (Cq), 129.5 (Cq), 128.8 (CH), 127.8 (CH), 127.1 (CH), 125.2 (CH), 124.3 (CH), 118.7 
(CH), 113.7 (CH), 106.9 (CH), 91.5 (Cq), 57.9 (Cq), 55.2 (CH3), 43.0 (CH2), 39.3 (CH2), 
34.3 (Cq), 31.2 (CH3), 29.3 (CH3), 18.6 (CH3).  
IR (ATR): 2958, 1686, 1606, 1511, 1490, 1301, 1243, 741 cm–1.  
MS (EI) m/z (relative intensity) 454 (46) [M]+, 292 (92), 277 (53), 262 (24), 121 (100).  
HR-MS (EI): m/z calcd for C30H34N2O2+ 454.2620, found 454.2608 [M]+. 
Synthesis of 8,8a-Dimethyl-1-(4-methoxybenzyl)-3a-(4-methoxyphenyl)-3,3a,8,8a- 
tetrahydropyrrolo[2,3-b]indol-2(1H)-one (98ag): 
The general procedure B was followed using 2-(1,2-dimethyl-
1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (97a) (161 mg, 
0.50 mmol) and bis(4-methoxyphenyl)iodonium tosylate (26g) 

















chromatography (n-hexane/EtOAc: 1/1) yielded 98ag (178 mg, 83%) as a pale white solid (m. 
p. = 71–72 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.16 (ddd, J = 7.6, 7.6, 1.3 Hz, 1H), 7.00–6.93 (m, 3H), 6.87 
(d, J = 8.4 Hz, 2H), 6.80-6.75 (m, 3H), 6.71 (d, J = 8.8 Hz, 2H), 6.27 (d, J = 7.6 Hz, 1H), 4.57 
(d, J = 16.0 Hz, 1H), 4.30 (d, J = 16.0 Hz, 1H), 3.76 (s, 6H), 3.44 (d, J = 16.6 Hz, 1H), 3.11 (d, 
J = 16.6 Hz, 1H), 2.69 (s, 3H), 1.05 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 172.4 (Cq), 158.6 (Cq), 158.4 (Cq), 148.9 (Cq), 134.5 (Cq), 
131.6 (Cq), 129.5 (Cq), 128.8 (CH), 128.6 (CH), 127.8 (CH), 124.1 (CH), 118.8 (CH), 113.7 
(CH), 113.6 (CH), 106.9 (CH), 91.5 (Cq), 57.6 (Cq), 55.2 (CH3), 55.1 (CH3), 43.0 (CH2), 
39.3 (CH2), 29.3 (CH3), 18.4 (CH3).  
IR (ATR): 2935, 1682, 1606, 1510, 1490, 1244, 1030, 748 cm–1.  
MS (EI) m/z (relative intensity) 428 (53) [M]+, 266 (100), 251 (82), 121 (90).  
HR-MS (EI): m/z calcd for C27H28N2O3+ 428.2100, found 428.2099 [M]+. 
Synthesis of 1-Benzyl-8,8a-dimethyl-3a-phenyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]-
indol-2(1H)-one (98bh): 
The general procedure B was followed using 
N-benzyl-2-(1,2-dimethyl-1H-indol-3-yl)acetamide (97b) (146 mg, 
0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 0.75 mmol). 
After 17 h, purification by column chromatography (n-hexane/EtOAc: 1/1) yielded 98bh 
(166 mg, 90%) as a pale white solid (m. p. = 68–69 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.31–7.23 (m, 3H), 7.21–7.11 (m, 4H), 7.06 (dd, J = 8.1, 
1.7 Hz, 2H), 7.01-6.88 (m, 3H), 6.76 (ddd, J = 7.4, 7.4, 1.0 Hz, 1H), 6.24 (d, J = 7.4 Hz, 1H), 
4.69 (d, J = 16.3 Hz, 1H), 4.33 (d, J = 16.3 Hz, 1H), 3.52 (d, J = 16.7 Hz, 1H), 3.16 (d, J = 
16.7 Hz, 1H), 2.66 (s, 3H), 1.08 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 172.4 (Cq), 148.9 (Cq), 139.6 (Cq), 137.2 (Cq), 134.4 (Cq), 
128.9 (CH), 128.4 (CH), 128.3 (CH), 127.4 (CH), 127.3 (CH), 126.8 (CH), 126.6 (CH), 124.2 
(CH), 118.8 (CH), 107.0 (CH), 91.4 (Cq), 58.2 (Cq), 43.5 (CH2), 39.1 (CH2), 29.2 (CH3), 
18.4 (CH3).  










MS (EI) m/z (relative intensity) 368 (64) [M]+, 236 (61), 220 (44), 158 (20), 132 (33), 91 
(100).  
HR-MS (EI): m/z calcd for C25H24N2O+ 368.1889, found 368.1880 [M]+. 
Synthesis of 3a-Phenyl-1,8,8a-trimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol- 
2(1H)-one (98ch): 
The general procedure B was followed using 
2-(1,2-dimethyl-1H-indol-3-yl)-N-methylacetamide (97c) (108 mg, 
0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 0.75 mmol). 
After 17 h, purification by column chromatography (n-hexane/EtOAc: 1/1) yielded 98ch 
(126 mg, 86%) as a pale white solid (m. p. = 190–191 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.31–7.21 (m, 3H), 7.18 (ddd, J = 7.6, 7.6, 1.2 Hz, 1H), 7.04 
(dd, J = 8.0, 1.7 Hz, 2H), 6.91 (dd, J = 7.6, 7.6, 1.2 Hz, 1H), 6.72 (ddd, J = 7.6, 7.6, 1.0 Hz, 1H), 
6.51 (dd, J = 7.6, 1.0 Hz, 1H), 3.35 (d, J = 16.4 Hz, 1H), 3.00 (s, 3H), 2.96 (d, J = 16.4 Hz, 1H), 
2.80 (s, 3H), 1.12 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 171.78 (Cq), 149.0 (Cq), 139.7 (Cq), 134.6 (Cq), 128.9 (CH), 
128.4 (CH), 127.5 (CH), 127.2 (CH), 124.3 (CH), 119.0 (CH), 106.6 (CH), 90.9 (Cq), 57.7 
(Cq), 39.8 (CH2), 30.0 (CH3), 26.6 (CH3), 17.4 (CH3).  
IR (ATR): 2924, 1681, 1605, 1492, 1236, 1037, 740, 693 cm–1.  
MS (EI) m/z (relative intensity) 292 (88) [M]+, 234 (44), 220 (38), 158 (18), 56 (100).  
HR-MS (EI): m/z calcd for C19H20N2O+ 292.1576, found 292.1583 [M]+. 
Synthesis of 8,8a-Dimethyl-3a-phenyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol2(1H)-one 
(98dh): 
The general procedure B was followed using 
2-(1,2-dimethyl-1H-indol-3-yl)acetamide (97d) (101 mg, 0.50 mmol) and 
diphenyliodonium tosylate (26h) (339 mg, 0.75 mmol). After 17 h, 
purification by column chromatography (n-hexane/EtOAc: 1/1) yielded 98dh (114 mg, 82%) 
as a pale white solid (m. p. = 206–208 °C).  
1H NMR (300 MHz, CDCl3): δ = 8.08 (s, 1H), 7.30–7.20 (m, 3H), 7.19 (ddd, J = 7.8, 7.0, 
















7.0, 1.0 Hz, 1H), 6.55 (dd, J = 7.8, 1.0 Hz, 1H), 3.42 (d, J = 16.8 Hz, 1H), 2.90 (d, J = 16.8 Hz, 
1H), 2.80 (s, 3H), 1.14 (s, 3H).  
13C NMR(75 MHz, CDCl3):δ = 175.4 (Cq), 150.0 (Cq), 139.7 (Cq), 135.1 (Cq), 128.9 (CH), 
128.3 (CH), 127.4 (CH), 127.3 (CH), 124.3 (CH), 119.3 (CH), 108.0 (CH), 88.6 (Cq), 58.5 
(Cq), 41.2 (CH2), 28.9 (CH3), 21.3 (CH3).  
IR (ATR): 3060, 1692, 1487, 1365, 748, 700 cm–1.  
MS (EI) m/z (relative intensity) 278 (100) [M]+, 236 (61), 234 (51), 220 (51), 194 (10), 158 
(22), 118 (13).  
HR-MS (EI): m/z calcd for C18H18N2O+ 278.1419, found 278.1424 [M]+. 
Synthesis of 8,8a-Dimethyl-1,3a-diphenyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol- 
2(1H)-one (98eh): 
The general procedure B was followed using 
2-(1,2-dimethyl-1H-indol-3-yl)-N-phenylacetamide (97e) (139 mg, 
0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 0.75 mmol). 
After 17 h, purification by column chromatography (n-hexane/EtOAc: 1/1) yielded 98eh 
(94 mg, 53%) as a pale white solid (m. p. = 172–173 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.43–7.35 (m, 3H), 7.32–7.22 (m, 4H), 7.14–7.08 (m, 2H), 
7.05–6.99 (m, 3H), 6.79 (ddd, J = 7.4, 7.4, 1.0 Hz, 1H), 6.53 (d, J = 7.4 Hz, 1H), 3.63 (d, J = 
16.7 Hz, 1H), 3.15 (dd, J = 16.7 Hz, 1H), 2.44 (s, 3H), 1.28 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 172.1 (Cq), 149.0 (Cq), 139.5 (Cq), 136.6 (Cq), 134.5 (Cq), 
129.7 (CH), 129.4 (CH), 129.2 (CH), 128.5 (CH), 128.4 (CH), 127.4 (CH), 127.3 (CH), 124.5 
(CH), 118.9 (CH), 106.4 (CH), 92.8 (Cq), 58.6 (Cq), 39.2 (CH2), 29.1 (CH3), 19.4 (CH3).  
IR (ATR): 3019, 2926, 1690, 1489, 1381, 1102, 759, 697 cm–1.  
MS (EI) m/z (relative intensity) 354 (41) [M]+, 234 (72), 220 (100), 158 (49), 118 (93), 77 
(28).  














The general procedure B was followed using 2-(1-butyl-2-methyl-
1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (97f) (182 mg, 
0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 
0.75 mmol). After 17 h, purification by column chromatography (n-hexane/ EtOAc: 1/1) 
yielded 98fh (180 mg, 82%) as a pale red solid (m. p. = 62–63 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.30–7.21 (m, 3H), 7.14 (ddd, J = 7.7, 7.7, 1.3 Hz, 1H), 7.06 
(dd, J = 8.1, 1.7 Hz, 2H), 6.97 (dd, J = 7.7, 1.3 Hz, 1H), 6.89 (d, J = 8.6 Hz, 2H), 6.75–6.70 (m, 
3H), 6.26 (dd, J = 7.7, 1.0 Hz, 1H), 4.46 (d, J = 16.0 Hz, 1H), 4.32 (d, J = 16.0 Hz, 1H), 3.76 (s, 
3H), 3.51 (d, J = 16.4 Hz, 1H), 3.18–3.10 (m, 1H), 3.11 (d, J = 16.4 Hz, 1H), 2.89–2.79 (m, 
1H), 1.60–1.47 (m, 1H), 1.40–1.15 (m, 3H), 1.03 (s, 3H), 0.86 (t, J = 7.2 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ = 172.0 (Cq), 158.4 (Cq), 147.9 (Cq), 139.1 (Cq), 134.6 (Cq), 
129.5 (Cq), 128.7 (CH), 128.2 (CH), 127.9 (CH), 127.5 (CH), 127.2 (CH), 124.2 (CH), 118.5 
(CH), 113.6 (CH), 107.1 (CH), 91.5 (Cq), 58.1 (Cq), 55.2 (CH3), 42.7 (CH2), 42.5 (CH2), 38.5 
(CH2), 30.9 (CH2), 20.2 (CH2), 18.8 (CH3), 13.8 (CH3).  
IR (ATR): 2956, 1682, 1606, 1486, 1242, 740, 696 cm–1.  
MS (EI) m/z (relative intensity) 440 (51) [M]+, 278 (79), 263 (68), 220 (40), 200 (25), 121 
(100).  
HR-MS (EI): m/z calcd for C29H32N2O2+ 440.2464, found 440.2459 [M]+. 
Synthesis of 1-(4-Methoxybenzyl)-8a-methyl-8-octyl-3a-phenyl-3,3a,8,8a-tetrahydro- 
pyrrolo[2,3-b]indol-2(1H)-one (98gh): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-(2-methyl-1-octyl-1H-indol-3-yl)acetamide 
(97g) (210 mg, 0.50 mmol) and diphenyliodonium tosylate (26h) 
(339 mg, 0.75 mmol). After 17 h, purification by column chromatography (n-hexane/EtOAc: 
1/1) yielded 98gh (220 mg, 89%) as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 7.30–7.17 (m, 3H), 7.11 (ddd, J = 7.7, 7.7, 1.3 Hz, 1H), 7.04 

















3H), 6.23 (dd, J = 7.7, 0.9 Hz, 1H), 4.43 (d, J = 16.0 Hz, 1H), 4.32 (s, J = 16.0 Hz, 1H), 3.75 (s, 
3H), 3.49 (d, J = 16.5 Hz, 1H), 3.15 (d, J = 16.5 Hz, 1H), 3.13–3.05 (m, 1H), 2.88–2.78 (m, 
1H), 1.55–1.45 (m, 2H), 1.36–1.12 (m, 10H), 1.01 (s, 3H), 0.84 (t, J = 7.0 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ= 172.0 (Cq), 158.5 (Cq), 147.9 (Cq), 139.2 (Cq), 134.7 (Cq), 
129.6 (Cq), 128.7 (CH), 128.3 (CH), 128.0 (CH), 127.5 (CH), 127.3 (CH), 124.4 (CH), 118.6 
(CH), 113.7 (CH), 107.2 (CH), 91.5 (Cq), 58.1 (Cq), 55.3 (CH3), 43.0 (CH2), 42.6 (CH2), 
38.5 (CH2), 31.7 (CH2), 29.3 (CH2), 29.2 (CH2), 28.8 (CH2), 27.1 (CH2), 22.6 (CH2), 18.8 
(CH3), 14.1 (CH3).  
IR (ATR): 2925, 2854, 1686, 1606, 1511, 1486, 1242, 740, 696 cm–1.  
MS (EI) m/z (relative intensity) 496 (42) [M]+, 334 (62), 319 (55), 256 (33), 220 (32), 121 
(100).  
HR-MS (EI): m/z calcd for C33H40N2O2+ 496.3090, found 496.3090 [M]+. 
Synthesis of 8-Benzyl-1-(4-methoxybenzyl)-8a-methyl-3a-phenyl-3,3a,8,8a-
tetrahydropyrrolo[2,3-b]indol-2(1H)-one (98hh): 
The general procedure B was followed using 2-(1-benzyl- 
2-methyl-1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (97h) 
(199 mg, 0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 
0.75 mmol). After 17 h, purification by column chromatography 
(n-hexane/EtOAc: 1/1) yielded 98hh (125 mg, 53%) as a pale white solid (m. p. = 
166–167 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.30–7.18 (m, 6H), 7.12–7.08 (m, 4H), 7.03 (d, J = 7.4 Hz, 
2H), 6.87 (d, J = 8.6 Hz, 2H), 6.77 (dd, J = 4.8, 2.5 Hz, 1H), 6.72–6.68 (m, 2H), 6.10 (d, J = 
7.6 Hz, 1H), 4.57 (d, J = 16.1 Hz, 1H), 4.42 (d, J = 16.5 Hz, 1H), 4.35 (d, J = 16.1 Hz, 1H), 
3.84 (d, J = 16.5 Hz, 1H), 3.74 (s, 3H), 3.55 (d, J = 16.7 Hz, 1H), 3.18 (d, J = 16.7 Hz, 1H), 
1.10 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 172.5 (Cq), 158.5 (Cq), 148.2 (Cq), 139.0 (Cq), 138.6 (Cq), 
134.0 (Cq), 129.3 (Cq), 128.8 (CH), 128.4 (CH), 128.4 (CH), 128.0 (CH), 127.9 (CH), 127.5 
(CH), 127.1 (CH), 126.7 (CH), 124.4 (CH), 119.2 (CH), 113.8 (CH), 108.1 (CH), 92.0 (Cq), 










IR (ATR): 3011, 1668, 1501, 1486, 1244, 1030, 739, 695 cm–1.  
MS (EI) m/z (relative intensity) 474 (41) [M]+, 312 (40), 297 (44), 207 (25), 121 (100), 91 
(64).  
HR-MS (EI): m/z calcd for C32H30N2O2
+ 474.2307, found 474.2315 [M]+. 
Synthesis of 1-(4-Methoxybenzyl)-8a-methyl-3a-phenyl-3,3a,8,8a-tetrahydropyrrolo-
[2,3-b]indol-2(1H)-one (98ih): 
The general procedure B was followed using 
N-(4-methoxybenzyl)-2-(2-methyl-1H-indol-3-yl)acetamide (97i) 
(154 mg, 0.50 mmol) and diphenyliodonium tosylate (26h) (339 mg, 
0.75 mmol). After 17 h, purification by column chromatography (n-hexane/EtOAc: 1/1) 
yielded 98ih (161 mg, 84%) as a pale white solid (m. p. = 200–201 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.28–7.20 (m, 3H), 7.08–7.04 (m, 5H), 6.97 (d, J = 7.6 Hz, 
1H), 6.81 (dd, J = 7.8,7.6 Hz, 1H), 6.76 (d, J = 8.6 Hz, 2H), 6.31 (d, J = 7.7 Hz, 1H), 4.78 (d, J = 
15.5 Hz, 1H), 4.20 (d, J = 15.5 Hz, 1H), 3.77 (s, 3H), 3.46 (d, J = 16.6 Hz, 1H), 3.05 (d, J = 
16.6 Hz, 1H), 1.07 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 172.1 (Cq), 158.8 (Cq), 147.0 (Cq), 139.6 (Cq), 135.9 (Cq), 
129.8 (Cq), 128.6 (CH), 128.6 (CH), 128.4 (CH), 127.5 (CH), 127.3 (CH), 124.8 (CH), 120.6 
(CH), 114.0 (CH), 110.7 (CH), 89.3 (Cq), 58.1 (Cq), 55.3 (CH3), 42.2 (CH2), 39.9 (CH2), 21.4 
(CH3).  
IR (ATR): 3301, 2934, 1671, 1512, 1245, 1033, 751, 504 cm–1.  
MS (EI) m/z (relative intensity) 384 (22) [M]+, 222 (20), 207 (100), 121 (79).  
HR-MS (EI): m/z calcd for C25H24N2O2+ 384.1838, found 384.1839 [M]+. 
Synthesis of 8a-n-Butyl-1-(4-methoxybenzyl)-3a-phenyl-3,3a,8,8a-tetrahydro-
pyrrolo-[2,3-b]indol-2(1H)-one (98jh): 
The general procedure B was followed using 
2-(2-n-butyl-1H-indol-3-yl)-N-(4-methoxybenzyl)acetamide (97j) 
(98 mg, 0.28 mmol) and diphenyliodonium tosylate (26h) (190 mg, 
0.42 mmol). After 17 h, purification by column chromatography (n-hexane/ EtOAc: 4/1) 

















1H NMR (300 MHz, CDCl3): δ = 7.26 (dd, J = 7.2, 6.9 Hz, 2H), 7.21 (dd, J = 6.9, 6.9 Hz, 
1H), 7.18 (d, J = 7.2 Hz, 2H), 7.06 (d, J = 7.8 Hz, 2H), 7.01 (ddd, J = 7.5, 7.5, 1.2 Hz, 1H), 
6.86 (dd, J = 7.5, 0.9 Hz, 1H), 6.78 (d, J = 7.8 Hz, 2H), 6.71 (ddd, J = 7.5, 7.5, 0.9 Hz, 1H), 
6.23 (dd, J = 7.5, 1.2 Hz, 1H), 4.92 (d, J = 15.4 Hz, 1H), 4.05 (d, J = 15.4 Hz, 1H), 4.03 (s, 
1H), 3.79 (s, 3H), 3.50 (d, J = 16.3 Hz, 1H), 3.03 (d, J = 16.3 Hz, 1H), 1.78 (dt, J = 14.4, 
7.3 Hz, 1H), 1.65 (dt, J = 14.4, 7.3 Hz, 1H), 0.99–0.77 (m, 4H), 0.56 (t, J = 7.1 Hz, 3H).  
13C NMR (126 MHz, CDCl3): δ = 172.4 (Cq), 158.8 (Cq), 146.3 (Cq), 139.4 (Cq), 137.8 (Cq), 
129.5 (Cq), 128.7 (CH), 128.2 (CH), 128.2 (CH), 127.1 (CH), 127.0 (CH), 123.9 (CH), 120.3 
(CH), 113.9 (CH), 110.50 (CH), 91.8 (Cq), 57.6 (Cq), 55.3 (CH3), 42.3 (CH2), 39.5 (CH2), 
33.2 (CH2), 24.6 (CH2), 22.3 (CH2), 13.4 (CH3).  
IR (ATR): 3329, 2952, 1660, 1610, 1511, 1248, 1028, 750 cm–1.  
MS (EI) m/z (relative intensity) 426 (14) [M]+, 249 (100), 206 (36), 121 (76).  
HR-MS (EI): m/z calcd for C28H30N2O2+ 426.2307, found 426.2316 [M]+. 
Synthesis of 8a-n-Butyl-1-methyl-3a-phenyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]in-
dol-2(1H)-one (98kh): 
The general procedure B was followed using 2-(2-n-butyl-1H-indol-
3-yl)-N-methylacetamide (97k) (61 mg, 0.25 mmol) and 
diphenyliodonium tosylate (26h) (170 mg, 0.375 mmol). After 17 h, 
purification by column chromatography (n-hexane/EtOAc: 1/1) yielded 98kh (47 mg, 59%) 
as a pale white solid (m. p. = 76–78 °C).  
1H NMR (400 MHz, CDCl3): δ = 7.27 (dd, J = 7.2, 6.9 Hz, 2H), 7.23 (dd, J = 6.9, 6.9 Hz, 
1H), 7.17 (d, J = 7.2 Hz, 1H), 7.09 (ddd, J = 7.7, 7.7, 1.2 Hz, 1H), 6.86 (dd, J = 7.7, 0.9 Hz, 
1H), 6.75 (ddd, J = 7.7, 7.7, 0.9 Hz, 1H), 6.71 (dd, J = 7.8, 1.2 Hz, 1H), 4.53 (s, 1H), 3.48 (d, 
J = 16.3 Hz, 1H), 2.91 (d, J = 16.3 Hz, 1H), 2.77 (s, 3H), 1.78–1.67 (m, 1H), 1.66–1.55 (m, 
1H), 1.11–0.97 (m, 1H), 0.97–0.84 (m, 3H), 0.60 (t, J = 6.9 Hz, 3H).  
13C NMR (126 MHz, CDCl3): δ = 171.8 (Cq), 146.3 (Cq), 139.5 (Cq), 138.1 (Cq), 128.5 (CH), 
128.2 (CH), 127.1 (CH), 127.1 (CH), 124.3 (CH), 120.6 (CH), 110.4 (CH), 90.6 (Cq), 57.8 
(Cq), 39.8 (CH2), 32.7 (CH2), 24.8 (CH2), 24.5 (CH3), 22.4 (CH2), 13.4 (CH3).  










MS (EI) m/z (relative intensity) 320 (28) [M]+, 277 (11), 263 (11), 206 (27), 98 (100).  
HR-MS (EI): m/z calcd for C21H24N2O+ 320.1889, found 320.1896 [M]+. 
Synthesis of 1-Methyl-3a-phenyl-8a-phenylethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]-
indol-2(1H)-one (98lh): 
The general procedure B was followed using 
N-methyl-2-(2-phenylethyl-1H-indol-3-yl)acetamide (97l) (73 mg, 
0.25 mmol) and diphenyliodonium tosylate (26h) (170 mg, 0.375 mmol). 
After 17 h, purification by column chromatography (n-hexane/EtOAc: 1/1) yielded 98lh 
(61 mg, 66%) as a pale white solid (m. p. = 208–210 °C).  
1H NMR (400 MHz, CDCl3): δ = 7.36 (dd, J = 7.2, 6.9 Hz, 2H), 7.32 (dd, J = 6.9, 6.9 Hz, 
1H), 7.28 (d, J = 7.2 Hz, 2H), 7.18–7.08 (m, 4H), 6.90 (dd, J = 7.5, 0.9 Hz, 1H), 6.79 (ddd, 
J = 7.5, 7.5, 0.9 Hz, 1H), 6.75 (dd, J = 7.5, 1.2 Hz, 1H), 6.64 (dd, J = 7.8, 1.5 Hz, 2H), 3.59 (d, 
J = 16.4 Hz, 1H), 3.04 (d, J = 16.4 Hz, 1H), 2.86 (s, 3H), 2.28 (dt, J = 12.6, 4.8 Hz, 1H), 2.14 
(td, J = 12.6, 4.8 Hz, 1H), 2.05 (ddd, J = 14.6, 12.4, 4.9 Hz, 1H), 1.97 (ddd, J = 14.6, 12.4, 
4.9 Hz, 1H).  
13C NMR (126 MHz, CDCl3): δ = 171.7 (Cq), 146.0 (Cq), 140.3 (Cq), 139.4 (Cq), 137.9 (Cq), 
128.6 (CH), 128.4 (CH), 128.3 (CH), 127.8 (CH), 127.4 (CH), 127.2 (CH), 126.0 (CH), 124.4 
(CH), 120.9 (CH), 110.6 (CH), 90.2 (Cq), 57.9 (Cq), 39.9 (CH2), 35.6 (CH2), 29.5 (CH2), 
24.5 (CH3).  
IR (ATR): 3364, 2940, 1667, 1605, 1482, 1116, 751, 700 cm–1. 
MS (EI) m/z (relative intensity) 368 (39) [M]+, 263 (12), 206 (23), 146 (100), 118 (10), 105 
(16), 91 (21).  
HR-MS (EI): m/z calcd for C25H24N2O+ 368.1889, found 368.1893 [M]+. 
Synthesis of 8a-(Cyclopropylmethyl)-1-methyl-3a-phenyl-3,3a,8,8a-tetrahydro- 
pyrrolo-[2,3-b]indol-2(1H)-one (98mh): 
The general procedure B was followed using 
2-[2-(cyclopropylmethyl)-1H-indol-3-yl]-N-methylacetamide (97m) 
(51 mg, 0.21 mmol) and diphenyliodonium tosylate (26h) (145 mg, 














yielded 98mh (34 mg, 51%) as a pale white solid (m. p. = 91–93 °C). 
1H NMR (300 MHz, CDCl3): δ = 7.47–7.34 (m, 5H), 7.23 (dd, J =7.5, 1.0 Hz, 1H), 7.13 (ddd, 
J = 7.6, 7.6, 1.2 Hz, 1H), 6.81 (ddd, J = 7.6, 7.6, 1.0 Hz, 1H), 6.73 (dd, J = 7.6, 1.2 Hz, 1H), 
4.78 (s, 1H), 2.98 (d, J = 15.2 Hz, 1H), 2.70 (d, J = 15.2 Hz, 1H), 2.60 (s, 3H), 1.36–1.28 (m, 
1H), 0.62–0.48 (m, 1H), 0.39–0.26 (m, 1H), –0.12 to –0.20 (m, 1H), –0.24 to –0.35 (m, 1H).  
13C NMR (126 MHz, CDCl3): δ = 173.2 (Cq), 146.2 (Cq), 136.5 (Cq), 132.9 (Cq), 128.9 (CH), 
128.8 (CH), 128.5 (CH), 128.4 (CH), 125.4 (CH), 119.3 (CH), 109.5 (CH), 93.2 (Cq), 55.6 
(Cq), 41.2 (CH2), 40.7 (CH2), 24.7 (CH3), 6.6 (CH), 5.0 (CH2), 4.2 (CH2).  
IR (ATR): 3280, 2905, 1666, 1472, 1380, 1253, 743 cm–1.  
MS (EI) m/z (relative intensity) 318 (26) [M]+, 263.2 (10), 206 (18), 118 (100), 77 (12).  
HR-MS (EI): m/z calcd for C21H22N2O+ 318.1732, found 318.1736 [M]+. 
Synthesis of Ethyl 4-{1-Methyl-2-oxo-3a-phenyl-2,3,3a,8-tetrahydropyrrolo[2,3-b]- 
indol-8a(1H)-yl}butanoate (98nh): 
The general procedure B was followed using ethyl 
4-{(3-[2-(methylamino)-2-oxoethyl]-1H-indol-2-yl)butanoate 
(97n) (76 mg, 0.25 mmol) and diphenyliodonium tosylate (26h) 
(170 mg, 0.375 mmol). After 17 h, purification by column chromatography (n-hexane/ EtOAc: 
1/1) yielded 98nh (52 mg, 55%) as a pale white solid (m. p. = 128–130 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.32–7.22 (m, 3H), 7.17 (dd, J = 6.6, 1.7 Hz, 2H), 7.10 
(ddd, J = 7.6, 7.6, 1.3 Hz, 1H), 6.86 (dd, J = 7.6, 0.9 Hz, 1H), 6.77 (ddd, J = 7.6, 7.6, 0.9 Hz, 
1H), 6.72 (dd, J = 7.6, 1.3 Hz, 1H), 4.47 (s, 1H), 4.01 (dt, J = 7.0, 2.6 Hz, 2H), 3.47 (d, J = 
16.4 Hz, 1H), 2.96 (d, J = 16.4 Hz, 1H), 2.80 (s, 3H), 1.97 (dt, J = 9.2, 7.0 Hz, 1H), 1.90 (dt, J 
= 9.2, 7.0 Hz, 1H), 1.83 (ddd, J = 14.5, 9.4, 5.7 Hz, 1H), 1.60 (ddd, J = 14.5, 9.4, 5.7 Hz, 1H), 
1.31–1.21 (m, 2H), 1.18 (t, J = 7.1 Hz, 3H).  
13C NMR (126 MHz, CDCl3): δ = 172.5 (Cq), 171.6 (Cq), 146.2 (Cq), 139.4 (Cq), 137.8 (Cq), 
128.6 (CH), 128.4 (CH), 127.3 (CH), 127.1 (CH), 124.4 (CH), 120.8 (CH), 110.4 (CH), 90.2 
(Cq), 60.4 (CH2), 57.8 (Cq), 39.9 (CH2), 33.7 (CH2), 32.6 (CH2), 24.4 (CH3), 18.4 (CH2), 
14.2 (CH3).  









MS (EI) m/z (relative intensity) 378 (42) [M]+, 333 (12), 263 (18), 206 (31), 156 (100), 115 
(12).  
HR-MS (EI): m/z calcd for C23H26N2O3+ 378.1943, found 378.1946 [M]+. 
Synthesis of (E)-3a-Styryl-1,8,8a-trimethyl-3,3a,8,8a-tetrahydropyrrolo-[2,3-b]-
indol-2(1H)-one (98cq): 
The general procedure B was followed using 
2-(1,2-dimethyl-1H-indol-3-yl)-N-methylacetamide (97c) (43 mg, 
0.2 mmol) and (phenyl)(styryl)iodonium triflate (26q) (137 mg, 
0.3 mmol). After 17 h, purification by column chromatography 
(n-hexane/ EtOAc: 1/2) yielded 98cq (40 mg, 63%) as a pale white solid (m. p. = 71–73 °C).  
1H NMR (300 MHz, CDCl3): δ = 7.33–7.20 (m, 5H), 7.16 (ddd, J = 7.7, 7.7, 1.3 Hz, 1H), 
7.03 (dd, J = 7.7, 0.9 Hz, 1H), 6.75 (ddd, J = 7.7, 7.7, 0.9 Hz, 1H), 6.46 (dd, J = 7.7, 1.3 Hz, 
1H), 6.22 (d, J = 16.4 Hz, 1H), 6.17 (d, J = 16.4 Hz, 1H), 3.01 (s, 3H), 2.91 (s, 2H), 2.77 (s, 
3H), 1.49 (s, 3H).  
13C NMR (126 MHz, CDCl3): δ = 171.3 (Cq), 148.5 (Cq), 136.4 (Cq), 131.3 (Cq), 131.0 (CH), 
129.2 (CH), 128.9 (CH), 128.4 (CH), 127.7 (CH), 126.3 (CH), 124.5 (CH), 118.6 (CH), 106.5 
(CH), 90.1 (Cq), 55.8 (Cq), 40.1 (CH2) , 30.0 (CH3), 26.4 (CH3), 17.1 (CH3).  
IR (ATR): 2924, 1680, 1489, 1232, 741, 693 cm–1.  
MS (EI) m/z (relative intensity) 318 (34) [M] +, 292 (9), 246 (9), 158 (21), 56 (100). 




















70 °C, 30 min
 
A mixture of 8,8a-dimethyl-1-(4-methoxybenzyl)-3a-phenyl-3,3a,8,8a-tetrahydropyrrolo- 
[2,3-b]indol-2(1H)-one (98ah) (80 mg, 0.2 mmol) and LiAlH4 (68 mg, 1.8 mmol) in 










excess of EtOAc was carefully added dropwise to quench the reaction. At ambient 
temperature, the reaction mixture was washed with brine (10 mL), and the aqueous layer was 
extracted with EtOAc (2 × 100 mL). The organic layers were combined, and the solvents 
were removed in vacuo. The residue was purified by column chromatography on silica gel 
(n-hexane/EtOAc: 20/1) to yield 117ah (68 mg, 88%) as a red oil.  
1H NMR (400 MHz, CDCl3): δ = 7.34–7.22 (m, 7H), 7.16 (dd, J = 7.3, 7.3 Hz, 1H), 
6.92–6.84 (m, 3H), 6.66 (dd, J = 7.1, 7.4 Hz, 1H), 6.45 (d, J = 7.4 Hz, 1H), 4.13 (d, J = 
12.9 Hz, 1H), 3.81 (s, 3H), 3.43 (d, J = 12.9 Hz, 1H), 2.92 (s, 3H), 2.86 (dd, J = 11.8, 8.7 Hz, 
1H), 2.75 (dd, J = 17.6, 10.2 Hz, 1H), 2.49 (ddd, J = 10.2, 8.7, 5.7 Hz, 1H), 2.10 (dd, J = 11.8, 
5.7 Hz, 1H), 0.96 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 158.5 (Cq), 152.3 (Cq), 143.8 (Cq), 134.6 (Cq), 132.6 (Cq), 
129.3 (CH), 128.5 (CH), 127.9 (CH), 127.7 (CH), 126.3 (CH), 124.5 (CH), 116.9 (CH), 113.6 
(CH), 104.9 (CH), 93.1 (Cq), 64.1 (Cq), 55.3 (CH3), 52.4 (CH2), 49.3 (CH2), 37.9 (CH2), 
31.5 (CH3), 19.7 (CH3). 
IR (ATR): 2931, 1601, 1510, 1242, 1032, 742 cm–1.  
MS (EI) m/z (relative intensity) 384 (49) [M]+, 263 (10), 221 (100), 163 (22), 135 (21), 121 
(84), 77 (18).  
HR-MS (EI): m/z calcd for C26H28N2O+ 384.2202, found 384.2219 [M]+. 
5.4.4 Analytical Data for Arylated Peptide-Containing Indolylacetamides 
Synthesis of Ethyl [2-(2-Phenyl-1H-indol-3-yl)acetyl]-L-phenylalanyl-glycinate (100ah): 
The general procedure C was followed using ethyl 
[2-(1H-indol-3-yl)acetyl]-L-phenylalanylglycinate (99a) 
(102 mg, 0.250 mmol) and diphenyliodonium tosylate (26h) 
(170 mg, 0.375 mmol). After 17 h, purification by column 
chromatography (n-hexane/EtOAc: 1/1) yielded 100ah 
(101 mg, 83%) as a pale white solid (m. p. = 220–221 °C).  
1H NMR (500 MHz, d6-DMSO): δ = 11.18 (s, 1H), 8.47 (t, J = 5.8 Hz, 1H), 8.21 (d, J = 
8.4 Hz, 1H), 7.70 (d, J = 7.7 Hz, 2H), 7.48 (dd, J = 7.7, 7.7 Hz, 2H), 7.37 (d, J = 8.0 Hz, 1H), 












2H),7.22–7.18 (m, 1H), 7.10 (ddd, J = 8.0, 7.0, 1.2 Hz, 1H), 6.94 (ddd, J = 7.9, 7.0, 1.1 Hz, 1H), 
4.61 (ddd, J = 9.9, 8.4, 4.1 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.92 (dd, J = 17.5, 5.8 Hz, 1H), 
3.84 (dd, J = 17.5, 5.8 Hz, 1H), 3.66 (d, J = 15.8 Hz, 1H), 3.60 (d, J = 15.8 Hz, 1H), 3.07 (dd, 
J = 13.9, 4.1 Hz, 1H), 2.83 (dd, J = 13.9, 9.9 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, d6-DMSO): δ = 171.8 (Cq), 170.6 (Cq), 169.6(Cq), 137.7 (Cq), 135.8 
(Cq), 135.8(Cq), 132.4 (Cq), 129.1(CH), 128.7 (Cq), 128.5 (CH), 128.0 (CH), 128.0 (CH), 
127.4 (CH), 126.2 (CH), 121.4 (CH), 119.0 (CH), 118.6 (CH), 110.8 (CH), 105.7 (Cq), 
60.4(CH2), 54.8(CH2), 53.8 (CH), 37.6 (CH2), 31.5 (CH2), 14.0 (CH3).  
IR (ATR): 3375, 3283, 1735, 1642, 1528, 1335, 1026, 772, 745, 699 cm–1. 
MS (EI) m/z (relative intensity) 483 (12) [M]+, 223 (51), 206 (100), 179 (18).  
HR-MS (EI): m/z calcd for C29H29N3O4+ 483.2158, found 483.2152 [M]+. 
Synthesis of Ethyl {2-[2-(4-Fluorophenyl)-1H-indol-3-yl]acetyl}-L-phenylalanyl-glycinate 
(100ai): 
The general procedure C was followed using ethyl 
[2-(1H-indol-3-yl)acetyl]-L-phenylalanyl-glycinate (99a) 
(102 mg, 0.250 mmol) and bis(4-fluorophenyl)iodonium 
tosylate (26i) (183 mg, 0.375 mmol). After 17 h, 
purification by column chromatography (n-hexane/EtOAc: 
3/2) yielded 100ai (89 mg, 71%) as a light brown solid (m. 
p. = 218–220 °C). 
1H NMR (500 MHz, d6-DMSO): δ = 11.21 (s, 1H), 8.50 (t, J = 5.8 Hz, 1H), 8.31 (d, J = 
8.5 Hz, 1H), 7.78 (ddd, J = 8.5, 5.3, 2.5 Hz, 2H), 7.40–7.17 (m, 9H),7.11 (ddd, J= 8.0, 7.0, 
1.2 Hz, 1H), 6.96 (ddd, J = 7.9, 7.0, 1.1 Hz, 1H), 4.65 (ddd, J = 9.8, 8.4, 4.1 Hz, 1H), 4.14 (q, 
J = 7.1 Hz, 2H), 3.93 (dd, J = 17.4, 5.8 Hz, 1H), 3.87 (dd, J = 17.4, 5.8 Hz, 1H), 3.65 (d, J = 
15.8 Hz, 1H), 3.59 (d, J = 15.8 Hz, 1H), 3.11 (dd, J = 13.9, 4.1 Hz, 1H), 2.87 (dd, J = 13.9, 
9.8 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, d6-DMSO): δ = 171.6 (Cq), 170.4 (Cq), 169.4 (Cq), 161.4 (d, JC–F = 
244.9 Hz, Cq), 137.6 (Cq), 135.6 (Cq), 134.7 (Cq), 129.8 (d, JC–F = 8.0 Hz, CH), 129.0 (CH), 












118.6 (CH), 115.3 (d, JC–F = 21.3 Hz, CH), 110.7 (CH), 105.7 (Cq), 60.3 (CH2), 53.8 (CH), 
40.7 (CH2), 37.6 (CH2), 31.4 (CH2), 14.0 (CH3). 
19F NMR (283 MHz, d6-DMSO):δ = –109.8 (dd, J = 9.2, 4.9 Hz). 
IR (ATR): 3394, 3271, 3066, 1744, 1646, 1502, 1199, 1045, 841, 744, 698 cm–1. 
MS (ESI) m/z (relative intensity) 1025 (15) [2M+Na]+, 524 (30) [M+Na]+.  
HR-MS (ESI): m/z calcd for C29H29FN3O4+ 502.2142, found 502.2144 [M+H]+. 
Synthesis of Ethyl {2-[2-(4-Chlorophenyl)-1H-indol-3-yl]acetyl}-L-phenylalanyl-glycinate 
(100aj): 
The general procedure C was followed using ethyl 
[2-(1H-indol-3-yl)acetyl]-L-phenylalanyl-glycinate (99a) 
(102 mg, 0.250 mmol) and bis(4-chlorophenyl)iodonium 
tosylate (26j) (196 mg, 0.375 mmol). After 17 h, 
purification by column chromatography (n-hexane/EtOAc: 
2/1→1/1) yielded 100aj (81 mg, 63%) as a light brown 
solid (m. p. = 240–242 °C).  
1H NMR (500 MHz, d6-DMSO): δ = 11.23 (s, 1H), 8.48 (t, J = 5.9 Hz, 1H), 8.31 (d, J = 
8.5 Hz, 1H), 7.77–7.70 (m, 2H), 7.54–7.47 (m, 2H), 7.36 (dd, J = 14.1, 8.0 Hz, 2H), 7.31–7.17 
(m, 5H), 7.10 (ddd, J = 8.1, 7.1, 1.0 Hz, 1H), 6.94 (ddd, J = 7.9, 7.0, 1.1 Hz, 1H), 4.62 (ddd, J = 
10.0, 8.7, 4.2 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.91 (dd, J = 17.3, 5.9 Hz, 1H), 3.85 (dd, J = 
17.3, 5.8 Hz, 1H), 3.65 (d, J = 15.6 Hz, 1H), 3.58 (d, J = 15.6 Hz, 1H), 3.08 (dd, J = 13.8, 4.1 
Hz, 1H), 2.85 (dd, J = 13.8, 10.1 Hz, 1H), 1.21 (t, J = 7.1 Hz, 3H). 
13C NMR(126 MHz, d6-DMSO): δ = 171.6 (Cq), 170.3 (Cq), 169.4 (Cq), 137.6 (Cq), 135.7 
(Cq), 134.3 (Cq), 131.9 (Cq), 131.1 (Cq), 129.4 (CH), 129.0 (CH), 128.6 (Cq), 128.4 (CH), 
127.8 (CH), 126.0 (CH), 121.6 (CH), 119.0 (CH), 118.6 (CH), 110.8 (CH), 106.3 (Cq), 60.3 
(CH2), 53.8 (CH), 40.7 (CH2), 37.6 (CH2), 31.4 (CH2), 14.0 (CH3).  
IR (ATR): 3401, 3260, 3263, 1746, 1645, 1515, 1197, 1092, 1012, 834, 627 cm–1.  
MS (ESI) m/z (relative intensity) 1061/1059/1057 (9/54/84) [2M+Na]+, 542/540 (32/100) 
[M+Na]+.  












Synthesis of Ethyl {2-[2-(4-Bromophenyl)-1H-indol-3-yl]acetyl}-L-phenylalanylglycinate 
(100ak): 
The general procedure C was followed using ethyl 
[2-(1H-indol-3-yl)acetyl]-L-phenylalanyl-glycinate (99a) 
102 mg, 0.250 mmol) and bis(4-bromphenyl)iodonium 
tosylate (26k) (229 mg, 0.375 mmol). After 17 h, 
purification by column chromatography (n-hexane/EtOAc: 
3/2) yielded 100ak (86 mg, 61%) as a light brown solid (m. 
p. = 244–247 °C).  
1H NMR (500 MHz, d6-DMSO): δ = 11.23 (s, 1H), 8.46 (t, J = 5.9 Hz, 1H), 8.30 (d, J = 8.6 Hz, 
1H), 7.66 (dd, J = 8.8, 1.7 Hz, 2H), 7.63 (dd, J = 8.8, 1.7 Hz, 2H), 7.35 (dd, J = 13.1, 8.0 Hz, 
2H), 7.30–7.17 (m, 5H), 7.10 (ddd, J = 8.1, 7.0, 1.0 Hz, 1H), 6.93 (ddd, J = 7.9, 7.0, 1.1 Hz, 1H), 
4.61 (ddd, J = 10.0, 8.6, 4.2 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.90 (dd, J = 17.3, 5.9 Hz, 1H), 
3.84 (dd, J = 17.3, 5.9 Hz, 1H), 3.63 (d, J = 15.7 Hz, 1H), 3.57 (d, J = 15.7 Hz, 1H), 3.07 (dd, 
J = 13.8, 4.1 Hz, 1H), 2.83 (dd, J = 13.8, 10.0 Hz, 1H), 1.20 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, d6-DMSO): δ = 171.6 (Cq), 170.3 (Cq), 169.4 (Cq), 137.6 (Cq), 135.7 
(Cq), 134.3 (Cq), 131.5 (Cq), 131.3 (CH), 129.7 (CH), 128.9 (CH), 128.6 (Cq), 127.8 (CH), 
126.0 (CH), 121.6 (CH), 120.5 (Cq), 119.0 (CH), 118.6 (CH), 110.8 (CH), 106.3 (Cq), 60.3 
(CH2), 53.8 (CH), 40.7 (CH2), 37.6 (CH2), 31.4 (CH2), 14.0 (CH3).  
IR (ATR): 3310, 3060, 1741, 1646, 1527, 1203, 1007, 829, 735 cm–1.  
MS (ESI) m/z (relative intensity) 1149/1147/1145 (22/44/22) [2M+Na]+, 586/584 (100/100) 
[M+Na]+. 
HR-MS (ESI): m/z calcd for C29H29BrN3O4+ 562.1336, found 562.1331 [M+H]+. 
Synthesis of Ethyl (2-{2-[4-(tert-Butyl)phenyl]-1H-indol-3-yl}acetyl)-L-phenylalanyl-
glycinate (100al): 
The general procedure C was followed using ethyl 
[2-(1H-indol-3-yl)acetyl]-L-phenylalanyl-glycinate (99a) 
(102 mg, 0.250 mmol) and bis(4-tert-butylphenyl)- 





















purification by column chromatography (n-hexane/EtOAc: 1/1) yielded 100al (117 mg, 87%) 
as a pale white solid (m. p. =223–225 °C).  
1H NMR (500 MHz, d6-DMSO): δ = 11.09 (s, 1H), 8.45 (t, J = 5.9 Hz, 1H), 8.15 (d, J = 
8.5 Hz, 1H), 7.60 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.1 Hz, 1H), 7.29 
(d, J = 7.9 Hz, 1H), 7.27 (dd, J = 8.2, 1.5 Hz, 2H), 7.26–7.23 (m, 2H), 7.22–7.18 (m, 1H), 
7.07 (dd, J = 8.0, 7.0 Hz, 1H), 6.92 (dd, J = 7.9, 7.0 Hz, 1H), 4.64 (ddd, J = 9.4, 8.5, 4.1 Hz, 
1H), 4.11 (q, J = 7.1 Hz, 2H), 3.91 (dd, J = 17.4, 5.9 Hz, 1H), 3.83 (dd, J = 17.4, 5.9 Hz, 1H), 
3.61 (d, J = 15.9 Hz, 1H), 3.58 (d, J = 15.9 Hz, 1H), 3.08 (dd, J = 13.9, 4.1 Hz, 1H), 2.84 (dd, 
J = 13.9, 9.4 Hz, 1H), 1.34 (s, 9H), 1.21 (t, J = 7.1 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.6 (Cq), 170.4 (Cq), 169.4 (Cq), 149.6 (Cq), 137.6 
(Cq), 135.7 (Cq), 135.5 (Cq), 129.4 (Cq), 128.9 (CH), 128.7 (Cq), 127.8 (CH), 127.5 (CH), 
126.0 (CH), 125.1 (CH), 121.1 (CH), 118.7 (CH), 118.4 (CH), 110.6 (CH), 105.2 (Cq), 60.3 
(CH2), 53.7 (CH), 40.7 (CH2), 37.6 (CH2), 34.2 (CH2), 31.6 (Cq), 31.0 (CH3), 14.0 (CH3).  
IR (ATR): 3265, 2960, 1749, 1647, 1569, 1511, 1191, 1095, 739 cm–1.  
MS (ESI) m/z (relative intensity) 1101 (28) [2M+Na]+, 562 (100) [M+Na]+, 540 (20) [M+H]+.  
HR-MS (ESI): m/z calcd for C33H36N3O4+ 538.2700, found 538.2706 [M–H]+. 
Synthesis of Ethyl {2-[2-(4-Methoxyphenyl)-1H-indol-3-yl]acetyl}-L-phenylalanyl-
glycinate (100ag): 
The general procedure C was followed using ethyl 
[2-(1H-indol-3-yl)acetyl]-L-phenylalanyl-glycinate (99a) 
(102 mg, 0.250 mmol) and bis(4-methoxyphenyl)- 
iodonium tosylate (26g) (192 mg, 0.375 mmol). After 17 h, 
purification by column chromatography (n-hexane/EtOAc: 
1/1) yielded 100ag (96 mg, 75%) as a light brown solid 
(m. p. =199–202 °C). 
1H NMR (500 MHz, d6-DMSO): δ = 11.06 (s, 1H), 8.46 (t, J = 5.9 Hz, 1H), 8.17 (d, J = 
8.4 Hz, 1H), 7.63 (d, J = 8.6 Hz, 2H), 7.35–7.14 (m, 7H),7.05 (dd, J = 8.1, 7.0 Hz, 1H), 7.02 
(d,J = 8.6 Hz, 2H), 6.91 (dd, J = 7.9, 7.0 Hz, 1H), 4.62 (ddd, J = 9.4, 8.4, 4.1 Hz, 1H), 4.11 (q, 












3.60 (d, J = 15.8 Hz, 1H), 3.54 (d, J = 15.8 Hz, 1H), 3.07 (dd, J = 13.8, 4.1 Hz, 1H), 2.83 (dd, 
J = 13.8, 9.4 Hz, 1H), 1.20 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, d6-DMSO): δ = 171.6 (Cq), 170.5 (Cq), 169.4 (Cq), 158.6 (Cq), 137.6 
(Cq), 135.7 (Cq), 135.4 (Cq), 129.1 (CH), 129.0 (CH), 128.7 (Cq), 127.8 (CH), 126.0 (CH), 
124.8 (Cq), 120.9 (CH), 118.6 (CH), 118.4 (CH), 113.9 (CH), 110.5 (CH), 104.7 (Cq), 60.3 
(CH2), 55.1 (CH3), 53.8 (CH), 40.7 (CH2), 37.6 (CH2), 31.6 (CH2), 14.0 (CH3). 
IR (ATR): 3397, 3263, 3061, 1751, 1644, 1504, 1248, 1177, 1027, 835, 727, 697 cm–1.  
MS (ESI) m/z (relative intensity) 1049 (10) [2M+Na]+, 536 (100) [M+Na]+.  
HR-MS (ESI): m/z calcd for C30H32N3O5+ 514.2336, found 514.2322 [M+H]+. 
Synthesis of Ethyl {2-[2-(2,4-Dimethylphenyl)-1H-indol-3-yl]acetyl}-L-phenylalanyl-
glycinate (100am): 
The general procedure C was followed using ethyl 
[2-(1H-indol-3-yl)acetyl]-L-phenylalanyl-glycinate (99a) 
(102 mg, 0.250 mmol) and bis(2,4-dimethylphenyl)- 
iodonium tosylate (26m) (191 mg, 0.375 mmol). After 
17 h, purification by column chromatography 
(n-hexane/EtOAc: 1/1) yielded 100am (50 mg, 39%) as a 
pale white solid (m. p. = 110–112 °C).  
1H NMR (500 MHz, d6-DMSO): δ = 10.94 (s, 1H), 8.40 (t, J = 5.9 Hz, 1H), 7.91 (d, J = 
8.4 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.27–7.20 (m, 7H), 7.14 (s, 1H), 7.04 (ddd, J = 8.0, 7.0, 
0.9 Hz, 1H), 6.92 (ddd, J = 7.9, 7.0, 1.0 Hz, 1H), 4.59 (ddd, J = 9.4, 8.4, 4.3 Hz, 1H), 4.10 (q, 
J = 7.1 Hz, 2H), 3.87 (dd, J = 17.4, 5.9 Hz, 1H), 3.82 (dd, J = 17.4, 5.9 Hz, 1H), 3.36 (d, J = 
15.8 Hz, 1H), 3.30 (d, J = 15.8 Hz, 1H),3.03 (dd, J = 13.8, 4.3 Hz, 1H), 2.79 (dd, J = 13.9, 
9.4 Hz, 1H), 2.33 (s, 3H), 2.14 (s, 3H), 1.18 (t, J = 7.1 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.5 (Cq), 170.1 (Cq), 169.3 (Cq), 137.5 (Cq), 137.2 
(Cq), 136.8 (Cq), 135.9 (Cq), 135.4 (Cq), 130.6 (CH), 130.5 (CH), 129.0 (Cq), 128.9 (CH), 
127.8 (CH), 127.6 (Cq), 126.0 (CH), 125.9 (CH), 120.6 (CH), 118.7 (CH), 118.2 (CH), 110.4 
(CH), 105.9 (Cq), 60.3 (CH2), 53.6 (CH), 40.7 (CH2), 37.6 (CH2), 31.4 (CH2), 20.7 (CH3), 













IR (ATR): 3252, 3058, 1740, 1638, 1194, 739, 698 cm–1.  
MS (ESI) m/z (relative intensity) 624 (64) [M-2H+5Na]+, 556 (36) [M-H+2Na]+, 510 (100) 
[M-H]+, 471 (12), 407 (8), 293 (20).  
HR-MS (ESI): m/z calcd for C31H32N3O4+ 510.2387, found 510.2380 [M–H]+. 
Synthesis of Ethyl [2-(2-Phenyl-1H-indol-3-yl)acetyl]glycinate (100bh): 
The general procedure C was followed using ethyl 
[2-(1H-indol-3-yl)acetyl]glycinate (99b) (65 mg, 0.250 mmol) and 
diphenyliodonium tosylate (26h) (170 mg, 0.375 mmol). After 
17 h, purification by column chromatography (n-hexane/EtOAc: 
2/1) yielded 100bh (70 mg, 83%) as a pale white solid (m. p. = 114–115 °C).  
1H NMR (500 MHz, CDCl3): δ = 8.86 (s, 1H), 7.57 (d, J = 7.9 Hz, 1H), 7.56 (d, J = 8.5 Hz, 
2H), 7.44 (dd, J = 8.5, 8.0 Hz, 2H), 7.40 (d, J = 8.3 Hz, 1H), 7.36 (dd, J = 8.0, 8.0 Hz, 1H), 
7.24 (ddd, J = 7.9, 6.9, 1.0 Hz, 1H), 7.17 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 6.33 (t, J = 6.1 Hz, 
1H), 4.10 (q, J = 7.1 Hz, 2H), 3.92 (d, J = 6.1 Hz, 2H), 3.85 (s, 2H), 1.19 (t, J = 7.1 Hz, 3H).  
13C NMR (126 MHz, CDCl3): δ = 171.7 (Cq), 169.5 (Cq), 136.9 (Cq), 135.9 (Cq), 131.8 (Cq), 
129.1 (CH), 128.8 (Cq), 128.3 (CH), 127.9 (CH), 123.0 (CH), 120.5 (CH), 118.9 (CH), 111.1 
(CH), 105.1 (Cq), 61.3 (CH2), 41.4 (CH2), 32.7 (CH2), 14.1 (CH3).  
IR (ATR): 3379, 3297, 1720, 1645, 1536, 1451, 1199, 1022, 732 cm–1.  
MS (EI) m/z (relative intensity) 336 (35) [M]+, 206 (100), 179 (15).  
HR-MS (EI): m/z calcd for C20H20N2O3+ 336.1474, found 336.1467 [M]+. 
Synthesis of Methyl [2-(2-Phenyl-1H-indol-3-yl)acetyl]-L-alaninate (100ch): 
The general procedure C was followed using methyl 
[2-(1H-indol-3-yl)acetyl]-L-alaninate (99c) (65 mg, 0.250 mmol) 
and diphenyliodonium tosylate (26h) (170 mg, 0.375 mmol). 
After 17 h, purification by column chromatography 
(n-hexane/EtOAc: 2/1) yielded 100ch (69 mg, 82%) as a pale 
















1H NMR(300 MHz, CDCl3): δ = 8.91 (s, 1H), 7.64–7.51 (m, 3H), 7.48–7.33 (m, 4H), 7.23 
(ddd, J = 8.2, 7.0, 1.0 Hz, 1H), 7.17 (ddd, J = 8.0, 7.0, 1.2 Hz, 1H), 6.33 (d, J = 7.8 Hz, 1H), 
4.61 (dt, J = 7.8, 7.2 Hz, 1H), 3.84 (s, 2H), 3.63 (s, 3H), 1.24 (d, J = 7.2 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ = 173.0 (Cq), 171.2 (Cq), 136.8 (Cq), 136.0 (Cq), 132.0 (Cq), 
129.0 (CH), 128.7 (Cq), 128.1 (CH), 127.8 (CH), 122.7 (CH), 120.2 (CH), 118.6 (CH), 111.2 
(CH), 104.8 (Cq), 52.2 (CH3), 47.9 (CH), 32.8 (CH2), 17.9 (CH3).  
IR (ATR): 3275, 1737, 1645, 1514, 1450, 1210, 1153, 741, 697 cm–1.  
MS (EI) m/z (relative intensity) 336 (34) [M]+, 206 (100), 179 (13). 
HR-MS (EI): m/z calcd for C20H20N2O3+ 336.1474, found 336.1479 [M]+. 
Synthesis of Benzyl [2-(2-Phenyl-1H-indol-3-yl)acetyl]-L-tryptophanate (100dh): 
The general procedure C was followed using benzyl 
[2-(1H-indol-3-yl)acetyl]-L-tryptophanate (99d) (113 mg, 
0.250 mmol) and diphenyliodonium tosylate (26h) (170 mg, 
0.375 mmol). After 17 h, purification by column 
chromatography (n-hexane/EtOAc: 2/1) yielded 100dh (103 mg, 78%) as a yellow oil.  
1H NMR (300 MHz, CDCl3): δ =8.21 (s, 1H), 7.60 (s, 1H), 7.40 (d, J = 8.1 Hz, 1H), 
7.37–7.28 (m, 9H), 7.42–7.18 (m, 12H), 7.25–7.22 (m, 1H), 7.21 (d, J = 8.2 Hz, 2H), 7.11 
(ddd, J= 8.2, 6.9, 1.0 Hz, 1H), 7.08 (d, J= 7.4 Hz, 2H), 7.06 (ddd, J=7.9, 6.9, 1.3 Hz, 1H), 
6.93 (ddd, J=7.9, 6.9, 1.2 Hz, 1H), 6.25 (d, J=7.8Hz, 1H), 6.18 (d, J=2.0Hz, 1H), 4.99 (d, J = 
12.2 Hz, 1H), 4.96 (d, J = 12.2 Hz, 1H), 4.96 (ddd, J=7.8, 6.1, 5.7Hz, 1H), 3.77 (s, 2H), 3.18 
(dd, J = 14.8, 6.1 Hz, 1H), 3.13 (dd, J=14.8, 5.7Hz, 1H). 
13C NMR (126 MHz, CDCl3): δ = 171.3 (Cq), 171.1 (Cq), 136.6 (Cq), 135.8 (Cq), 135.7 (Cq), 
135.2 (Cq), 131.6 (Cq), 128.9 (CH), 128.7 (Cq), 128.4 (CH), 128.2 (CH), 128.1 (CH), 128.0 
(CH), 127.7 (CH), 127.1 (Cq), 122.7 (CH), 122.6 (CH), 121.9 (CH), 120.3 (CH), 119.5 (CH), 
118.8 (CH), 118.3 (CH), 110.9 (CH), 110.8 (CH), 109.1 (Cq), 105.1 (Cq), 67.1 (CH2), 52.5 
(CH), 32.9 (CH2), 27.4 (CH2). 
IR (ATR): 3279, 1732, 1651, 1496, 1455, 1186, 735, 695 cm–1.  
MS (ESI) m/z (relative intensity) 1055 (51) [2M+H]+, 550 (34) [M+Na]+, 528 (100) [M+H]+.  












Synthesis of Dimethyl [2-(2-Phenyl-1H-indol-3-yl)acetyl]glycyl-L-aspartate (100eh): 
The general procedure C was followed using 
dimethyl [2-(1H-indol-3-yl)acetyl]glycyl-L- 
aspartate (99e) (94 mg, 0.250 mmol) and 
diphenyliodonium tosylate (26h) (170 mg, 
0.375 mmol). After 17 h, purification by column chromatography (n-hexane/EtOAc: 1/5) 
yielded 100eh (77 mg, 68%) as a pale white solid (m. p. = 120–122 °C).  
1H NMR (500 MHz, CDCl3): δ = 9.34 (s, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.52 (d, J = 7.3 Hz, 
2H), 7.45 (dd, J = 7.6, 7.3 Hz, 2H), 7.39 (d, J = 8.0 Hz, 1H), 7.37 (dd, J = 7.6, 7.6 Hz, 1H), 
7.23 (dd, J = 8.0, 7.3 Hz, 1H), 7.17 (dd, J = 7.8, 7.3 Hz, 1H), 6.98 (d, J = 8.7 Hz, 1H), 6.49 (t, 
J = 5.4 Hz, 1H), 4.76 (ddd, J = 8.7, 4.8, 4.8 Hz, 1H), 3.88 (dd, J = 17.0, 5.4 Hz, 1H), 3.85 (s, 
2H), 3.81 (dd, J = 17.0, 5.4 Hz, 1H), 3.70 (s, 3H), 3.66 (s, 3H), 2.94 (dd, J = 17.1, 4.8 Hz, 1H), 
2.76 (dd, J = 17.1, 4.8 Hz, 1H).  
13C NMR(126 MHz, CDCl3): δ = 172.3 (Cq), 171.0 (Cq), 170.7 (Cq), 168.6 (Cq), 136.8 (Cq), 
136.0 (Cq), 131.9 (Cq), 128.8 (CH), 128.6 (Cq), 128.0 (CH), 127.9 (CH), 122.5 (CH), 120.1 
(CH), 118.4 (CH), 111.2 (CH), 104.5 (Cq), 52.6 (CH3), 51.9 (CH3), 48.3 (CH), 43.0 (CH2), 
35.8 (CH2), 32.6 (CH2).  
IR (ATR): 3276, 2875, 1735, 1642, 1528, 1335, 745 cm–1.  
MS (EI) m/z (relative intensity) 451 (9) [M]+, 291 (6), 233 (61), 206 (100), 179 (11).  
HR-MS (EI): m/z calcd for C24H25N3O6+ 451.1743, found 451.1731 [M]+. 
Synthesis of Benzyl [2-(2-Phenyl-1H-indol-3-yl)acetyl]-L-phenylalanyl-glycyl- 
L-prolinate (100fh): 
The general procedure C was followed 
using benzyl [2-(1H-indol-3-yl)acetyl]-
L-phenylalanyl-glycyl-L-prolinate (99f) 
(142 mg, 0.250 mmol) and diphenyliodonium tosylate (26h) (170 mg, 0.375 mmol). After 
























79%) as a pale white solid (m. p. = 102–103 °C).  
1H NMR (500 MHz, CDCl3): δ = 8.41 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.45–7.37 (m, 4H), 
7.37–7.29 (m, 4H), 7.22 (dd, J = 8.2, 1.3, 0.9 Hz, 1H), 7.15 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 
7.10–7.03 (m, 2H), 6.85 (t, J = 8.7 Hz, 1H), 6.84 (t, J = 4.7 Hz, 1H),6.72 (d, J = 8.3 Hz, 2H), 
6.23 (d, J = 8.8 Hz, 1H), 5.17 (dd, J = 12.7, 6.7 Hz, 2H), 4.74 (ddd, J = 8.8, 7.4, 5.6 Hz, 1H), 
4.56 (dd, J = 8.3, 3.1 Hz, 1H), 3.96 (dd, J = 17.5, 4.7 Hz, 1H), 3.85 (dd, J = 17.5, 4.7 Hz, 1H), 
3.79 (d, J = 8.7 Hz, 2H), 3.53 (dd, J = 13.6, 6.7 Hz, 1H), 3.40 (dd, J = 13.6, 6.7 Hz, 1H), 2.97 
(dd, J = 14.0, 5.8 Hz, 1H), 2.86 (dd, J = 14.0, 7.6 Hz, 1H), 2.25–2.13 (m, 1H), 2.06–1.93 (m, 
3H).  
13C NMR (75 MHz, CDCl3): δ = 171.6 (Cq),171.6 (Cq), 170.5 (Cq), 166.4 (Cq), 136.6 (Cq), 
136.0 (Cq), 135.8 (Cq), 135.5 (Cq), 131.8 (Cq), 129.1 (CH), 128.9 (CH), 128.7 (CH), 128.6 
(Cq), 128.4 (CH), 128.3 (CH), 128.1 (CH), 128.0 (CH), 127.9 (CH), 126.7 (CH), 122.9 (CH), 
120.6 (CH), 118.8 (CH), 111.0 (CH), 105.0 (Cq), 67.0 (CH2), 59.0 (CH), 54.1 (CH), 45.9 
(CH2), 41.9 (CH2), 37.6 (CH2), 32.8 (CH2), 29.0 (CH2), 24.6 (CH2).  
IR (ATR): 3284, 1740, 1634, 1496, 1452, 1168, 741, 696 cm–1.  
MS (EI) m/z (relative intensity) 642 (8) [M]+, 380 (11), 233 (74), 206 (100), 179 (14).  
HR-MS (EI): m/z calcd for C39H38N4O5+ 642.2842, found 642.2841 [M]+. 






The general procedure C was followed using methyl 
[2-(1H-indol-3-yl)acetyl]-L-phenylalanyl-glycyl-L-leucyl-glycyl-L-tryptophyl-L-alaninate (99g) 
(82 mg, 0.1 mmol) and diphenyliodonium tosylate (26h) (68 mg, 0.15 mmol) in DMF (2 mL). 
After 17 h, purification by column chromatography (EtOAc/MeOH: 50/1) yielded 100gh 



















1H NMR (500 MHz, d6-DMSO): δ = 11.16 (s, 1H), 10.76 (s, 1H), 8.38 (d, J = 7.1 Hz, 1H), 
8.24 (t, J = 5.7 Hz, 1H), 8.21 (d, J = 7.9 Hz, 1H), 8.09 (t, J = 8.3 Hz, 1H), 7.92 (d, J = 8.3 Hz, 
1H), 7.89 (d, J = 8.1 Hz, 1H), 7.68 (d, J = 7.2 Hz, 2H), 7.59 (d, J = 7.6 Hz, 1H), 7.45 (t, J = 
7.4 Hz, 2H), 7.37–7.34 (m, 1H), 7.33–7.28 (m, 3H), 7.25–7.16 (m, 5H), 7.13 (d, J = 1.9 Hz, 
1H), 7.07 (ddd, J= 7.9, 6.9, 1.3 Hz, 1H), 7.03 (ddd, J= 7.9, 6.9, 1.3 Hz, 1H), 6.97 (ddd, J = 
8.0, 6.9, 1.2 Hz, 1H), 6.91 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 4.65–4.55 (m, 2H), 4.35–4.25 (m, 
2H), 3.77 (d, J = 5.4 Hz, 2H), 3.67 (dd, J = 15.5, 6.3 Hz, 1H), 3.60 (s, 3H), 3.58–3.55 (m, 3H), 
3.14 (dd, J = 14.7, 4.7 Hz, 1H), 3.07 (dd, J = 13.8, 4.5 Hz, 1H), 2.92 (dd, J = 14.7, 8.6 Hz, 
1H), 2.84 (dd, J = 13.8, 9.6 Hz, 1H), 1.60 (qqt, J = 6.6, 6.6, 5.6 Hz, 1H), 1.46 (dd, J = 10.5, 
5.6 Hz, 2H), 1.28 (d, J = 7.3 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.83 (d, J = 6.6 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 172.5 (Cq), 171.9 (Cq), 171.4 (Cq), 171.0 (Cq), 170.6 
(Cq), 168.3 (Cq), 168.1 (Cq), 137.6 (Cq), 135.8 (Cq), 135.7 (Cq), 135.6 (Cq), 132.2 (Cq), 
128.9 (CH), 128.6 (Cq), 128.4 (CH), 127.8 (CH), 127.7 (CH), 127.2 (CH), 127.1 (Cq), 126.0 
(CH), 123.4 (CH), 121.2 (CH), 120.6 (CH), 118.8 (CH), 118.5 (CH), 118.2 (CH), 118.0 (CH), 
111.0 (CH), 110.7 (CH), 109.7 (Cq), 105.5 (Cq), 54.2 (CH), 53.0 (CH), 51.7 (CH3), 51.0 
(CH), 47.5 (CH), 41.9 (CH2), 41.8 (CH2), 40.8 (CH2), 37.5 (CH2), 31.6 (CH2), 27.7 (CH2), 
24.0 (CH), 22.9 (CH3), 21.5 (CH3), 16.8 (CH3). 
IR (ATR): 3289, 1744, 1623, 1518, 1216, 739, 697 cm–1.  
MS (ESI) m/z (relative intensity) 931 (56) [M+2NH4–H]+, 895 (100) [M–H]+, 855 (28), 819 
(46) [M–Ph]+.  
HR-MS (ESI): m/z calcd for C50H56N8NaO8+ 919.4113, found 919.4122 [M+Na]+. 
5.4.5 Analytical Data for Arylated Tryptophan-Containing Peptides 
Synthesis of Ethyl Acetyl-L-alanyl-L-phenyltryptophyl-glycinate (102ah): 
The general procedure D1 was followed using ethyl 
acetyl-L-alanyl-L-tryptophyl-glycinate (101a) (80 mg, 
0.2 mmol) and diphenyliodonium tosylate (26h) (136 mg, 
0.3 mmol). After 17 h, purification by column 
chromatography (DCM/MeOH: 15/1) yielded 102ah 
















The general procedure D3 was followed using ethyl acetyl-L-alanyl-L-tryptophyl-glycinate 
(101a) (80 mg, 0.2 mmol) and diphenyliodonium tosylate (26h) (136 mg, 0.3 mmol) with 
water (3.0 mL). After 24 h, purification by column chromatography (DCM/MeOH: 15/1) 
yielded 102ah (67 mg, 70%) as a pale white solid. 
1H NMR (500 MHz, d6-DMSO): δ = 11.16 (s, 1H), 8.15 (t, J = 5.8 Hz, 1H), 7.96 (d, J = 
7.1 Hz, 1H), 7.91 (d, J = 8.3 Hz, 1H), 7.68 (d, J = 7.6 Hz, 2H), 7.66 (dd, J = 7.8, 1.2 Hz, 1H), 
7.47 (dd, J = 7.6, 7.6 Hz, 2H), 7.36 (dddd, J = 7.6, 7.6, 1.1, 1.1 Hz, 1H), 7.31 (dd, J = 8.0, 
1.3 Hz, 1H), 7.06 (ddd, J = 8.1, 7.0, 1.2 Hz,1H), 6.99 (ddd, J = 7.8, 7.0, 1.3 Hz, 1H), 4.65 
(ddd, J = 8.3, 7.2, 7.2 Hz, 1H), 4.19 (dq, J = 7.1, 7.1 Hz, 1H), 4.01 (q, J = 7.0 Hz, 2H), 3.67 
(dd, J = 17.5, 5.8 Hz, 1H), 3.56 (dd, J = 17.5, 5.8 Hz, 1H), 3.29 (dd, J = 15.3, 7.2 Hz, 1H), 
3.08 (dd, J = 15.3, 7.2 Hz, 1H), 1.77 (s, 3H), 1.12 (t, J = 7.0 Hz, 3H), 1.05 (d, J = 7.1 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.7 (Cq), 171.3 (Cq), 169.0 (Cq), 169.0 (Cq), 135.7 
(Cq), 135.2 (Cq), 132.5 (Cq), 128.8 (Cq), 128.3 (CH), 128.0 (CH), 127.1 (CH), 121.2 (CH), 
119.0 (CH), 118.4 (CH), 110.8 (CH), 107.3 (Cq), 60.2 (CH2), 53.7 (CH), 48.3 (CH), 40.8 
(CH2), 27.9 (CH2), 22.4 (CH3), 17.7 (CH3), 14.0 (CH3).  
IR (ATR): 3273, 1752, 1632, 1541, 1376, 1203, 1023, 748, 699 cm–1.  
MS (ESI) m/z (relative intensity) 979 (25) [2M+Na]+, 501 (100) [M+Na]+, 479 (75) [M+H]+, 
366 (12), 235 (13). 
HR-MS (ESI): m/z calcd for C26H31N4O5+ 479.2289, found 479.2294 [M+H]+. 
Synthesis of Ethyl Acetyl-L-alanyl-L-(4-fluorophenyl)tryptophyl-glycinate (102ai): 
The general procedure D1 was followed using ethyl 
acetyl-L-alanyl-L-tryptophyl-glycinate (101a) (80 mg, 
0.2 mmol) and bis(4-fluorophenyl)iodonium tosylate (26i) 
(147 mg, 0.3 mmol). After 17 h, purification by column 
chromatography (DCM/MeOH: 15/1) yielded (102ai) 
(92 mg, 93%) as a pale white solid (m. p. = 208–210 °C).  
The general procedure D3 was followed using ethyl acetyl-L-alanyl-L-tryptophyl-glycinate 
(101a) (80 mg, 0.2 mmol) and bis(4-fluorophenyl)iodonium tosylate (26i) (147 mg, 0.3 mmol) 
















yielded 102ai (94 mg, 95%) as a pale white solid. 
1H NMR(500 MHz, d6-DMSO): δ = 11.13 (s, 1H), 8.11 (t, J = 5.8 Hz, 1H), 7.90 (d, J = 
7.2 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.73–7.68 (m, 2H), 7.66 (dd, J = 7.9, 1.2 Hz, 1H), 
7.34–7.27 (m, 3H), 7.09 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.98 (ddd, J = 7.9, 7.0, 1.3 Hz, 1H), 
4.64 (ddd, J = 8.4, 7.1, 7.1 Hz, 1H), 4.19 (dq, J = 7.2, 7.2 Hz, 1H), 4.03 (dq, J = 7.1, 1,7 Hz, 
2H), 3.70 (dd, J = 17.3, 5.8 Hz, 1H), 3.59 (dd, J = 17.7, 5.8 Hz, 1H), 3.25 (dd, J = 14.4, 
7.1 Hz, 1H), 3.06 (dd, J = 14.4, 7.1 Hz, 1H), 1.79 (s, 3H), 1.14 (t, J = 7.1 Hz, 3H), 1.07 (d, J = 
7.2 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.7 (Cq), 171.2 (Cq), 169.0 (Cq), 169.0 (Cq), 162.2 
(d, JC-F = 244.4 Hz, Cq), 135.6 (Cq), 134.3 (Cq), 130.1 (d, JC-F = 8.1 Hz, CH), 129.1 (d, JC-F = 
3.0 Hz, Cq), 128.6 (Cq), 121.2 (CH), 118.9 (CH), 118.5 (CH), 115.2 (d, JC-F = 21.3 Hz, CH), 
110.8 (CH), 107.3 (Cq), 60.2 (CH2), 53.6 (CH), 48.2 (CH), 40.8 (CH2), 27.8 (CH2), 22.4 
(CH3), 17.7 (CH3), 13.9 (CH3).  
19F NMR (282 MHz, d6-DMSO): δ = –110.03 (dd, J = 9.9, 4.4 Hz).  
IR (ATR): 3272, 1748, 1632, 1539, 1213, 1163, 845, 747 cm–1.  
MS (ESI) m/z (relative intensity) 1015 (33) [2M+Na]+, 519 (100) [M+Na]+, 497 (74) [M+H]+, 
384 (12), 253 (15). 
HR-MS (ESI): m/z calcd for C26H30FN4O5+ 497.2195, found 497.2200 [M+H]+. 
Synthesis of Ethyl Acetyl-L-alanyl-L-(4-chlorophenyl)tryptophyl-glycinate (102aj): 
The general procedure D1 was followed using ethyl 
acetyl-L-alanyl-L-tryptophyl-glycinate (101a) (80 mg, 
0.2 mmol) and bis(4-chlorophenyl)iodonium tosylate 
(26j) (156 mg, 0.3 mmol). After 17 h, purification by 
column chromatography (DCM/MeOH: 15/1) yielded 102aj (96 mg, 94%) as a pale white 
solid (m. p. = 241–243 °C).  
The general procedure D3 was followed using ethyl acetyl-L-alanyl-L-tryptophyl-glycinate 
(101a) (80 mg, 0.2 mmol) and bis(4-chlorophenyl)iodonium tosylate (26j) (156 mg, 0.3 mmol) 
with water (3.0 mL). After 24 h, purification by column chromatography (DCM/MeOH: 15/1) 
















1H NMR (500 MHz, d6-DMSO): δ = 11.19 (s, 1H), 8.15 (t, J = 5.8 Hz, 1H), 7.93 (d, J = 
7.2 Hz, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.70 (d, J = 8.5 Hz, 2H), 7.67 (d, J = 7.9 Hz, 1H), 7.52 
(d, J = 8.5 Hz, 2H), 7.33 (d, J = 8.0 Hz, 1H), 7.09 (dd, J = 8.0, 7.5 Hz, 1H), 6.99 (dd, J = 7.9, 
7.5 Hz, 1H), 4.65 (ddd, J = 8.4, 7.1, 7.1 Hz, 1H), 4.19 (dq, J = 7.2, 7.2 Hz, 1H), 4.03 (dq, J = 
7.1, 1,7 Hz, 2H), 3.70 (dd, J = 17.7, 5.8 Hz, 1H), 3.59 (dd, J = 17.7, 5.8 Hz, 1H), 3.25 (dd, J = 
14.4, 7.1 Hz, 1H), 3.08 (dd, J = 14.4, 7.1 Hz, 1H), 1.80 (s, 3H), 1.15 (t, J = 7.1 Hz, 3H), 1.08 
(d, J = 7.2 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.8 (Cq), 171.2 (Cq), 169.0 (Cq), 169.0 (Cq), 135.8 
(Cq), 133.9 (Cq), 131.8 (Cq), 131.4 (Cq), 129.7 (CH), 128.7 (Cq), 128.3 (CH), 121.5 (CH), 
119.1 (CH), 118.6 (CH), 110.9 (CH), 107.9 (Cq), 60.3 (CH2), 53.6 (CH), 48.3 (CH), 40.8 
(CH2), 27.9 (CH2), 22.4 (CH3), 17.7 (CH3), 14.0 (CH3).  
IR (ATR): 3273, 1750, 1631, 1534, 1201, 1092, 748, 698 cm–1.  
MS (ESI) m/z (relative intensity) 1051/1049/1047/ (3/19/29) [2M+Na]+, 537/535 (32/100) 
[M+Na]+, 515/513 (20/61) [M+H]+, 402/400 (4/11), 271/269 (5/14).  
HR-MS (ESI): m/z calcd for C26H30ClN4O5+ 513.1899, found 513.1905 [M+H]+. 
Synthesis of Ethyl Acetyl-L-alanyl-L-(4-bromophenyl)tryptophyl-glycinate (118ak): 
The general procedure D1 was followed using ethyl 
acetyl-L-alanyl-L-tryptophyl-glycinate (101a) (80 mg, 
0.2 mmol) and bis(4-bromophenyl)iodonium tosylate 
(26k) (183 mg, 0.3 mmol). After 17 h, purification by 
column chromatography (n-hexane/EtOAc/MeOH: 
1/4/0.2) yielded 102ak (88 mg, 79%) as a pale white solid (m. p. = 239–241 °C).  
The general procedure D3 was followed using ethyl acetyl-L-alanyl-L-tryptophyl-glycinate 
(101a) (80 mg, 0.2 mmol) and bis(4-bromophenyl)iodonium tosylate (26k) (183 mg, 
0.3 mmol) with water (3.0 mL). After 24 h, purification by column chromatography 
(n-hexane/EtOAc/MeOH: 1/4/0.2) yielded 102ak (60 mg, 54%) as a pale white solid. 
1H NMR (500 MHz, d6-DMSO): δ = 11.19 (s, 1H), 8.14 (t, J = 5.8 Hz, 1H), 7.92 (d, J = 
7.2 Hz, 1H), 7.91 (d, J = 8.3 Hz, 2H), 7.69–7.62 (m, 5H), 7.34 (d, J = 8.1 Hz, 1H), 7.10 (dd, 
















(dq, J = 7.2, 7.2 Hz, 1H), 4.04 (dq, J = 7.1, 1.7 Hz, 2H), 3.70 (dd, J = 17.7, 5.8 Hz, 1H), 3.59 
(dd, J = 17.7, 5.8 Hz, 1H), 3.28 (dd, J = 14.4, 7.1 Hz, 1H), 3.08 (dd, J = 14.4, 7.1 Hz, 1H), 
1.79 (s, 3H), 1.15 (t, J = 7.1 Hz, 3H), 1.08 (d, J = 7.2 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.7 (Cq), 171.2 (Cq), 169.0 (Cq), 169.0 (Cq), 135.8 
(Cq), 133.9 (Cq), 131.7 (Cq), 131.2 (CH), 129.9 (CH), 128.7 (Cq), 121.5 (CH), 120.3 (Cq), 
119.0 (CH), 118.6 (CH), 110.9 (CH), 107.9 (Cq), 60.3 (CH2), 53.6 (CH), 48.3 (CH), 40.8 
(CH2), 27.9 (CH2), 22.4 (CH3), 17.7 (CH3), 13.9 (CH3).  
IR (ATR): 3273, 1737, 1631, 1538, 1192, 827, 738, 698 cm–1.  
MS (ESI) m/z (relative intensity) 1139/1137/1135 (15/30/15) [2M+Na]+, 581/579 (100/100) 
[M+Na]+, 559/557 (63/63) [M+H]+, 446/444 (14/14), 315/313 (13/13). 
HR-MS (ESI): m/z calcd for C26H30BrN4O5+ 557.1394, found 557.1400 [M+H]+. 
Synthesis of Ethyl Acetyl-L-alanyl-L-(4-tert-butylphenyl)tryptophyl-glycinate (102al): 
The general procedure D3 was followed using ethyl 
acetyl-L-alanyl-L-tryptophyl-glycinate (101a) (80 mg, 
0.2 mmol) and bis(4-tert-butylphenyl)iodonium tosylate 
(26l) (169 mg, 0.3 mmol) with water (3.0 mL). After 
24 h, purification by column chromatography 
(n-hexane/EtOAc/ MeOH: 1/4/0.2) yielded 102al (82 mg, 77%) as a pale white solid (m. p. = 
168–170 °C). 
1H NMR (500 MHz, d6-DMSO): δ = 11.05 (s, 1H), 8.12 (t, J = 5.8 Hz, 1H), 7.93 (d, J = 
7.2 Hz, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 8.7 Hz, 2H), 7.49 
(d, J = 8.7 Hz, 2H), 7.31 (dd, J = 8.1 Hz, 1H), 7.06 (dd, J = 8.1, 7.2 Hz, 1H), 7.97 (dd, J = 8.0, 
7.2 Hz, 1H), 4.65 (ddd, J = 8.2, 7.1, 7.1 Hz, 1H), 4.19 (dq, J = 7.2, 7.2 Hz, 1H), 4.03 (dq, J = 
7.1, 1.7 Hz, 2H), 3.69 (dd, J = 17.3, 5.8 Hz, 1H), 3.57 (dd, J = 17.3, 5.8 Hz, 1H), 3.32 (dd, J = 
14.5, 7.1 Hz, 1H), 3.11 (dd, J = 14.5, 7.1 Hz, 1H), 1.78 (s, 3H), 1.34 (s, 9H), 1.14 (t, J = 
7.1 Hz, 3H), 1.07 (d, J = 7.2 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.7 (Cq), 171.3 (Cq), 169.1 (Cq), 169.0 (Cq), 149.4 
(Cq), 135.6 (Cq), 135.1 (Cq), 129.7 (Cq), 128.8 (CH), 127.6 (CH), 125.1 (CH), 121.0 (CH), 
















(CH2), 34.3 (CH2), 31.0 (CH3), 27.9 (Cq), 22.4 (CH3), 17.7 (CH3), 13.9 (CH3).  
IR (ATR): 3280, 2962, 1738, 1639, 1507, 1196, 1019, 836, 741 cm–1.  
MS (ESI) m/z (relative intensity) 1091 (50) [2M+Na]+, 557 (100) [M+Na]+, 535 (92) [M+H]+, 
422 (8), 291 (4). 
HR-MS (ESI): m/z calcd for C30H39N4O5+ 535.2915, found 535.2920 [M+H]+. 
Synthesis of Ethyl Acetyl-L-alanyl-L-(4-methoxyphenyl)tryptophyl-glycinate (102ag): 
The general procedure D1 was followed using ethyl 
acetyl-L-alanyl-L-tryptophyl-glycinate (101a) (80 mg, 
0.2 mmol) and bis(4-methoxyphenyl)iodonium tosylate 
(26g) (154 mg, 0.3 mmol). After 17 h, purification by 
column chromatography (n-hexane/EtOAc/MeOH: 
1/4/0.2) yielded 102ag (86 mg, 85%) as a pale white solid (m. p. = 230–232 °C).  
The general procedure D2 was followed using ethyl acetyl-L-alanyl-L-tryptophyl-glycinate 
(101a) (80 mg, 0.2 mmol) and (mesityl)(4-methoxyphenyl)iodonium tosylate (26r) (157 mg, 
0.3 mmol). After 24 h, purification by column chromatography (n-hexane/EtOAc/MeOH: 
1/4/0.2) yielded 102ag (65 mg, 64%) as a pale white solid. 
The general procedure D3 was followed using ethyl acetyl-L-alanyl-L-tryptophyl-glycinate 
(101a) (80 mg, 0.2 mmol) and bis(4-methoxyphenyl)iodonium tosylate (26g) (154 mg, 
0.3 mmol) with water (3.0 mL). After 24 h, purification by column chromatography 
(n-hexane/EtOAc/MeOH: 1/4/0.2) yielded 102ag (81 mg, 80%) as a pale white solid. 
1H NMR (500 MHz, d6-DMSO): δ = 11.03 (s, 1H), 8.09 (t, J = 5.7 Hz, 1H), 7.91 (d, J = 
7.2 Hz, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.64 (d, J = 8.2 Hz, 1H), 7.62 (d, J = 8.8 Hz, 2H), 7.31 
(d, J = 8.0 Hz, 1H), 7.07 (dd, J =8.0, 7.0 Hz, 1H), 7.04 (d, J = 8.8 Hz, 2H), 6.98 (dd, J = 8.2, 
7.0 Hz, 1H), 4.64 (ddd, J = 8.3, 7.0, 7.0 Hz, 1H), 4.20 (dq, J = 7.2, 7.2 Hz, 1H), 4.04 (dq, J = 
7.1, 1.7 Hz, 2H), 3.82 (s, 3H), 3.71 (dd, J = 17.3, 5.7 Hz, 1H), 3.60 (dd, J = 17.3, 5.7 Hz, 1H), 
3.27 (dd, J = 14.4, 7.0 Hz, 1H), 3.06 (dd, J = 14.4, 7.0 Hz, 1H), 1.79 (s, 3H), 1.15 (t, J = 
7.1 Hz, 3H), 1.08 (d, J = 7.2 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.6 (Cq), 171.3 (Cq), 169.0 (Cq), 169.0 (Cq), 158.4 
















118.3 (CH), 113.8 (CH), 110.6 (CH), 106.4 (Cq), 60.2 (CH2), 55.1 (CH3), 53.67 (CH), 48.3 
(CH), 40.8 (CH2), 27.9 (CH2), 22.4 (CH3), 17.7 (CH3), 14.0 (CH3).  
IR (ATR): 3279, 1733, 1632, 1539, 1246, 1181, 1033, 775, 744 cm–1.  
MS (ESI) m/z (relative intensity) 1039 (63) [2M+Na]+, 531 (94) [M+Na]+, 509 (100) [M+H]+, 
396 (9), 265 (13). 
HR-MS (ESI): m/z calcd for C27H33N4O6+ 509.2395, found 509.2400 [M+H]+. 
Synthesis of Ethyl Acetyl-L-alanyl-L-(2,4-dimethylphenyl)tryptophyl-glycinate (102am): 
The general procedure D1 was followed using ethyl 
acetyl-L-alanyl-L-tryptophyl-glycinate (101a) (80 mg, 
0.2 mmol) and bis(2,4-dimethylphenyl)iodonium 
tosylate (26m) (153 mg, 0.3 mmol). After 17 h, 
purification by column chromatography 
(n-hexane/EtOAc/MeOH: 1/4/0.2) yielded 102am (52 mg, 51%) as a pale white solid (m. p. = 
144–146 °C).  
The general procedure D3 was followed using ethyl acetyl-L-alanyl-L-tryptophyl-glycinate 
(101a) (80 mg, 0.2 mmol) and bis(2,4-dimethylphenyl)iodonium tosylate (26m) (153 mg, 
0.3 mmol) with water (3.0 mL). After 24 h, purification by column chromatography 
(n-hexane/EtOAc/MeOH: 1/4/0.2) yielded 102am (72 mg, 71%) as a pale white solid. 
1H NMR (500 MHz, d6-DMSO): δ = 10.87 (s, 1H), 7.97 (t, J = 5.7 Hz, 1H), 7.85 (d, J = 
7.3 Hz, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.58 (d, J = 8.2 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.24 
(d, J = 7.8 Hz, 1H), 7.14 (s, 1H), 7.08 (d, J = 8.0 Hz, 1H), 7.06 (dd, J = 8.2, 7.5 Hz, 1H), 6.99 
(dd, J = 7.8, 7.5 Hz, 1H), 4.52 (ddd, J = 8.3, 7.8, 7.8 Hz, 1H), 4.16 (dq, J = 7.3, 7.3 Hz, 1H), 
4.04 (dq, J = 7.1, 1.7 Hz, 2H), 3.69 (dd, J = 17.4, 5.7 Hz, 1H), 3.62 (dd, J = 17.4, 5.7 Hz, 1H), 
3.06 (dd, J = 14.3, 7.8 Hz, 1H), 2.82 (dd, J = 14.3, 7.8 Hz, 1H), 2.35 (s, 3H), 2.12 (s, 3H), 
1.77 (s, 3H), 1.15 (t, J = 7.1 Hz, 3H), 1.05 (d, J = 7.3 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.5 (Cq), 171.3 (Cq), 169.1 (Cq), 168.8 (Cq), 137.1 
(Cq), 136.8 (Cq), 135.8 (Cq), 135.5 (Cq), 130.7 (CH), 130.4 (CH), 129.4 (Cq), 127.8 (Cq), 
125.9 (CH), 120.5 (CH), 118.6 (CH), 118.1 (CH), 110.58 (CH), 107.2 (Cq), 60.2 (CH2), 53.5 

















13.9 (CH3).  
IR (ATR): 3279, 2982, 1626, 1523, 1458, 1371, 1194, 744 cm–1.  
MS (ESI) m/z (relative intensity) 1035 (59) [2M+Na]+, 529 (91) [M+Na]+, 507 (100) [M+H]+, 
394 (13), 263 (14). 
HR-MS (ESI): m/z calcd for C28H35N4O5+ 507.2602, found 507.2607 [M+H]+. 
Synthesis of Methyl Acetyl-L-alanyl-L-phenyltryptophyl-L-alaninate (102bh): 
The general procedure D1 was followed using methyl 
acetyl-L-alanyl-L-tryptophyl-L-alaninate (101b) (80 mg, 
0.2 mmol) and diphenyliodonium tosylate (26h) 
(136 mg, 0.3 mmol). After 17 h, purification by column 
chromatography (DCM/MeOH: 15/1) yielded 102bh 
(94 mg, 98%) as a pale white solid (m. p. = 253–255 °C).  
The general procedure D3 was followed using methyl acetyl-L-alanyl-L-tryptophyl-L-alaninate 
(101b) (80 mg, 0.2 mmol) and diphenyliodonium tosylate (26h) (136 mg, 0.3 mmol) with 
water (3.0 mL). After 24 h, purification by column chromatography (n-hexane/EtOAc/MeOH: 
1/4/0.2) yielded 102bh (52 mg, 54%) as a pale white solid. 
1H NMR (500 MHz, d6-DMSO): δ = 11.12 (s, 1H), 7.96 (d, J = 7.2 Hz, 1H), 7.95 (d, J = 
7.2 Hz, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.69 (d, J = 7.5 Hz, 1H), 7.68 (d, J = 7.5 Hz, 2H), 7.48 
(dd, J = 7.5, 7.5 Hz, 2H), 7.37 (dd, J = 7.5, 7.5 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.08 (dd, 
J = 8.0, 7.0 Hz, 1H), 6.98 (dd, J = 7.5, 7.0 Hz, 1H), 4.61 (ddd, J = 8.3, 7.6, 7.6 Hz, 1H), 4.20 
(dq, J = 7.2, 7.2 Hz, 1H), 4.11 (dq, J = 7.2, 7.2 Hz, 1H), 3.49 (s, 3H), 3.34 (dd, J = 14.6, 
7.6 Hz, 1H), 3.11 (dd, J = 14.6, 7.6 Hz, 1H), 1.80 (s, 3H), 1.20 (d, J = 7.2 Hz, 3H), 1.03 (d, 
J = 7.2 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 172.2 (Cq), 171.6 (Cq), 170.6 (Cq), 169.2 (Cq), 135.7 
(Cq), 135.1 (Cq), 132.6 (Cq), 128.8 (Cq), 128.3 (CH), 127.9 (CH), 127.0 (CH), 121.2 (CH), 
119.0 (CH), 118.4 (CH), 110.8 (CH), 107.4 (Cq), 53.7 (CH3), 51.6 (CH), 48.6 (CH), 47.5 
(CH), 27.4 (CH2), 22.4 (CH3), 17.4 (CH3), 16.9 (CH3).  
IR (ATR): 3273, 1743, 1633, 1538, 1201, 1055, 742, 696 cm–1.  

















366 (8), 235 (13). 
HR-MS (ESI): m/z calcd for C26H31N4O5+ 479.2289, found 479.2294 [M+H]+. 
Synthesis of Ethyl Acetyl-L-phenylalanyl-L-phenyltryptophyl-glycinate (102ch): 
The general procedure D1 was followed using ethyl 
acetyl-L-phenylalanyl-L-tryptophyl-glycinate (101c) 
(122 mg, 0.255 mmol) and diphenyliodonium tosylate 
(26h) (173 mg, 0.382 mmol). After 17 h, purification by 
column chromatography (DCM/MeOH: 10/1) yielded 
102ch (122 mg, 86%) as a pale white solid (m. p. = 215–217 °C). 
1H NMR (500 MHz, d6-DMSO): δ = 11.18 (s, 1H), 8.24 (t, J = 5.6 Hz, 1H), 8.20 (d, J = 
8.3 Hz, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.68 (d, J = 7.7 Hz, 2H), 7.47 
(dd, J = 7.7, 7.7 Hz, 2H), 7.37 (dd, J = 7.7, 7.7 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.20 (d, J = 
7.1 Hz, 2H), 7.16–7.12 (m, 3H), 7.08 (dd, J = 8.1, 7.0 Hz, 1H), 6.98 (dd, J = 7.9, 7.0 Hz, 1H), 
4.69 (ddd, J = 8.2, 7.2, 7.2 Hz, 1H), 4.46 (ddd, J = 9.8, 8.3, 4.5 Hz, 1H), 4.01 (dq, J = 7.1, 
1.7 Hz, 2H), 3.68 (dd, J = 17.3, 5.6 Hz, 1H), 3.55 (dd, J = 17.3, 5.6 Hz, 1H), 3.28 (dd, J = 
14.5, 7.2 Hz, 1H), 3.07 (dd, J = 14.5, 7.2 Hz, 1H), 2.87 (dd, J = 13.9, 4.5 Hz, 1H), 2.64 (dd, 
J = 13.9, 9.8 Hz, 1H), 1.68 (s, 3H), 1.12 (t, J = 7.1 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.2 (Cq), 170.6 (Cq), 169.0 (Cq), 168.8 (Cq), 137.7 
(Cq), 135.7 (Cq), 135.3 (Cq), 132.5 (Cq), 128.9 (CH), 128.7 (Cq), 128.3 (CH), 128.0 (CH), 
127.7 (CH), 127.1 (CH), 125.9 (CH), 121.2 (CH), 119.0 (CH), 118.4 (CH), 110.8 (CH), 107.1 
(Cq), 60.2 (CH2), 53.8 (CH), 53.7 (CH), 40.8 (CH2), 37.2 (CH2), 28.2 (CH2), 22.4 (CH3), 
14.0 (CH3). 
IR (ATR): 3444, 1661, 1051, 1023, 1004, 821, 759 cm–1.  
MS (ESI) m/z (relative intensity) 1131 (16) [2M+Na]+, 577 (100) [M+Na]+, 555 (32) [M+H]+, 
430 (6), 366 (8). 
HR-MS (ESI): m/z calcd for C32H34N4NaO5+ 557.2421, found 557.2427 [M+Na]+. 
Synthesis of Dimethyl Acetyl-glycyl-L-phenyltryptophyl-L-glutamate (102dh): 






























(101d) (92 mg, 0.2 mmol) and diphenyliodonium tosylate (26h) (136 mg, 0.3 mmol). After 
17 h, purification by column chromatography (n-hexane/EtOAc/MeOH: 1/4/0.2) yielded 
102dh (60 mg, 56%) as a pale white solid (m. p. = 172–174 °C). 
The general procedure D3 was followed using dimethyl acetyl-glycyl-L-tryptophyl-L- 
glutamate (101d) (92 mg, 0.2 mmol) and diphenyliodonium tosylate (26h) (136 mg, 0.3 mmol) 
with water (3.0 mL). After 24 h, purification by column chromatography 
(n-hexane/EtOAc/MeOH: 1/4/0.2) yielded 102dh (25 mg, 23%) as a pale white solid. 
1H NMR (500 MHz, d6-DMSO): δ = 11.12 (s, 1H), 8.14 (d, J = 7.7 Hz, 1H), 7.98 (t, J = 
5.5 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.67 (d, J = 7.4 Hz, 2H), 7.48 
(dd, J = 7.4, 7.4 Hz, 2H), 7.37 (dd, J = 7.4, 7.4 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.08 (dd, 
J = 8.0, 7.1 Hz, 1H), 6.98 (dd, J = 7.9, 7.1 Hz, 1H), 4.68 (ddd, J = 8.4, 7.8, 7.8 Hz, 1H), 4.24 
(dt, J = 7.7, 5.5 Hz, 1H), 3.64 (dd, J = 16.5, 5.7 Hz, 1H), 3.57 (s, 3H), 3.48 (s, 3H), 3.45 (dd, 
J = 16.5, 5.7 Hz, 1H), 3.31 (d, J = 14.4, 7.8 Hz, 1H), 3.07 (dd, J = 14.4, 7.8 Hz, 1H), 2.28 (t, 
J = 7.7 Hz, 2H), 1.94 (dt, J = 7.7, 5.5 Hz, 1H), 1.82 (dt, J = 7.7, 5.5 Hz, 1H), 1.80 (s, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 172.3 (Cq), 171.2 (Cq), 171.0 (Cq), 169.4 (Cq), 168.3 
(Cq), 135.7 (Cq), 135.1 (Cq), 132.5 (Cq), 128.7 (Cq), 128.3 (CH), 127.9 (CH), 127.0 (CH), 
121.1 (CH), 118.9 (CH), 118.4 (CH), 110.8 (CH), 107.3 (Cq), 53.7 (CH), 51.6 (CH), 51.2 
(CH3), 51.0 (CH3), 42.1 (CH2), 29.4 (CH2), 27.8 (CH2), 26.0 (CH2), 22.3 (CH3).  
IR (ATR): 3272, 1733, 1635, 1521, 1436, 1204, 742, 698 cm–1.  
MS (ESI) m/z (relative intensity) 1095 (29) [2M+Na]+, 559 (100) [M+Na]+, 537 (67) [M+H]+, 
438 (4), 362 (4).  
HR-MS (ESI): m/z calcd for C28H33N4O7+ 537.2344, found 537.2349 [M+H]+. 
Synthesis of Ethyl Acetyl-L-alanyl-L-(4-tolyl)tryptophyl-glycinate (102as): 
The general procedure D2 was followed using ethyl 
acetyl-L-alanyl-L-tryptophyl-glycinate (101a) (80 mg, 
0.2 mmol) and (mesityl)(p-tolyl)iodonium tosylate (26s) 
(152 mg, 0.3 mmol) with water. After 24 h, purification 
by column chromatography (n-hexane/EtOAc/MeOH: 
















The general procedure D3 was followed using ethyl acetyl-L-alanyl-L-tryptophyl-glycinate 
(101a) (80 mg, 0.2 mmol) and bis(p-tolyl)iodonium tosylate (26x) (144 mg, 0.3 mmol). After 
24 h, purification by column chromatography (n-hexane/EtOAc/MeOH: 1/4/0.2) yielded 
102as (60 mg, 61%) as a pale white solid. 
1H NMR (500 MHz, d6-DMSO): δ = 11.05 (s, 1H), 8.08 (t, J = 5.7 Hz, 1H), 7.90 (d, J = 
7.2 Hz, 1H), 7.81 (d, J = 8.3 Hz, 1H), 7.64 (d, J = 7.9 Hz, 1H), 7.57 (d, J = 8.1 Hz, 2H), 7.31 
(d, J = 8.0 Hz, 1H), 7.28 (t, J = 8.1 Hz, 2H), 7.06 (dd, J = 8.0, 7.0 Hz, 1H), 6.97 (dd, J = 7.9, 
7.0 Hz, 1H), 4.64 (ddd, J = 8.3, 7.1, 7.1 Hz, 1H), 4.18 (dq, J = 7.2, 7.2 Hz, 1H), 4.04 (dq, J = 
7.1, 1.7 Hz, 2H), 3.70 (dd, J = 17.2, 5.7 Hz, 1H), 3.58 (dd, J = 17.2, 5.7 Hz, 1H), 3.28 (dd, J = 
14.4, 7.1 Hz, 1H), 3.09 (dd, J = 14.4, 7.1 Hz, 1H), 2.37 (s, 3H), 1.79 (s, 3H), 1.15 (t, J = 
7.1 Hz, 3H), 1.08 (d, J = 7.2 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.6 (Cq), 171.3 (Cq), 169.1 (Cq),169.0 (Cq), 136.4 
(Cq), 135.6 (Cq), 135.3 (Cq), 129.7 (Cq), 128.9 (CH), 128.8 (Cq), 127.8 (CH), 121.0 (CH), 
118.8 (CH), 118.3 (CH), 110.7 (CH), 106.9 (Cq), 60.2 (CH2), 53.70 (CH), 48.3 (CH), 40.8 
(CH2), 27.9 (CH2), 22.4 (CH3), 20.8 (CH3), 17.7 (CH3), 13.9 (CH3).  
IR (ATR): 3272, 1733, 1632, 1540, 1193, 1025, 742 cm–1.  
MS (ESI) m/z (relative intensity) 1007 (44) [2M+Na]+, 515 (100) [M+Na]+, 493 (89) [M+H]+, 
380 (14), 249 (11). 
HR-MS (ESI): m/z calcd for C27H33N4O5+ 443.2445, found 493.2451 [M+H]+. 
Synthesis of Ethyl Acetyl-L-alanyl-L-(3-trifluoromethylphenyl)tryptophyl-glycinate 
(102at): 
The general procedure D2 was followed using ethyl 
acetyl-L-alanyl-L-tryptophyl-glycinate (101a) (80 mg, 
0.2 mmol) and (mesityl)(3-trifluoromethylphenyl)-
iodonium tosylate (26t) (169 mg, 0.3 mmol). After 24 h, 
purification by column chromatography 
(n-hexane/EtOAc/MeOH: 1/1) yielded 102at (36 mg, 33%) as a pale white solid (m. p. = 
192–194 °C). 

















1H), 7.94 (s, 1H), 7.92–7.88 (m, 2H), 7.73–7.68 (m, 3H), 7.35 (d, J = 8.1 Hz, 1H), 7.12 (dd, 
J = 8.1, 7.5 Hz, 1H), 7.01 (dd, J = 7.9, 7.5 Hz, 1H), 4.65 (ddd, J = 8.4, 7.3, 7.3 Hz, 1H), 4.19 
(dq, J = 7.2, 7.2 Hz, 1H), 4.02 (dq, J = 7.1, 1.7 Hz, 2H), 3.65 (dd, J = 17.3, 5.8 Hz, 1H), 3.56 
(dd, J = 17.3, 5.8 Hz, 1H), 3.34 (dd, J = 14.4, 7.3 Hz, 1H), 3.12 (dd, J = 14.4, 7.3 Hz, 1H), 
1.79 (s, 3H), 1.13 (t, J = 7.1 Hz, 3H), 1.07 (d, J = 7.2 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.7 (Cq), 171.0 (Cq), 169.0 (Cq), 168.9 (Cq), 135.9 
(Cq), 133.5 (Cq), 133.4 (Cq), 131.9 (CH), 129.4 (CH), 129.2 (q, JC–F = 31.6 Hz, Cq), 128.6 
(Cq), 124.2 (q, JC–F = 3.8 Hz, CH), 124.0 (q, JC–F = 271.7 Hz, CF3), 123.5 (q, JC–F = 3.8 Hz, 
CH), 121.8 (CH), 119.2 (CH), 118.7 (CH), 111.0 (CH), 108.4 (Cq), 60.2 (CH2), 53.4 (CH), 
48.2 (CH), 40.7 (CH2), 27.8 (CH2), 22.4 (CH3), 17.7 (CH3), 13.9 (CH3).  
19F NMR (376 MHz, d6-DMSO): δ = –61.02 (s).  
IR (ATR): 3266, 1719, 1635, 1542, 1327, 1024, 1000, 690 cm–1.  
MS (ESI) m/z (relative intensity) 1115 (56) [2M+Na]+, 569 (100) [M+Na]+, 547 (100) 
[M+H]+, 434 (19), 303 (16). 
HR-MS (ESI): m/z calcd for C27H30F3N4O5+ 547.2163, found 547.2168 [M+H]+. 
Synthesis of Ethyl Acetyl-L-alanyl-L-(naphthalen-1-yl)tryptophyl-glycinate (102au): 
The general procedure D2 was followed using ethyl 
acetyl-L-alanyl-L-tryptophyl-glycinate (101a) (80 mg, 
0.2 mmol) and (mesityl)(naphthalen-1-yl)iodonium 
tosylate (26u) (163 mg, 0.3 mmol). After 24 h, 
purification by column chromatography 
(n-hexane/EtOAc/MeOH: 1/1) yielded 102au (74 mg, 
70%) as a pale white solid (m. p. = 128–130 °C). 
1H NMR (500 MHz, d6-DMSO): δ = 11.18 (s, 1H), 8.03 (d, J = 7.0 Hz, 1H), 8.01 (d, J = 
8.3 Hz, 1H), 7.90 (d, J = 5.3 Hz, 1H), 7.83 (d, J = 7.2 Hz, 1H), 7.76 (d, J = 7.8 Hz, 1H), 
7.66–7.60 (m, 3H), 7.57–7.52 (m, 2H), 7.47 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H), 7.34 (dd, J = 8.1, 
1.0 Hz, 1H), 7.12 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 7.06 (ddd, J = 7.9, 7.1, 1.0 Hz, 1H), 4.55 
(ddd, J = 8.3, 7.3, 7.3 Hz, 1H), 4.12 (dq, J = 7.0, 7.0 Hz, 1H), 4.00 (dq, J = 7.1, 1.7 Hz, 2H), 
















2.86 (d, J = 14.4 Hz, 1H), 1.77 (s, 3H), 1.12 (t, J = 7.1 Hz, 3H), 1.03 (d, J = 7.0 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.5 (Cq), 171.1 (Cq), 169.0 (Cq), 168.8 (Cq), 135.8 
(Cq), 134.3 (Cq), 133.0 (Cq), 131.9 (Cq), 130.2 (Cq), 128.8 (CH), 128.2 (CH), 127.9 (CH), 
127.8 (Cq), 126.2 (CH), 125.7 (CH), 125.6 (CH), 125.2 (CH), 120.9 (CH), 118.8 (CH), 118.4 
(CH), 110.8 (CH), 108.7 (Cq), 60.2 (CH2), 53.5 (CH), 48.2 (CH), 40.6 (CH2), 27.8 (CH2), 
22.4 (CH3), 17.8 (CH3), 13.9 (CH3).  
IR (ATR): 3281, 1736, 1636, 1506, 1371, 1197, 779, 743 cm–1.  
MS (ESI) m/z (relative intensity) 1079 (58) [2M+Na]+, 551 (96) [M+Na]+, 529 (100) [M+H]+, 
416 (17), 285 (13). 
HR-MS (ESI): m/z calcd for C30H33N4O5+ 529.2445, found 529.2451 [M+H]+. 
Synthesis of Ethyl Acetyl-L-alanyl-L-(N-acetyl-L-phenylalanine)tryptophyl-glycinate 
(102av): 
The general procedure D2 was followed using 
ethyl acetyl-L-alanyl-L-tryptophyl-glycinate (101a) 
(80 mg, 0.2 mmol) and (mesityl)(N-acetyl-L- 
phenylalanine)iodonium tosylate (26v) (191 mg, 
0.3 mmol). After 24 h, purification by column chromatography (n-hexane/EtOAc/MeOH: 
1/4/0.4) yielded 102av (66 mg, 53%) as a pale white solid (m. p. = 176–178 °C).  
1H NMR (500 MHz, d6-DMSO): δ = 11.10 (s, 1H), 8.35 (d, J = 7.7 Hz, 1H), 8.10 (t, J = 
5.7 Hz, 1H), 7.91 (d, J = 7.1 Hz, 1H), 7.86 (d, J = 8.3 Hz, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.62 
(d, J = 8.2 Hz, 2H), 7.32 (d, J = 8.2 Hz, 2H), 7.31 (d, J = 8.1 Hz, 1H), 7.06 (ddd, J = 8.1, 7.0, 
1.0 Hz, 1H), 6.97 (ddd, J = 7.9, 7.0, 0.9 Hz, 1H), 4.65 (ddd, J = 8.3, 7.1, 7.1 Hz, 1H), 4.52 
(ddd, J = 9.3, 7.7, 5.7 Hz, 1H), 4.19 (dq, J = 7.1, 7.1 Hz, 1H), 4.02 (dq, J = 7.2, 1.7 Hz, 2H), 
3.70 (dd, J = 17.3, 5.7 Hz, 1H), 3.63 (s, 3H), 3.58 (dd, J = 17.3, 5.7 Hz, 1H), 3.29 (dd, J = 
14.4, 7.1 Hz, 1H), 3.10 (dd, J = 14.4, 7.1 Hz, 1H), 3.08 (dd, J = 13.8, 5.7 Hz, 1H), 2.95 (dd, 
J = 13.8, 9.3 Hz, 1H), 1.83 (s, 3H), 1.79 (s, 3H), 1.15 (t, J = 7.2 Hz, 3H), 1.08 (d, J = 7.1 Hz, 
3H). 
13C NMR (126 MHz, d6-DMSO): δ = 171.9 (Cq), 171.7 (Cq), 171.3 (Cq), 169.1 (Cq), 169.0 


















127.7 (CH), 121.1 (CH), 118.9 (CH), 118.4 (CH), 110.7 (CH), 107.2 (Cq), 60.2 (CH2), 53.7 
(CH), 53.5 (CH), 51.7 (CH3), 48.3 (CH), 40.8 (CH2), 36.4 (CH2), 28.0 (CH2), 22.4 (CH3), 
22.2 (CH3), 17.7 (CH3), 14.0 (CH3). 
IR (ATR): 3280, 1738, 1637, 1540, 1199, 1013, 738 cm–1.  
MS (ESI) m/z (relative intensity) 1265 (22) [2M+Na]+, 644 (100) [M+Na]+, 622 (96) [M+H]+, 
509 (9), 378 (5). 
HR-MS (ESI): m/z calcd for C32H40N5O8+ 622.2871, found 622.2877 [M+H]+. 
Synthesis of Ethyl Acetyl-L-alanyl-L-(N-phenylacetyl-glycine)tryptophyl-glycinate 
(102aw): 
The general procedure D2 was followed 
using ethyl acetyl-L-alanyl-L-tryptophyl- 
glycinate (101a) (80 mg, 0.2 mmol) and 
(mesityl)(N-phenylacetyl-glycine)iodonium 
tosylate (26w) (191 mg, 0.3 mmol). After 
24 h, purification by column chromatography (n-hexane/EtOAc/MeOH: 1/4/0.4) yielded 
102aw (45 mg, 36%) as a pale white solid (m. p. = 135–137 °C).  
1H NMR (500 MHz, d6-DMSO): δ = 11.08 (s, 1H), 8.50 (t, J = 5.9 Hz, 1H), 8.11 (t, J = 
5.8 Hz, 1H), 7.90 (d, J = 7.2 Hz, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.62 
(d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.0 Hz, 1H), 7.07 (dd, J = 8.0, 
7.0 Hz, 1H), 6.97 (dd, J = 7.9, 7.0 Hz, 1H), 4.66 (ddd, J = 8.3, 7.2, 7.2 Hz, 1H), 4.19 (dq, J = 
7.2, 7.2 Hz, 1H), 4.10 (q, J = 7.1 Hz, 2H), 4.03 (dq, J = 7.1, 1.7 Hz, 2H), 3.86 (d, J = 5.9 Hz, 
2H), 3.70 (dd, J = 17.3, 5.8 Hz, 1H), 3.60 (dd, J = 17.3, 5.8 Hz, 1H), 3.56 (s, 2H), 3.31 (dd, 
J = 14.4, 7.2 Hz, 1H), 3.10 (dd, J = 14.4, 7.2 Hz, 1H), 1.79 (s, 3H), 1.19 (t, J = 7.1 Hz, 3H), 
1.15 (t, J = 7.1 Hz, 3H), 1.07 (d, J = 7.2 Hz, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 171.7 (Cq), 171.2 (Cq), 170.3 (Cq), 169.6 (Cq), 169.0 
(Cq), 169.0 (Cq), 135.6 (Cq), 135.0 (Cq), 134.9 (Cq), 130.7 (Cq), 129.0 (CH), 128.8 (Cq), 
127.7 (CH), 121.1 (CH), 118.9 (CH), 118.4 (CH), 110.7 (CH), 107.1 (Cq), 60.3 (CH2), 60.2 
(CH2), 53.7 (CH), 48.3 (CH), 41.6 (CH2), 40.8 (CH2), 40.7 (CH2), 27.9 (CH2), 22.4 (CH3), 



















IR (ATR): 3280, 1738, 1640, 1526, 1373, 1196, 1010, 744 cm–1.  
MS (ESI) m/z (relative intensity) 1265 (12) [2M+Na]+, 644 (100) [M+Na]+, 622 (89) [M+H]+, 
509 (10), 378 (5), 242 (6). 
HR-MS (ESI): m/z calcd for C32H40N5O8+ 622.2871, found 622.2877 [M+H]+. 
Synthesis of N-acetyl-L-(phenyl)tryptophan (102gh): 
The general procedure D3 was followed using N-acetyl-L-tryptophan 
(101g) (49 mg, 0.2 mmol) and diphenyl- iodonium tosylate (26h) 
(136 mg, 0.3 mmol). After 24 h, purification by column 
chromatography (n-hexane/EtOAc/MeOH/AcOH: 1/5/0.5/0.02) 
yielded 102gh (55 mg, 85%) as a pale white solid (m. p. = 
155–157 °C).  
1H NMR (500 MHz, d6-DMSO): δ = 11.14 (s, 1H), 8.07 (d, J = 8.1 Hz, 1H), 7.74–7.67 (m, 
3H), 7.48 (dd, J = 7.3, 7.3 Hz, 2H), 7.37 (d, J = 7.2 Hz, 1H), 7.35 (dd, J = 7.3, 7.3 Hz, 1H), 
7.08 (dd, J = 7.2, 7.2 Hz, 1H), 6.99 (dd, J = 7.2, 7.2 Hz, 1H), 4.55 (ddd, J = 8.1, 7.7, 7.7 Hz, 
1H ), 3.34 (dd, J = 14.3, 7.7 Hz, 1H), 3.12 (dd, J = 14.3, 7.7 Hz, 1H), 1.70 (s, 3H).  
13C NMR (126 MHz, d6-DMSO): δ = 173.6 (Cq), 168.6 (Cq), 135.7 (Cq), 134.9 (Cq), 132.7 
(Cq), 128.8 (Cq), 128.4 (CH), 127.8 (CH), 127.0 (CH), 121.1 (CH), 119.0 (CH), 118.4 (CH), 
110.8 (CH), 108.0 (Cq), 53.6 (CH), 27.7 (CH2), 22.4 (CH3).  
IR (ATR): 3280, 1715, 1650, 1523, 1448, 1237, 741 cm–1.  
MS (ESI) m/z (relative intensity) 667 (44) [2M+Na]+, 345 (100) [M+Na]+, 323 (50) [M+H]+, 
264 (13), 206 (19). 











5.4.6 UV-Visible and Fluorescence Data for Arylated Tryptophan-Containing Peptides 
UV-Visible spectroscopic analysis of compound 101a in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
Fluorescence emission spectra of compound 101a in DMSO (excitation at 283 nm). 
 
y = 7036,9x 
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Experimental Section 
UV-Visible spectroscopic analysis of compound 102ah in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
Fluorescence emission spectra of compound 102ah in DMSO (excitation at 308 nm). 
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Experimental Section 
UV-Visible spectroscopic analysis of compound 102ai in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
Fluorescence emission spectra of compound 102ai in DMSO (excitation at 310 nm). 
 
  
y = 17027x 
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Experimental Section 
UV-Visible spectroscopic analysis of compound 102aj in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
Fluorescence emission spectra of compound 102aj in DMSO (excitation at 313 nm). 
 
  
y = 20028x 
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Experimental Section 
UV-Visible spectroscopic analysis of compound 102ak in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
No fluorescence emission of the peptide 102ak in DMSO was detected. 
  
y = 22414x 
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Experimental Section 
UV-Visible spectroscopic analysis of compound 102al in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
Fluorescence emission spectra of compound 102al in DMSO (excitation at 311 nm). 
 
  
y = 24701x 
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Experimental Section 
UV-Visible spectroscopic analysis of compound 102ag in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
Fluorescence emission spectra of compound 102ag in DMSO (excitation at 310 nm). 
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Experimental Section 
UV-Visible spectroscopic analysis of compound 102am in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
Fluorescence emission spectra of compound 102am in DMSO (excitation at 295 nm). 
 
  
y = 18447x 
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Experimental Section 
UV-Visible spectroscopic analysis of compound 102as in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
Fluorescence emission spectra of compound 102as in DMSO (excitation at 310 nm). 
 
  
y = 21822x 
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Experimental Section 
UV-Visible spectroscopic analysis of compound 102at in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
Fluorescence emission spectra of compound 102at in DMSO (excitation at 312 nm). 
 
  
y = 22515x 
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Experimental Section 
UV-Visible spectroscopic analysis of compound 102au in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
Fluorescence emission spectra of compound 102au in DMSO (excitation at 282 nm). 
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Experimental Section 
UV-Visible spectroscopic analysis of compound 102av in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
Fluorescence emission spectra of compound 102av in DMSO (excitation at 311 nm). 
 
  
y = 19967x 
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Experimental Section 
UV-Visible spectroscopic analysis of compound 102aw in DMSO (the concentration range is 
shown in the figure key, in mol·dm-3). 
 
 
Fluorescence emission spectra of compound 102aw in DMSO (excitation at 310 nm). 
 
 
y = 13361x 
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°C degree Celsius 
CAPT chiral anion phase transfer 
cat. catalytic 
Cbz benzyloxycarbonyl 
CMD concerted metalation deprotonation 
conv. conversion 
Cys cysteine 
δ chemical shift 
DCE 1,2-dichloroethane 





ee enantiomeric excess 
EI electron ionization 
equiv equivalent 
ESI electronspray ionization 
et al. et alia 
Fmoc fluorenylmethyloxycarbonyl 







HMBC heteronuclear multiple bond correlation 
HR high resolution 
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List of Abbreviations 
HPLC high-performance liquid chromatography 
i.e. id est 
Imes 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene 
Int. intensity 
IR infrared spectroscopy 
J coupling constant 
KIE kinetic isotope effect 





mCPBA meta-chloroperoxybenzoic acid 








m. p. melting point 
MTBE methyl tert-butyl ether 
MW microwave 
m/z mass to charge ratio 
n- normal- 
NBS N-bromosuccinimide 
NHC N-heterocyclic carbene 













ppm parts per million 
PPTS pyridinium p-toluenesulfonate 
Py pyridine 
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SET single electron transfer 
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